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Abstract 
 
Metalloenzymes have gained interest in drug development. In this study, small 
molecules with metal binding groups were synthesized to target two 
metalloenzymes: alkaline nuclease (UL12) that causes a viral infection resulted in 
the simplex herpes 1 disease. The other enzyme was E. coli enolase which is 
essential for the survival of several pathogens. Three general motifs were modified 
in this study inspired from natural products. Tropolone was diversified through 
aminocarbonylation and cross coupling reaction with diethyl phosphite to provide a 
series of tropolone derivatives. Pyridone series which has two sites for 
diversifications was also prepared. The last series was based on 8-hydroxyquinoline-
7-carboxylic acid motif. In addition to these three motifs, the natural product SF-
2312 and its analogs were prepared to target E. coli enolase.  
Results showed that the SF-2312 was potent against enolase with IC50 of 33 nM. The 
other three motifs had moderate activity against enolase with IC50 between 8 and 20 
µM. The crystal structures of enolase co-crystallized with SF-2312 and the substrate 
2-PGA were determined. These structures were used in molecular docking and the  
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results of this experiment indicated that interactions with Lys392 is essential for 
potency against enolase.  
Screening of the synthesized compounds against the alkaline nuclease enzyme 
resulted in one lead motif. The 8-hydroxyquinoline-7-carboxamide derivatives with 
hydrophobic residues were active against this enzyme with IC50 between 6 and 10 
µM. Molecular modeling was conducted on the crystal structure of the protein 
homolog of UL12 (KSHV-SOX). The results of this experiment showed that 
interactions of ligands with Tyr373 led to a significant activity against UL12.   
The APT1 enzyme was targeted using analogs of palmostatin M. The initial results 
indicated that the polarity of the chain at C4 is essential in the activity of this motif. 
The presence of an alkene residue at C3 diminished the activity of the probes. 
Reduction of the a-alkylidene-b-lactone series and screening the corresponding 
analogs revealed that trans-analogs with a sulfoxide group in the chain at C4 were 
active. Analogs where the chain at C3 of the b-lactone contains sulfonamide are in 
the process of screening.  
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Chapter one 
Introduction and overview  
Metalloenzymes are proteins that incorporate a variety of metal ions in the active site. More than 
one third of the enzymes are metalloenzymes. The presence of metal ions in the active site of these 
enzymes plays key roles in the biological activity of all living organisms. The metals are usually 
located in the pocket of the enzyme and interact with the nearby residues. These interactions 
stabilize the structure of the enzyme and they are important for the enzyme functioning. Many of 
these enzymes are involved in electron transfer, regulating blood pH, DNA transcription, gene 
regulation and catalyzing chemical transformations.1,2 Misregulation of metalloenzymes has been 
linked to human diseases such as cancer,3 HIV and heart diseases.1 In addition, it has been found 
that metalloenzymes are associated with bacterial pathogens and viral infections.1,4  
The unique function of metalloenzymes in both prokaryotes and eukaryotes and their importance 
in the biochemical reactions make them useful targets for drug development. Inhibitors that target 
these enzymes are designed to chelate the metal ions in the active site and inhibit the activity of 
the enzyme. There are two main interactions with the metal ions in the active site of an enzyme. 
The amino acid residues in the enzyme pocket-cysteine, histidine, aspartic acid or glutamate- 
coordinate with the metal cation using sulfur, nitrogen or oxygen atoms. The second interaction 
involves the native ligand/substrate which occupies the active site and undergoes chemical 
transformation. Non-covalent interactions stabilize the ligand in the active site by formation of 
hydrogen bonds, hydrophobic interactions, pi-cation and dipole-dipole interactions. A designed 
molecule that chelates the metal ion and displaces the native ligand is an inhibitor. Metalloenzymes 
appear to be a fruitful area for drug discovery and development. The structure-based drug design 
has been used frequently in developing new inhibitors to target metalloenzymes.5,6   
 
 
2 
1.1. Structure-Based drug design  
The structure-based drug design is usually used to develop new ligands/inhibitors. In this approach, 
biophysical techniques (nuclear magnetic resonance-NMR, surface plasmon resonance-SPR, 
protein homology modeling, protein X-ray crystallography) are used to identify lead compounds 
or hits. This method has the advantage of finding lead compounds with improved physicochemical 
properties compared to the traditional drug discovery (high throughput screening-HTS). In many 
cases HTS provides lead compounds but it has some challenges and limitations. For instance, a 
specific assay is required to be developed and modified to enable screening of large set of 
compounds. This is a time-consuming experiment which requires preparing and processing of the 
data. In most cases the hits identified from HTS have moderate activity (1-10  µM) with poor 
physicochemical properties.7,8  
The process of structure-based drug design involves multiple cycles and it is iterative before a 
molecule is clinically tested. The first step involves choosing a drug target that is linked to a human 
disease and it has a defined active site. This step is followed by structural determination of the 
target protein in complex with a molecule to reveal binding interactions in the active site residues. 
Both molecular modeling and biochemical assays are used in this step. A protein crystal structure 
is a useful source for studying and revealing the interactions of inhibitors with the active site 
residues. The following section has a list of screening methods for drug development based on the 
spectroscopic techinques.9  
1.2. Biophysical methods in protein-ligand analysis  
1.2.1 Nuclear magnetic resonance (NMR)  
NMR based screening is one of the methods used for drug development. It is used to study the 
binding between small molecules and the drug target protein. This technique is based on the 
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resonance frequencies of nuclei present in both protein and ligand. The nuclei can be naturally 
present (1H) or incorporated-isotopically enriched (13C, 15N) into the target protein. These nuclei 
are sensitive to their local environment, solvent rearrangement and conformational changes. 
Several NMR experiments can be used to study these changes; both one and two-dimensional 
NMR methods are usually carried out to probe these interactions. Experiments that study protein 
conformations and ligand-protein interactions can be done using this technique. These experiments 
include through bond coupling,1H-13C or 1H-15N heteronuclear single quantum correlation 
(HSQC), and through space coupling experiments, nuclear overhauser effect (NOE). This method 
is limited to protein with 25-30 kDa in size and it is used when crystals of the protein do not diffract 
well and result in disorder structure.8,10  
1.2.2 Surface plasmon resonance (SPR) 
Surface plasmon resonance is used for screening of molecules with molecular weight of 100-300 
Da. This technique has the advantage of not using labeling and provides a real time analysis. A 
real time analysis has the advantage of studying the kinetics of binding (slow/fast binding) which 
is a powerful tool for SAR analysis. It also provides information about the dissociation/association 
equilibrium constant of protein with a ligand. However, the limitation of this method arises form 
the possibility of the protein to form aggregates which results in false positive signal. In addition, 
this method requires the immobilization of the protein on the surface area which adds more steps 
resulting in time consuming to this method.11,12  
1.2.3 X-ray crystallography  
X-ray crystallography is the most powerful method in drug development. It provides detailed 
structural information on protein-ligand interactions. The method has been used as the standard 
tool to obtain information at the atomic resolution level of macromolecules. It provides accurate 
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and reliable data about the protein conformational changes upon binding the ligand in the active 
site. In the crystallization process, the target protein needs to be purified and has a purity of > 95% 
and mass of 10-50 mg. To study the interactions of weak binding ligands; the test compounds need 
to be soluble at the millimolar concentrations. Both soaking and co-crystallization methods are 
commonly used in preparing the crystals.13,14  
In the co-crystallization method, the ligand is added to the target protein solution to form a complex 
prior to crystallization. The solubility of ligands in the target protein solution is crucial for 
successful crystallization. In most cases ligand binding to the protein results in structural 
conformational changes compared to the apo-protein which might reduce the chances of getting 
crystals of the protein complex. To overcome these difficulties, a crystallization screening is 
usually carried out to find the appropriate crystallization conditions. This screening might include 
changing the ligand-protein ratios, pH and the components of the buffer medium.13 
The second common method of crystallization is the soaking method. It involves the incubation of 
the ligand with the preformed crystals of the apo-protein. The ligand diffuses to the crystal lattice 
and binds to the active site. This is a feasible method since the crystal contains channels that are 
filled with solvent that can be displaced by the ligand. Several factors affect the success of this 
method which include: the solvent used to dissolve the ligand, the diffusion rate of the ligand into 
the active site of the protein and the temperature of crystallization. The presence of the natural 
ligand bound to the protein results in the stabilization of the protein, sometimes the replacement 
of this ligand by another molecule can lead to conformational changes of the protein structure and 
hence crystal cracking. The co-crystallization is the method of choice if soaking fails.13 
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1.2.4 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry is a technique commonly used to determine the thermodynamic 
parameters for a protein-ligand binding. This technique provides useful information regarding the 
affinity, stoichiometry and enthalpy for the protein-ligand interactions. The experiment is 
conducted by titrating one reactant (ligand) into the protein solution under isothermal conditions. 
Each injection of the titrant results in a chemical reaction that either absorbs or releases heat. This 
heat is proportional to the amount of ligand binds to the protein [protein-ligand complex]. The data 
obtained from this experiment provides quantitative measurements of the binding affinity (Gibbs 
free energy  DG).15  
Gibbs free energy has two contributions: the enthalpy (DH) and the entropy (DS). The enthalpy 
reflects the strength of the ligand bound to the protein active site which depends on the interactions 
between ligand and protein target. Strong interactions (H-bonds, pi-cation, electrostatic) result in 
high enthalpic values whereas weak interactions show low values of DH compared to those 
existing with solvent. Conversely, entropy is a reflection of the solvation entropy and 
conformational change upon ligand binding to the protein. Binding of the ligand to the protein 
results in the displacement of solvent molecules and an increase in the entropy. This increase 
contributes to the solvation entropy. However, upon ligand binding, the active site residues and 
some part of the protein undergo structural conformations and both protein and ligand lose 
conformational flexibility. This result causes a negative change in the conformational entropy 
which indicates high affinity of ligand that results in conformational constrain of the active site.16  
1.2.5 Thermal shift assay 
Thermal shift assay (TSA) is a method that targets the protein stability as a function of temperature 
increase. It is used to study the thermal stabilization of protein upon ligand binding. This method 
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relies on the principle of thermodynamic stabilization of the protein target as a result of ligand 
binding. When a ligand binds to a protein, it undergoes structural and conformational changes that 
results in the increase of the protein-ligand interactions. These interactions (H-bonding, 
electrostatic, van der walls, pi-cation) lead to an increase in the stabilization of the target protein. 
This method has the advantageous to screen ligands quickly in a high throughput screening 
experiment.17  
1.2.6 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) is a method used to measure the heat capacity of the 
protein-complex as a function of temperature. The focus of this method is on the thermodynamic 
parameters controlling the conformational transitions as a result of ligand binding to a protein. It 
measures the heat capacity ( DCp) of a protein-ligand and determines the thermal transition or 
melting temperature (Tm). This method has the advantage of providing a direct measure of the 
stability of protein as a function of ligand binding. ITC experiments give binding energy for 
medium to tight binding complexes and requires the binding to be two-states. Unlike ITC, DSC 
provides information about very tight binding and allows the determination of the intermediates 
states in the pathway upon ligand binding. The method requires the ligand concentration to be 
much higher than protein-ligand dissociation constant (kd). Further, the unfolding process must be 
described by two states, native and denatured. Any intermediates form will require more 
complicated analysis of the data. Finally, the ligand shouldn’t bind to the denatured protein, 
otherwise, the binding affinity will be underestimated.18,19 
1.3. Druggability of a target protein    
Druggability is defined as the ability to modulate a target protein with small-molecule drug. It 
evaluates the ability of small drug-like molecules to bind a protein and alter its activity. This will 
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assess if changing the normal activity of a target protein can result in a therapeutic effect.20 The 
shape of the binding sites varies from being a spherical or form a curve groove. Catalytic sites can 
be found in large and deep clefts with an average volume of 930-610 Å3. The volume of a drug-
like compounds was found to be 439 Å3 with the majority above 200 Å3. 21 
Drug identification is usually started by searching the literature for novel targets. Thousands of 
scientists are working to understand molecular pathways and the function of genes that cause 
illness. In searching for drug targets there are factors that determines the ideality of drug target. 
The target needs to have a function in the pathophysiology of a disease (disease modifying). A 
homolog of the protein target should be available if the 3D structure is not determined. The target 
should have a workable assay that can be used in a high throughput screening with no competing 
pathways for its biological function.22    
1.4. Binding site ligandability 
 The structure and chemistry of the active site affect the ability of a protein target to bind a small 
drug-like molecule. It is required for a molecule to have strong interactions with the active site in 
order to stabilize the protein and result in a reasonable therapeutic effect. There are different 
software packages that screen and identify favorable interaction energies, H-bonding, van der 
waals, hydrophobic and pi-cation interactions, using Q-SiteFinder and i-Site.23 Metalloproteins are 
found to be hot targets for drug discovery. In most of these proteins, the metal binding site is found 
to be a hot spot and several attempts are made to develop small molecules that chelate the metal 
ion. However, targeting metal binding site can result in a broad-spectrum of inhibition. The drug 
like-molecules with chelating groups have no selectivity in distinguishing between metal ions. 
This limits their selectivity and specificity for metalloproteins. Although this is a short come of 
targeting metalloproteins using this strategy, they still can be modified to form interactions with 
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non-metal sites. An approach to overcome the lack of selectivity is to add additional hydrophobic 
group to the drug like-molecule that forms new interactions with the non-metal ion.24 
The interactions of water molecules with an active site have been used to quantify ligandability of 
a protein target. A small drug-like molecule that is able to bind the protein, it requires the 
displacement of bound water molecules from the protein hydration site. Quantifying the 
interactions of water molecules with a protein allows the prediction for protein target to be a 
potential drug target that binds to a small molecule.  One method to quantify these interactions is 
to search for hydration sites on the protein surface and estimate their binding free energy. Then, 
this free energy is used to predict or rank sites for ligandability. For instance, strongly bound water 
molecules will result in a high desolvation penalty if a ligand binds with high affinity to the protein. 
Despite this method provides a metric data about a protein ligandability; it is noteworthy to 
mention that protein molecules are dynamic which results in continuous changes of the solvent 
molecules on the surface of the protein.25   
1.5. Medicinally relevant metalloenzymes with their inhibitors 
1.5.1. Inhibitors targeting bacteria 
1-Deoxyxylulose-5-phosphate reductoisomerase 
The enzyme 1-deoxyxylulose-5-phosphate reductoisomerase (DXR or IspC) is found in both 
gram-negative and some gram-positive bacteria. This enzyme is essential for these organisms and 
it is absent in humans. Its absence in humans makes it a promising target for antimicrobial drug 
discovery. This enzyme catalyzes the formation of 2-C-methyl-D-erythritol phosphate (MEP) 
from 1-deoxy-D-xylulose-5-phosphate (DXP) in the presence of NADPH and a divalent metal ion 
(Mg2+, Co2+), scheme 1.1.26  
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The product MEP is a precursor in the non-mevalonate pathway for the synthesis of isoprenoids. 
Isoprenoids are essential for cell survivals; they are the building blocks for the synthesis of 
biological molecules such as bactoprenols. Bactoprenols are associated with the biosynthesis of 
peptidoglycans which are components of the bacterial cell wall.27 In addition, isoprenoids include 
essential metabolites: sterols, carotenoids, long acyclic isoprenic chains- ubiquinones, 
menaquinone and plastoquinone. Sterols are present in most eukaryotes and act as membrane 
stabilizer and in vertebrates as precursors for steroidal hormones. So, the isoprenoids have essential 
function in both eukaryotes and prokaryotes.28  
The metalloenzyme (DXR) was found to be a promising target for antibacterial drug development. 
The natural product fosmidomycin was reported to be an inhibitor of DXR. This small molecule 
contains both a phosphonic and hydroxamic acid metal binding groups. The crystal structure of 
DXR co-crystallized with fosmidomycin in the presence of NADPH shows the hydroxamic group 
coordinates with the Mg2+ ion (Figure 1.1).29 
 
 
Figure 1.1. Crystal structure of DXR complexed with fosmidomycin and NADPH (PDB code 2EGH). 
FDP), suggesting the possibility of feedback regulation of the
MEP pathway via inhibition of IspF. However, to our
knowledge, the biochemical evaluation of IDP/DMADP,
FDP, or GDP as inhibitors of IspF has not been reported. In
the present study to understand regulation of isoprenoid
biosynthesis and identify new mechanisms of inhibition of this
unique enzyme, we show that IspF is not inhibited by IDP,
DMADP, GDP, or FDP under standard assay conditions.
Contrary to our expectations, we have observed apparent
enhancement of enzyme activity and subtle stabilizing effects on
IspF activity by several downstream isoprenoid diphosphates.
This unexpected outcome led to analysis of all MEP pathway
intermediates as possible modulators of IspF activity, revealing
the greatest enhancement of IspF activity and most striking
activity-sustaining effects by the first committed pathway
intermediate, methylerythritol phosphate (MEP). Here, we
report the biochemical characterization of MEP-induced
activation/stabilization of IspF and show that the 2C-methyl-
D-erythritol scaffold itself drives this effect. Our studies come
full circle to demonstrate biochemical inhibition of IspF by
FDP, only in the presence of MEP. This work is of interest
because it reveals a possible feed-forward regulatory mechanism
for MEcDP production via MEP-induced activation/stabiliza-
tion of IspF and supports an isoprenoid biosynthesis regulatory
mechanism via feedback inhibition of the IspF-MEP complex
by downstream isoprenoids.
■ RESULTS AND DISCUSSION
Characterization of IspF Activity by HPLC and NMR.
The biochemical evaluation of IspF is challenging because of
the difficulties in accessing the substrate, CDPME2P, coupled
with the instability of the substrate under a variety of assay
conditions. In addition, the IspF product MEcDP (Figure 2)
does not bear a chromophore and therefore is not detectable by
HPLC-UV analysis. Thus, IspF-catalyzed formation of MEcDP
from CDPME2P was confirmed using a two-dimensional H−
P−P NMR method developed in our lab19,20 (Supplementary
Figure S2a,b). Formation of CMP in this reaction was
confirmed by HPLC comparison to an authentic sample. An
HPLC-based assay monitoring enzyme-catalyzed CMP for-
mation from CDPME2P was previously developed for
characterization of IspF.13 Here, we have optimized assay
conditions to prevent degradation of the CDPME2P and
ensure reproducible HPLC retention times for substrate and
product (Supplementary Figure S2c). First, we have
determined that use of HEPES, Tris, MOPS, TEA, and Tricine
buffers promotes degradation of the substrate CDPME2P to
CDP at both 37 and 20 °C. Substrate degradation in these
buffers is enhanced with increasing BSA or MgCl2 concen-
trations. However, 50 mM phosphate buffer causes only minor
substrate degradation at 37 °C, and no degradation is observed
at 20 °C. Thus, the standard assay conditions reported here
include the use of phosphate buffer at 20 °C.
Second, quenching of the enzyme reaction with EDTA or
organic solvent (MeOH) results in unreliable retention times
and peak areas of the product, CMP. This problem is resolved
through the use of 0.1% SDS to quench reactions.21−24 Under
these optimized assay conditions, a pH/rate analysis indicates
the E. coli IspF enzyme exhibits an apparent maximal rate at pH
7.4 in 50 mM phosphate buffer (Supplementary Figure S3).
Detailed kinetic analysis of IspF-catalyzed formation of CMP
suggests that IspF follows hyperbolic kinetics, and kinetic
parameters (Km
CDPME2P = 339 ± 32 μM and kcat = 61 ± 3
min−1; Table 1 and Supplementary Figure S4) are comparable
to those previously reported.25 Various inhibitors of IspF have
been reported25−27 including CDP.26 For further validation of
this HPLC-based assay, we tested inhibition of IspF by CDP.
Under optimized conditions and in the presence of 100 μM
CDPME2P, an IC50 of 768 μM was determined for CDP
(Supplementary Figure S5).
Figure 1. Methylerythritol phosphate (MEP) pathway.
Figure 2. Proposed IspF reaction mechanism depicting substrate positioning and charge stabilization by Zn2+ and Mg2+.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb300243w | ACS Chem. Biol. 2012, 7, 1702−17101703
Scheme 1.1.The biosynthesis of MEP is catalyzed by IscpC/DXR enzyme.27 
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Peptide deformylase  
Peptide deformylase (PDF) is a metalloenzyme that contains a Zn2+ metal ion in the active site. 
The role of this enzyme is to catalyze the removal of the N-terminal formyl group from the initiator 
methionine protein (scheme 1.2).30 The deformylation of a-NH2 is required in the process of 
protein biosynthesis. However, this enzyme has been found to be essential for bacterial cells but it 
is not required in mammalian cells. This makes the enzyme an attractive target for designing a 
bacterial inhibitor.31 
 
 
 
Scheme 1.2. the removal of the formyl group by the enzyme PDF. 
The natural product actinonin was found to inhibit the PDF enzyme. Actinonin is produced by the 
gram-positive actinobacterium Streptomyces roseopallidus and it is a natural antibiotic. Recent 
studies show that actinonin can’t be used for therapeutics even though it is potent for PDF enzyme. 
 This inhibitor targets several metalloenzymes and it is exported by the bacterial efflux pumps 
which decreases its availability inside the cells. Although this molecule is not a promising drug; it 
has been used as a reference for developing inhibitors for PDF. Actinonin contains a metal binding 
group (hydroxamic acid) that coordinates with the Zn2+ ion in the enzyme pocket of PDF. This 
binding results in the inhibition of this hydrolytic enzyme (Figure 1.2).32  
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Figure 1.2. Crystal structure of PDF enzyme co-crystallized with the inhibitor actinonin (PDB code 1LRU). 
VanX enzyme  
VanX is one of the five proteins (VanR, -S, -H, -A, -X) that involves in the bacterial vancomycin 
resistance. This enzyme contains a Zn2+ metal ion in the binding pocket and it is found in both 
gram-positive and gram-negative bacteria. The function of VanX is to hydrolyze D-Ala-D-Ala 
dipeptide into two D-Ala amino acids. The dipeptide D-Ala-D-Ala is the binding site where 
vancomycin antibiotic binds and inhibits cell wall biosynthesis in bacteria. Vancomycin resistant 
bacteria have adapted a strategy to modify the dipeptide D-Ala-D-Ala to D-Ala-D-lactate. This 
modification alters the binding of vancomycin to the dipeptide which results in 1000-fold less 
potency (Figure 1.3). So, targeting VanX enzyme would re-establish the potency of vancomycin 
against bacteria. The crystal structure of VanX shows that Zn2+ metal ion coordinates to the 
residues His184, His116 and Asp123. 33 It was found that this active site is small and only small 
inhibitors can fit inside the enzyme pocket. A known inhibitor of VanX is 2,3-dimercaptopropanol 
with IC50 of 0.32 nM.31  
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Figure 1.3. (a) Crystal structure of VanX enzyme with the binding pocket residues coordinate to Zn2+ metal ion (PDB 
code 1R44). (b) Structure of vancomycin binding with the N-Acyl-D-Ala-D-Ala forming five H-bonds and the lack 
of additional H-bond with the newly modified protein N-Acyl-D-Ala-D-lactate.33  
 
Bacillus anthracis dihydrofolate reductase enzyme  
Anthrax is a sever infectious disease that is caused by the Gram-positive bacterium Bacillus 
anthracis. Anthrax can be contracted through the skin, injection or by inhalation. This disease 
shows resistance against multiple antibiotic families: trimethoprim, sulfonamides and some 
cephalosporin drugs. These drugs were designed to target the Bacillus anthracis dihydrofolate 
enzyme (baDHFR). This enzyme is essential for the survival and pathogenesis of anthrax. DHFR 
is required for the generation/cycling of tetrahydrofolate (THF) that is necessary for several 
biosynthetic pathways. Loss of DHFR function results in a decrease of THF which causes genomic 
and proteomic instability and consequently cell death. The crystal structure of DHFR bound to the 
anticancer and anti-inflammatory drug methotrexate was determined (Figure 1.4). Methotrexate 
structure was used as a model to design new inhibitors for this enzyme.34  
medicinal chemistry challenge. The likely mechanism for D,
D-dipeptide hydrolysis, is shown in Fig. 2C with Glu-181 acting
as catalytic base and Arg-71 as a cationic coordinator both in
the ground state and for stabilization of the developing
negative charge in the tetrahedral adduct (18, 20). The struc-
ture predicted Asp-123, Asp-142, and Tyr-21 residues for the
recognition of the D-Ala-D-Ala dipeptide substrate !-NH3!
and Ser-114 for the carboxylate group. Site-directed mutagen-
esis of active site residues has revealed roles consistent with
predictions of recognition and catalysis (20).
VanX Homologs in the Bacteria That Produce Vancomycin
and Related Glycopeptide Antibiotics. In many instances,
bacteria that produce antibiotics have evolved strategies and
mechanisms that provide immunity to the action of the
antibiotic, and there is a general supposition that immunity
mechanisms will have coevolved with antibiotic biosynthesis
genes to protect the producing organisms (21, 22). Streptomy-
ces toyocaensis synthesizes and secretes a vancomycin-type
glycopeptide antibiotic (A47934), and the molecular basis of
immunity for this organism and most likely for Amylocatopsis
orientalis, which produces vancomycin, has been recently de-
convoluted (14, 15, 23, 24). PCR probes to EntVanX zinc-
binding motif revealed an S. toyocaensis VanX homologue
(StoVanX) with 63% similarity to EntVanX, and sequencing
analysis then indicated a three-gene operon in S. toyocaensis
and A. orientalis equivalent and similarly oriented to the
vanHAX operon from (Fig. 3A). Expression and purification of
the StoVanX confirms it is a high efficiency D,D-dipeptidase
with unmodified N and C termini and that it lacks D-Ala-D-
lactate depsipeptide activity (15) (Table 2). These findings
suggest a conserved mechanism for the observed intrinsic
resistance of the antibiotic producers to the vancomycin class
of glycopeptides and that before S. toyocaensis produces the
glycopeptide A47934, it has D-Ala-D-Ala peptidoglycan ter-
mini and is sensitive to vancomycin-type antibiotics. Further-
more, S. toyocaensis possesses two D-,D-ligases: a D-Ala-D-
lactate ligase encoded by the vanHAX operon and a D-Ala-D-
Ala ligase encoded by a separate gene on the chromosome
(24). The S. toyocaensis vanHAX equivalents may be switched
on transcriptionally when the host turns on the cluster of genes
to synthesize the glycopeptide A47934 to reprogram PG
N-acyl-D-Ala-D-lactate (9). Vancomycin binds to the D-Ala-D-Ala
termini through a five-hydrogen bond network. The key hydrogen
bond between the D-Ala amide NH and the vancomycin backbone
carbonyl is lost in the N-acyl-D-Ala-D-lactate complex, resulting in a
1,000-fold reduction in the affinity of the antibiotic.
FIG. 1. (A) Vancomycin binds the D-Ala-D-Ala moiety of the
growing peptidoglycan and sterically occludes the transglycosylation
and transpeptidation steps of cell-wall assembly. The immature cell
wall results in cells susceptible to lysis through osmot c shock. (B) The
alternative cell-wall biosynthetic pathway of the VanH, -A, -X proteins,
producing peptidoglycan intermediates with D-Ala-D-lactate termini
in place of the usual D-Ala-D-Ala termini (12). Pyruvate is reduced to
D-lactate by the NADP-dependent dehydrogenase VanH, which is
then used as substrate for the ATP-dependent D-Ala-D-lactate dep-
sipeptide ligase VanA. The product D-Ala-D-lactate depsipeptide is
used by the enzyme MurF to produce the muramyl-peptidyl-D-lactate
intermediate and brought forward in subsequent cell-wall biosynthesis.
The zinc-dependent D, D-dipeptidase VanX, specifically hydrolyzes the
D-Ala-D-Ala dipeptide pool produced by the native D-Ala-D-Ala Ddl
ligase without hydrolyzing the D-Ala-D-lactate and in this way effec-
tively shunts the flux of the cell-wall biosynthesis to the ester termini.
Substitution of D-Ala by D-lactate does not impair crosslinking of the
modified precursors to the growing peptidoglycan chain, resulting in
a mechanically strong peptidoglycan layer and cell survival. (C)
Structures of the vancomycin complexes with N-acyl-D-Ala-D-Ala and
Table 1. VanX homologs
VanX source Role
Vancomycin-resistant
enterococci
Enterococcus faecium
Enterococcus faecalis
Reprogram cell walls for vancomycin
resistance in opportunistic pathogens
Glycopeptide producers
Streptomyces
toyocaensis
Amycolatopsis
orientalis
Coevolution of vanHAX operon with
antibiotic biosynthesis genes for
immunity
Stationary-phase survival
mechanism
Escherichia coli
Transport D-Ala-D-Ala from periplasm
back to cytoplasm as cell-wall
crosslinks are refashioned and use as
RpoS-mediated energy source
Reaction
D-Ala-D-Ala " H2O ¡
EZn -Enzyme
D-Ala!D-Ala
Colloquium Paper: Lessard and Walsh Proc. Natl. Acad. Sci. USA 96 (1999) 11029
b
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Figure 1.4. Crystal structure of DHFR bound to the drug methotrexate (PDB code 1RG7). 
 
1.5.2. Inhibitors targeting viruses 
HIV integrase 
The human immunodeficiency virus (HIV) is a retrovirus that enters the infected host cell and 
builds a DNA copy of its genome. HIV integrase is a viral metalloenzyme that is responsible for 
integrating its viral genome in the host cell genome. This integration activity starts by the binding 
of integrase to a short sequence at each end of the viral DNA (3` processing). Then, it removes 
dinucleotide from each end and inserts the viral DNA into the host cell. Both of these processes 
require the presence of a metal ion (Mg2+, Mn2+) for their activity. Since this enzyme is essential 
for viral replication, then it appears as a promising target for antiviral drug development.35 
Developing inhibitors for HIV integrase depends on the use of a metal binding group that 
coordinates to the metal ions in the catalytic site. The drug Raltegravir has been developed to 
inhibit HIV integrase that uses a metal binding group hydroxypyrimidinone to coordinate with the 
two Mg2+ ions. The crystal structure of Raltegravir co-crystallized with HIV integrase homologue 
(prototype foamy virus-PFV) is shown in Figure 1.5. This structure shows the binding of the 
carbonyl oxygen from the amide group and the hydroxyl of pyrimidinone to the second Mg2+ ion.36  
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Figure 1.5. Crystal structure of PFV complexed with Raltegravir (capped stick) and with DNA (blue), Mg2+ ions 
(pink), PDB code 3OYA.  
 
Targeting RNA polymerase of influenza virus 
Influenza viruses are causative agents for the respiratory diseases in humans. These viruses belong 
to the family Orthomyxoviridae. There are four types of influenza viruses, A, B, C and D. Influenza 
A and B cause the seasonal flu disease in every winter. Type C causes a mild respiratory illness 
while type D does not infect humans.37,38 Viral RNA polymerase catalyzes the synthesis of 
influenza virus mRNA in the nuclei of infected cells. This RNA-dependent enzyme is essential for 
viral replication and it is conservative among influenza A, B and C viruses. No homolog of this 
enzyme is found in mammalian cells and consequently it is a safe target for drug development in 
terms of selectivity.39  
The viral RNA polymerase enzyme contains two Mn2+ ions in the active site. The strategy used to 
develop inhibitors for this enzyme was to design small molecules with metal binding groups. 
Diketo acid derivatives were designed to target this enzyme (scheme 1.3). These derivatives were 
prepared with chelating groups that can coordinate with two metal ions (carboxylic and ketone 
groups).39  
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Scheme 1.3. General structure of diketo acid derivatives, R: aryl, alkyl group. 
1.6. Objective of this study 
1.6.1. Developing inhibitors for the herpes simplex virus alkaline nuclease enzyme (UL12) 
In this study we have developed three series of metal binding motifs that can chelate two metal 
ions in the active site of an enzyme. The motifs are inspired from the natural products tropolone, 
kojic acid and quinoline to target UL12 (Figure 1.6). Tropolone was modified by installing an 
amide moiety and phosphonic group. A library of pyridone derivatives were prepared with 
different functional groups. The last motif with quinoline core was synthesized by adding 
hydrophobic groups with different polarity. These compounds were screened against the alkaline 
nuclease enzyme at 15 µM. 
 
Figure 1.6. The three motifs used to target UL12 based on the three natural products. 
1.6.2. Targeting E. coli enolase enzyme focusing on structure-based drug design 
The enzyme enolase exists in both prokaryotes and eukaryotes. The role of this enzyme is to 
catalyze the dehydration of 2-phosphoglycerate (2-PGA) into 2-phosphoenolpyruvate (PEP) and 
the reverse reaction (Figure 1.7). The product PEP is used as a substrate in the glycolytic cycle to 
produce energy (ATP) and pyruvic acid. In addition, PEP is used as a cosubstrate with the 
nucleotide diphosphate acetylglucosamine (UDP-GlcNAc) to form UDP-GlcNAc-enolpyruvate a 
precursor in cell wall biosynthesis in bacteria.40 
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Figure 1.7. Formation of PEP from 2-PGA is catalyzed by enolase enzyme. 
 
The crystal structure of E. coli enolase in the apo-form has been determined in our lab and the 
active site contains Mg2+ ion. The presence of metal ion in the active site can be used to design 
inhibitors that coordinate to this metal. In this study, inhibitors for this enzyme have been 
developed with metal binding groups that coordinate with the Mg2+ ion and form non-covalent 
interactions with the active site residues. These inhibitors were prepared similar to the three motifs 
for the UL12. In addition, the natural product SF-2312 and its modified analog were prepared and 
screened against enolase.  
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Herpes simplex virus type 1 (HSV-1) 
 
2.1. Introduction to virus structure  
 
Viruses are small intracellular parasites that contain either RNA or DNA genome surrounded by a 
protective, virus-coded protein coat. Without a host cell, viruses can’t survive or carry out their 
functions or reproduce. They can’t synthesize their proteins since they lack ribosomes and must 
use the ribosomes of the host cells to translate viral mRNA into viral proteins. Viruses can’t 
generate or store energy in the form of adenosine triphosphate (ATP). They used the host cell to 
obtain their energy and the metabolic functions.1 
Viruses are classified based on their morphology and chemical compositions. Filamentous and 
pleomorphic viruses have a helical morphology. Whereas, many of the spherical viruses have an 
icosahedral morphology.  The genome of the virus may contain a single stranded (ss) or double 
stranded (ds) DNA or RNA. A complete virus particle is called a virion. The main function of the 
virion is to deliver its DNA or RNA genome into the host cell. This process is important so that 
the genome can be expressed (transcribed and translated) by the host cell. The viral genome is 
packaged inside the capsid. The capsid contains either (ssDNA/dsDNA) or (ssRNA/dsRNA). The 
nucleic acid-associated protein, called nucleoprotein, together with the genome, forms the 
nucleocapsid.1,2  
In order for the viruses to reproduce, they must enter the host cell. Once inside the cell, the virus 
uses the host cell cytoskeleton for navigation through the cell cytoplasm. The viral life cycle begins 
with the attachment of the virus to the host cell membrane. This incorporation allows the virus or 
viral particles to enter the cell. The viral genome then needs to be translocated to the nucleoplasm 
or cytoplasm where replication of the viral genome occurs. This replication allows the synthesis 
of the viral proteins and causes the infection.3,4  
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Viruses are divided into three types based on their replicative methods. First, latency phase where 
infection can occur by reactivation. It is characterized by long term persistent infection that fail to 
produce infectious virus. This occurs when the viruses fail to complete their life cycle as a result 
of host cell restriction factors, defective viral genome replication, lack of host resources or 
programmed delays in the infection cycle. Second, the hit and run approach where the virus 
propagates in different host cells and destroy them. They are highly infective and can be 
transmitted to new hosts. Some viruses belong to this family are influenza virus, rhinoviruses of 
common cold and measles. A part of this approach is the hit and stay, where the virus stays in the 
individual host and can be transmitted to other hosts. They usually replicate rapidly in the host cell 
but they are cleared from the system. The third method is the slow and low tactic where the viruses 
replicate continuously but at low level that does not cause cell damage and consequently does not 
provoke an immune response.5,6   
2.2 Herpes viruses 
  
The herpes viruses are DNA viruses able to cause infections in both human and animal populations. 
Virus type 1 and 2 (HSV-1 and HSV-2) are human neuroinvasive pathogens. Herpesviruses are  
large and diverse family composed of three subgroups, alpha, beta, and gamma. Herpesviruses can 
infect a diverse range of host cells but only eight herpesviruses are known to infect humans. These 
human herpesviruses include the alpha- herpesviruses, herpes simplex virus types 1 and 2 (HSV-
1 and HSV-2) and varicella-zoster virus (VZV), the beta- herpesviruses, cytomegalovirus (CMV) 
and human herpesviruses 6 and 7 (HHV-6 and HHV-7), and the gamma-herpes viruses, Epstein-
Barr virus (EBV).7  
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Varicella zoster virus (VZV) virus belongs to the a-herpesvirus family. It is highly infectious and 
it causes chickenpox disease. The genome of this virus is a linear (dsDNA) with a particle size of 
80-120 nm in diameter. The viral cycle begins when the virus interacts with the cell surface 
molecules of the host cell. These molecules are the receptors on the cell surface such as mannose-
6-phosphate or myelin associated glycoprotein. After entry, the virions undergo uncoating process, 
and transcription and replication. This virus is different from other herpesviruses in that the virion 
remains associated with cell. It is challenging to investigate the VZV pathogenesis since this virus 
is highly human specific that has no capacity to infect other species. Reactivation of the virus later 
in life results in herpes zoster or shingles. It causes skin rash with blistering in limited areas since 
the human body has immunity against it.8  
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) CMV and EBV viruses belong to the beta 
and gamma subfamily of Herpesviridae. They infect the epithelial cells; EBV infects B-cells 
whereas CMV enters monocytes besides lymphocytes. Infection of these viruses cause fever, sore 
throat, fatigue and swollen lymph nodes. CMV infections lead to birth defects whereas EBV is 
known to be tumorigenic.9 The three human herpesviruses HHV-6, HHV-7, and HHV-8 share a 
conserved amino acid sequence.  Human herpesvirus 8 (HHV-8) is also known as Kaposi sarcoma 
(KS)–associated herpesvirus. It is a form of cancer that became known through its diagnosis in 
patients with AIDS. The virus is common in sub- Saharan Africa a but rarer in other parts of the 
world.10  
2.2.1 Herpes simplex virus type 1 (HSV-1) 
The herpes simplex virus 1 (HSV-1) UL12 protein is an alkaline nuclease that is essential for viral 
replication. This has 5` to 3` exonuclease activity and shares homology with other nucleases from 
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the Herpesviridae family. It was found that viruses that can’t express UL12 have 100 to 1000-fold 
reduction in their replication cycle. In addition, the amino acid sequence of UL12 is well conserved 
among all other herpesviruses. For instance, glycine and serine residues of UL12 at positions 336 
and 338 respectively are highly conserved in UL12 homologues in other herpesviruses. Alanine 
substitutions for these conserved residues (G336A/S338A) in purified UL12 resulted in reduction 
of both endo- and exonuclease activities. This indicates that these residues were essential for both 
UL12 nuclease activities.11 Thus, it makes this enzyme an excellent target for developing antiviral 
therapy for HSV-1 virus.  
The crystal structure of UL12 has not been determined, however, the structure of a related 
herpesvirus “Kaposi’s sarcoma-associated herpesvirus” shut off and exonuclease (KSHV-SOX) 
complexed with DNA is available through Protein Data Bank (PDB).  This virus is known as 
Human Herpes Virus-8 and has both latent and lytic phases. The lytic phase is where the virus 
replicates and degrade host cell mRNA (shut off the host cell).  The active site shows the DNA 
binds where the phosphate group of DNA is in the vicinity of Mg2 (Figure 2.1).12 
      
Figure 2.1. a) Crystal structure of KSHV-SOX complexed with DNA (green), Mg2+ metal ions (purple). (b) The active 
site residues of KSHV-SOX and the phosphate group of DNA (the remaining of DNA bases were removed for clarity), 
PDB code 3POV. 
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The catalytic site has two Mg2+ ions, Mg1 interacts with the polar residues (Asp221, Ile245, and 
Glu244. It was reported that one metal ion is responsible for the deprotonation of water molecule 
and the generation of hydroxyanion. This ion acts as a nucleophile in the cleavage of the phosphate 
group of DNA. However, another method to generate the hydroxyanion is to use either Lys246 or 
Tyr373 to deprotonate the water molecule (H2O1) and form the nucleophile. The second metal ion 
(Mg2) is required to stabilize the pentavalent transition state intermediate that results from 
nucleophilic attack on the DNA phosphate group.12 
The structure of KSHV was used as a reference for developing antiviral therapy for UL12 nuclease 
enzyme. Nucleoside analogs (acyclovir and penciclovir) have been used to control HSV-1 and 
HSV-2 infections. These analogs resulted in the evolution of drug resistant mutant and they are 
not effective in immunocompromised adults. Therefore, new anti-HSV therapeutics need to be 
discovered and developed. A recent study showed that the natural product tropolone (b-
thujaplicinol) and derivatives of this tropolone (a-hydroxytropolones) suppress the replication of 
HSV-1 and HSV-2.13 This molecule has a metal binging group which can coordinates to metal 
ions.  
Three motifs with metal binding groups were modified to target UL12. The first derivative was 
based on the natural product tropolone. It was modified by installing amide and phosphonic acid 
groups. The second set was based on pyridone ring where two sites were modified. This motif has 
6-membered ring compared to 7-membered ring in tropolone. It was selected to have similarity 
with Raltegravir drug. The third set was prepared from 8-hydroxyquinoline-7-carboxylic acid 
which can coordinate to the metal ions through nitrogen and oxygen. It has a rigid biphenyl group 
that can form pi-pi staking with hydrophobic active site residues. The three motifs were chosen 
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with different chemical properties so as to provide information about the enzyme active site. 
Results from screening these molecules will be used to design more potent inhibitors for UL12.  
2.3. Results and discussions  
2.3.1. Targeting UL12 with tropolone derivatives 
The tropolone series was tested against the enzyme alkaline nuclease. The assay of this experiment 
was evaluated based on the fluorescence of picogreen. The loss of fluorescence indicates the 
activity of the enzyme and the tested compound didn’t inhibit the enzyme. The results showed that 
most of the derivatives didn’t inhibit the enzyme significantly (Table 2.1). Having a phenyl 
substituent as in T2 and a linear chain T6 didn’t make a difference in the inhibition. In addition, 
the presence of small hydrophobic group T8 and T10 didn’t show appreciable inhibition of the 
enzyme activity. Furthermore, replacing the amide moiety with phosphonic polar group T12 had 
no effect on the enzymatic activity. The presence of cyclohexyl group T4 gave consistent result 
with slightly higher inhibition value. This might suggest that a large hydrophobic group might be 
required for the inhibition (Figure 2.2). This series was used as a reference to develop different 
motifs and optimize the substituents.   
The presence of phosphonic group increases the polarity and solubility of tropolone. This 
derivative was water soluble compared to the other derivatives. It was prepared for testing by 
dissolving it in H2O compared to DMSO for other derivatives. This group was selected so as it can 
from H-bonding with the active site residues. The initial result indicates that increasing the polarity 
of this motif didn’t enhance the potency. This concluded that non-polar groups might be needed 
to target UL12.   
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Table 2.1. Assay results for UL12 inhibition using tropolone derivatives at 15 µM.   
Identifier Compound structure  RFU* 
T2  1.0 
T4 
 
1.3 
T6  1.2 
T8 
 
1.0 
T10 
 
0.90 
T12 
 
1.5 
 dsDNA 18.1 
*RFU: Relative fluorescence unit 
 
 
 
Figure 2.2. Results for the inhibition of UL12 using tropolone derivatives at 15 µM. 
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2.3.2. Targeting UL12 using 8-hydroxyquinoline-7-carboxamide derivatives 
The same protocol for testing tropolone was used for the hydroxyquinoline series. This motif 
contains a nitrogen atom in the quinoline ring that can coordinate through the lone pair to a metal 
ion. The result from the tropolone series showed that the presence of a hydrophobic group led to 
an increase in the potency against UL12. Different groups with different functional groups to 
accept or donate H-bonding were prepared. The initial screening of these compounds was 
promising and they showed potency against UL12 (Figure 2.3, Table 2.2).  
The initial screening provided information about the substituent effect on the inhibition of UL12. 
The results showed that the benzyl or morpholine group had no significant increase in potency 
(H1, H2 and H3). However, when the benzyl group was replaced by a substituted phenyl group 
there was a substantial increase in the potency (H4-H7). This reveales that a methylene spacer 
between the amide and the ipso carbon (Csp2) of the phenyl ring decreases the activity of this motif. 
Another factor plays in the activity of this motif was the type and position of the substituent on the 
phenyl ring. Substituents at the para position increased the activity compared to the ortho (H3 and 
H4). Replacing bromide with fluoride atom resulted in a decrease in the activity of this motif (H5, 
H7). Fluoride can form H-bonding and it has smaller atomic radius compared to bromide. This 
might suggest large hydrophobic substituents at the para position is essential for the potency of 
this motif (H6).  
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Figure 2.3. Inhibition of UL12 using hydroxyquinoline derivatives. 
 
 
Table 2.2. Picogreen assay for hydroxyquinoline derivatives against UL12 at 15 µM.  
Identifier Compound structure  RFU 
H1  1.2 
H2  1.1 
H3  1.6 
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For the potent compounds (H4 and H5) a dose response experiment was carried out to obtain half 
maximal inhibitory concentration (IC50). The IC50 for H4 was found to be 8.3  µM and for H5 6.6 
µM (Figure 2.4). The compound H5 has a bromide substituent at para position which can be 
further modified by cross coupling reactions and enhance its potency. The compound H4 can be 
modified to change physicochemical properties. The ester group can be hydrolyzed to form a 
carboxylic acid which can result in an increase in the solubility of this derivative in polar solvents.  
 
    
 
Figure 2.4. Dose response for compounds H4 (left) and H5 (right).  
 
2.3.3. Targeting UL12 with the pyridone derivatives 
Pyridone motif is different than the previous two motifs, it contains two sites for modifications (R1 
and R2). The strategy of preparing derivatives of this motif was to set one site fixed while varying 
the other position (Scheme 2.1).   
 
 
 
 
Scheme 2.1. Pyridone motif with two sites for diversifications (R1 and R2). 
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2.3.3.1 Pyridone derivatives with R1 benzyl group  
The first set of pyridone derivatives was synthesized while keeping R1 = Benzyl group and change  
R2. The goal was to investigate the effect of varying R2 on the activity of this motif against UL12 
while keeping R1 unchanged. All these derivatives were tested using the same protocol Picogreen 
assay (Table 2.3). 
Table 2.3. Picogreen assay of pyridone derivatives against UL12 at 15 µM. 
Identifier Compound structure RFU Identifier Compound structure  RFU 
P3 
 
0.99 P5 
 
0.78 
P7 
 
1.6 P9 
 
1.0 
P11 
 
0.78 P12 
 
1.2 
P14 
 
0.90 P16 
 
10.2 
dsDNA 18.1 
The result from this first set was consistent with the previous results. A hydrophobic group was 
required in order to increase the activity against UL12. Polar groups that can form H-bonding P12, 
P14 had low activity against UL12. The molecule P16 had a significant activity compared to the 
other derivatives in this series. This molecule has 4-bromophenyl substituent at R2 which can form 
pi-pi or pi-cation interactions (Figure 2.5).  
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Figure 2.5. Inhibition of UL12 at 15 µM for the first set of pyridone derivatives. 
 
2.3.3.2 Pyridone derivatives with R1 cyclopropyl group 
The second set of pyridone derivatives was prepared by keeping R1 = cyclopropyl and changing 
R2. In this series the cyclopropyl group was used to study if a small hydrophobic group compared 
to benzyl group can have a major impact on the activity of this motif against UL12 (Table 2.4).  
There was no significant increase in the activity of this series by replacing benzyl group with a 
cyclopropyl. The same trend was observed where installing hydrophobic groups at (R2, P34) led 
to an increase in the potency against UL12. Interestingly, this compound contains pyrazole ring 
and it can form H-bonding with the active site residues. In comparison, compound P27 has very 
low activity against nuclease enzyme even though it has the probability to chelate with a third 
metal ion and form additional H-bonding through the amide bond. These results provide 
information about the active site and help in designing a potent molecule. It is clear that polar 
groups in this motif do not increase the activity. In synthesizing these molecules, we wanted to 
have a balance between hydrophobic and polar group so they can result in drug like molecules.  
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Table 2.4. Picogreen nuclease assay of pyridone derivatives against UL12 at 15 µM.  
Identifier Compound structure RFU Identifier  Compound structure  RFU  
P18 
 
1.0  P20 
 
1.3 
P22 
 
1.2 P26 
 
1.0 
P27 
 
0.89 P29 
 
1.1 
P31 
 
1.3 P32 
 
0.90 
P34 
 
5.0  dsDNA 18.1 
The third set was designed based on the first two sets. In this set either R1 or R2 is chosen to be 
hydrophobic group (Table 2.5). The goal was to narrow down the screening and get additional 
information about the active site. The results of this set were consistent with our prediction and 
confirmed the need for a hydrophobic group at either R1 or R2. However, the activity of this motif 
was increased if R1 is a hydrophobic group (b-naphthyl) in P41 in comparison to R2 in P36. A 
significant increase in the activity had been achieved when both R1 and R2 are hydrophobic 
substituents as in P43. The result of this screening provided further information about the effect 
of substituents (R1, R2) on the activity of this motif against UL12. The future work in the design 
will be to change the substituents and functional groups on the hydrophobic moieties. This requires 
the optimization of the physicochemical properties of this motif while keeping the activity 
uncompromised.  
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Table 2.5. Picogreen assay for pyridone third set against UL12 at 15 µM.  
Identifier Compound structure RFU Identifier  Compound structure  RFU  
P38 
 
1.4 P40 
 
1.0 
P41 
 
6.3 P43  16.2 
P36 
 
4.6 dsDNA 18.3 
A dose response experiment was carried out to determine the IC50 for the molecules with high 
inhibitory values. Two molecules were selected (P43, P36) based on the initial screening using 
picogreen assay. The IC50 for P36 was determined to be 8.06 µM and for P43 to be 2.91 µM 
(Figure 2.6).  
 
Figure 2.6. Dose response curve for P36 (left) and P43 (right).  
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complexed with DNA was used for the molecular modeling. The structure does not contain any 
inhibitor but the site where DNA binds contains two Mg2+ ions. We concluded that the site with 
two Mg2+ ions is the active site of this protein. This site was used to dock ligands and study their 
interactions with the active site residues.  
2.4.1. Docking of Tropolone derivatives  
The first molecule to model was from the tropolone series T4. This compound was chosen to 
investigate its interactions with the active site since it gave slightly higher inhibitory value across 
tropolone carboxamide series. The docking view shows the tropolone metal binding groups 
coordinates with the two Mg2+ ions with a distance of 2.09 and 2.01 Å. The oxygen from the 
carbonyl group has H-bonding interactions with Glu184 and at the same time coordinates with 
Mg1 (Figure 2.7).  
 
 
Figure 2.7. Binding pose of T4 in the active site of KSHV, H-bonding is shown as yellow dashed lines, electrostatic 
interactions in pink dashed lines, ligand in capped stick.  
The second molecule in tropolone series was chosen with phosphonic acid moiety. This is a polar 
group which under physiological pH ionizes which might facilitate electrostatic interactions with 
the active site metal ions. Interestingly, this molecule bound to one Mg2 and it did not form any 
interactions with Mg1. It coordinated through the phosphonic acid group using the phosphonic 
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acid to Mg2 and the carbonyl oxygen of the tropolone ring (Figure 2.8). In addition, it forms H-
bonding between phosphine oxide and the hydroxyl group of Tyr373. Overall, the tropolone series 
did not have high potency against UL12. 
 
 
Figure 2.8. Binding view of T12 in the active site of KSHV, H-bonding is shown as yellow dashed lines, electrostatic 
interactions in pink dashed lines, ligand in capped stick.  
 
2.4.2. Docking of hydroxyquinoline derivatives 
Additional docking experiments were carried out to reveal the interactions of 8-hydroxyquinoline-
7-carboxamide motif with the active site of KSHV.  Derivatives of this motif showed promising 
results and it was important to identify the interactions of this motif with the active site residues. 
The same docking procedure and parameters were used for docking hydroxyquinoline derivatives 
as for tropolone derivatives.  
The binding view of H4 shows multiple interactions of this molecule with the active site. 
Electrostatic interactions exist between the nitrogen of quinoline ring with Mg1 and the amide 
carbonyl oxygen with Mg2. In addition, it forms H-bonding with Asp221 and edge to face pi 
interactions between Tyr373 and the phenyl of the amide residue. This last interaction might be 
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the reason why this motif had high activity against UL12. In comparison, the pyridone motif lacks 
this additional interaction which appears to be an important factor in the activity of these molecules 
against UL12 (Figure 2.9).  
 
 
Figure 2.9. Binding view of H4 in the active site of KSHV, H-bonding is shown as yellow dashed lines, electrostatic 
interactions in pink dashed lines, edge to face interactions in blue dashed lines.  
The second molecule in this series was chosen with 4-bromophenyl substituent (H5). This group 
increased the potency of both hydroxyquinoline and pyridone motifs.  The docking result was 
similar to H4 but with fewer interactions. This molecule coordinates with the two Mg2+ ions and 
form H-bonding interactions with Glu184. However, it lacks the edge to face pi interaction with 
Tyr373 compared to H4. This might be due to the presence of Bromide which is less electron 
withdrawing group compared to the ester in H4. The presence of a strong electron withdrawing 
group will reduce the electron density on the phenyl ring which facilitates edge to face pi 
interactions (Figure 2.10). Although this molecule lacks this type of interactions, it showed a 
significant activity against UL12.  The presence of hydrophobic group in the vicinity of Tyr373 
results in the blockage of DNA from binding to the active site even if it lacks edge to face pi 
interactions.  
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Figure 2.10. Pose view of H5 in the active site of KSHV. H-bonding is shown as yellow dashed lines, electrostatic 
interactions in pink dashed lines.  
 
Based on the above analysis the molecule H6 was docked in the active site. This molecule has two 
diversifications: a methylene spacer between amide group and the phenyl ring. In addition, it has 
isopropyl group instead of bromide or ester at the para position of the phenyl ring.  The results of 
docking showed that this molecule coordinates to Mg2 through the quinoline ring using the 
nitrogen atom. Interestingly, the 4-isopropyl-phenyl substituent is aligned to form pi-cation 
interactions with the Mg1. This interaction can stabilize this ligand in the active site and increases 
its binding affinity. Another interaction is an edge to face pi interaction with the quinoline ring and 
Tyr373 (Figure 2.11).  
 
 41 
 
Figure 2.11. Binding poses of H6 in the active site of KSHV. H-bonding is shown as yellow dashed lines, 
electrostatic interactions in pink dashed lines and edge to face pi interactions in light blue color. 
The molecule H7 had low activity and it intrigued us to figure out what type of interactions this 
compound makes. The difference between this molecule and H5 is the presence of a fluoride atom 
instead of bromide. The binding view of this molecule (H7) reveals the type of interactions it 
makes with the active site. As it occurs with other molecules in this series; it forms electrostatic 
integrations with the two Mg2+ ions. However, it lacks any interactions with Tyr373 and the phenyl 
ring is pointed away from Tyr373. This suggests that the lack of interactions with Tyr373 would 
always result in low activity against UL12 (Figure 2.12). This result supports the mechanism 
proposed regarding the role of Tyr373 in DNA cleavage as discussed early in the introduction and 
reported by Bagneris, et.al.12 
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Figure 2.12. Pose view of H7 in the active site of KSHV. H-bonding is shown as yellow dashed lines, electrostatic 
interactions in pink dashed lines. 
 
2.4.3. Docking of selected pyridone derivatives 
In general, the pyridone series had low activity against UL12 except few molecules with 
hydrophobic groups. The molecule P16 was docked and the interactions are shown in Figure 2.13. 
This molecule forms only electrostatic interactions with the two Mg2+ ions. No other interactions 
were shown in the active site. Again, it lacks the essential interactions with Tyr373.  
 
Figure 2.13. Binding view of P16 in the active site of KSHV. Electrostatic interactions are shown in dashed pink 
line. 
 
The molecule P43 had significant activity against UL12 and it is interesting to know if the same 
is true about this motif; formation of interactions with the Tyr373. The docking showed that the 
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molecule has indeed formed edge to face interactions with Tyr373. In addition, it coordinates to 
the two Mg2+ ions (Figure 2.14).  
 
Figure 2.14. Binding view of P43 in the active site of KSHV. Edge to face interactions is shown in dashed blue 
lines. 
2.5. Conclusion 
In this study small molecules were developed to target the alkaline nuclease enzyme (UL12). Three 
motifs were used in this study: tropolone, hydroxyquinoline and pyridone. Tropolone derivatives 
didn’t show a potency against this enzyme. The hydroxyquinoline series showed a significant 
activity against UL12. Among this series only the ones with hydrophobic moiety resulted in 
activity against UL12. The same was observed regarding the pyridone series. Molecular modeling 
of the active compounds revealed what could be a reason for this activity. The results from docking 
analysis showed that the presence of interactions with Tyr373 lead to a significant increase in the 
potency of the molecule being studied. The role of Tyr373 in the active site of KSHV-SOX appears 
to be important and essential in drug development for this target.  
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2.6. Materials and methods 
2.6.1. Molecular modeling 
Molecular modeling was carried out using Schrödinger Small-Molecule Drug Discovery and 
Biologics Suites 2017-4.14 The crystal structure of KSHV-SOX (PDB code 3POV) complexed 
with DNA was used. The structure was prepared for docking using Protein Preparation Wizard 
(Schrödinger 2017-4). Missing side chains were filled using prime. Water molecules greater than 
5 Å were deleted.  Heteroatoms states were generated using Epik15 with pH 7.0 ± 2.0 and zero-
order bonds to metals created, followed by the generation of metal binding states. Sample water 
orientations using PROPKA with pH 7.0, waters less than 3 H-bonds to non-waters were removed 
and the protein was minimized using OPLS316 to converge heavy atoms to an RMSD of 0.3 Å.  
The active site was defined using the receptor grid generation tool by picking the residues (Asp 
221, Ile 245, Glu 184 and Tyr 373) around the Mg2+ ion. Ligands with length less than or equal to 
15 Å was allowed for docking. All other parameters were used as is. All compounds were 
constructed using Maestro’s building tool17 and energetically minimized, LigPrep18 was used to 
generate different ionization states at pH 7.0 ± 2.0 using Epik.15 The ligands were desalted and 
different tautomers were generated. All dockings were carried out using Glide SP19 (version 7.7) 
and all other parameters kept with the default values.  
2.6.2. Picogreen assay20  
Linearized vector (pSak – 4 Kb) with 3’ overhangs diluted to (5 ng/ µL) in EB buffer (10 mM 
Tris-HCl pH 8.5).  dsDNA substrate can be diluted to appropriate concentration practical for the 
experiment.   PCR strip tube (8-tubes) containing the appropriate volume needed for the number 
of reactions planned were prepared.  Nuclease buffer was prepared by mixing 20 mM Tris-HCl 
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pH 8.2, 40 mM NaCl, 5 mM MgCl2 and 1 mM DTT (Add fresh from 1M stock before experiment). 
UL12 protein dilute to 25 ng/ µL using this buffer: 10% glycerol, 20 mM potassium phosphate pH 
8.0, 5 mM BME. 100  µL of 0.5 M EDTA was added to a column of 96-well plate for Quenching 
reaction. Number of columns with 200  µL of TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA) 
were marked for preparing reactions of PicoGreen analysis. PicoGreen reagent (Invitrogen Cat # 
P7581): a dilution of 1:200 in TE was made an amber or black plastic centrifuge tube and stored 
at room temp protected from light and used within 4 hours. Measurements were made with the 
Spectra Max 3 plate reader in a 96-well Fluotrac 200 black immunology plate (Greiner bio-one 
Cat # 655076/077) with excitation at 485 nm and emission at 520 nm, Cut Off 530 nm.  
Nuclease Reactions (30  µL final volume for each reaction): 
 
• Two cocktails were prepared on ice, one containing: nuclease buffer, ddH2O, and UL12 
and the second containing nuclease buffer and ddH2O for dsDNA control (see Reaction 
Table below) 
Reaction Table:  listed in the order of addition 
 
 UL12 
1x 
dsDNA 
1x 
10x nuclease buffer 3.0  µL 3.0  µL 
ddH2O 23.4   µL 24.5   µL 
UL12 (25 ng/ µL) 1.1  µL X 
100% DMSO or inhibitor*  0.5  µL 0.5  µL 
dsDNA substrate (5ng/ µL)** 2.0  µL 2.0  µL 
 *add to each well and incubate with UL12 10 min at 37 °C 
**add to start reaction after 10 min incubation with DMSO or compound 
 
27.5  µL from either UL12 or dsDNA was added to the cocktail into the appropriate wells of 96-
well PCR micro plate (BioRad Cat# MLL9601) contained in 96-well ice block to keep samples 
cold. The samples were then heated to 37 °C. 0.5  µL of appropriate compound was added using 
8-well multi-channel pipet, column by column (time 20 sec between each. Keep this time 
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interval consistent when adding dsDNA and EDTA in subsequent steps). UL12 was incubated 
with the compound 10 min, then the reaction was initiated with the addition of 2  µL dsDNA (10 
ng). After 15 min reaction was quenched with 3  µL of 0.5 M EDTA (45 mM final). Once final 
column of samples was quenched, the micro plate was moved to 96-well ice block. 67  µL of TE 
buffer was added to each well to increase the volume to 100  µL. 100  µL PicoGreen reagent was 
added and mixed well. 190 µL was added to the appropriate well of 96-well plate (Fluotrac 200 
black immunology plate). The fluorescence was measured in plate reader at an excitation of 485 
nm and emission 520 nm with cut off 530 nm.  
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Chapter Three 
 
 
Targeting E. coli enolase 
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3.1. Introduction  
 
Escherichia coli enolase is a metalloenzyme that exists in the cytoplasm of prokaryotes and 
eukaryotes. It is a glycolytic enzyme that reversibly dehydrate 2-phosphoglycerate (2-PGA) into 
2-phosphoenol pyruvate (PEP), Scheme 3.1. This enzyme requires the presence of the metal ion 
magnesium (Mg2+) in the active site. It has been reported that enolase might enhance bacterial 
resistance, invasiveness and tissue damage in host cells by its adhesive properties.1 In 
Streptococcus canis, enolase is displayed on the surface of this bacterium which acts as 
plasminogen binding protein into the host cell. Binding of this enzyme to the human plasminogen 
enhances bacterial survival and results in antibiotic resistance.2 It is also reported that enolase in 
Streptococcus pneumoniae when it binds to human plasminogen, facilitates its penetration through 
cell membrane to the host cell.3   
 
Scheme 3.1. Formation of PEP using enolase. 
In Pseudomonas aeroginosa bacterium, enolase is found to increase bacterial susceptibility to 
neutrophil that responsible for killing bacteria. It does so by altering the expression of two 
oxidative stress responsive genes (ahpB, ahpC) which results in bacterial tolerance to oxidative 
stresses and hence bacterial resistance.4 In addition, enolase is part of the bacterial RNA 
degradosome that plays a role in mRNA degradation. This degradation occurs when enolase alters 
specific messages that regulate the degradation enzymes involved in energy generating pathways.5 
The product of enolase catalytic activity (PEP) has been reported to be essential for bacteria. The 
product PEP is used as a substrate in the glycolytic cycle to produce energy (ATP) and pyruvic 
acid (Figure 3.1). In addition, PEP is used as a cosubstrate with the nucleotide diphosphate 
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acetylglucosamine (UDP-GlcNAc) to form UDP-GlcNAc-enolpyruvate a precursor in cell wall 
biosynthesis in bacteria. This process is catalyzed by the bacterial enzyme MurA (Figure 3.2-a).6  
 
Figure 3.1. Role of enolase in the glycolytic cycle.7 
 
MurA enzyme is conserved among both gram-positive and gram-negative bacterial species. 
Deleting this enzyme from E. coli and Sptreptococcus pneumeniae resulted in bacterial death. This 
enzyme does not have a mammalian homolog which makes it a good target for antibiotic drug 
development. The drug Fosfomycin is marketed as an antibiotic for MurA enzyme (Figure 3.2-b).8  
 
Figure 3.2. a) Use of PEP as a substrate by MurA in the synthesis of UDP-GlcNAc-enolpyruvate. B) Inhibition of 
MurA by the antibiotic Fosfomycin.8 
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MurA enzyme is essential for the biosynthetic pathway of peptidoglycan. It catalyzes the transfer 
of an enolpyruvate residue from phosphenolpyruvate to a position 3 of UDP-N-acetylglucosamine. 
This is the first step in the cell wall biosynthesis and MurA is highly conserved among various 
bacterial species.9 
The crystal structure of E. coli enolase has been reported in the literature10 and the active site 
contains Mg2+ ion (Figure 3.3). The presence of metal ion in the active site can be used to design 
inhibitors that coordinate to this metal and block the activity of this enzyme.  
 
Figure 3.3. The active site of E. coli enolase enzyme with the important residues labeled, Mg2+ ion in purple color 
(PDB code 1E9I). 
 
As discussed above, this enzyme is essential across various bacterial pathogens. Targeting this 
enzyme may result in developing abroad spectrum antibiotic. In this study, three motifs were used 
to target E. coli enolase: tropolone, hydroxyquinoline and pyridone. In addition to this series, the 
natural product SF-2312 was synthesized according to a reported method.11 Analog of this 
compound was synthesized where the phosphonic group is replaced by sulfonic acid group. We 
are intrigued in this natural product since it was reported to inhibit human enolase with IC50 in the 
nanomolar range.  
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Furthermore, studies showed that SF-2312 had a strong activity against several strains of bacteria; 
Salmonella and Staphylococcus and moderate activity against E. coli.12 The moderate activity of 
SF-2312 against E. coli enolase was hypothesized to its lack of penetration to cell membrane. The 
presence of phosphonic acid moiety with highly negative charge renders its permeability and 
consequently reduces its potency.  
3.2. Results and discussions 
The three proposed motifs and SF-2312 were screened against E. coli enolase. Similar derivatives 
used to target UL12 was used in this experiment. In designing these compounds, we focused on 
their ability to chelate metal ions. All of these derivatives were built with metal binding groups-
carboxamide and hydroxyl groups.   Most of the derivatives didn’t result in a significant activity 
against enolase enzyme between 10-20 µM concentrations. Enolase inhibition was measured 
spectroscopically by monitoring the formation of PEP from 2-PGA at 240 nm. The enzyme was 
incubated with the inhibitor first at room temperature. Then, the substrate 2-PGA was added and 
left for 5 min before measuring the absorbance.  This absorbance was compared to the absorbance 
of the enzyme in the absence of inhibitor. High absorbance indicates the formation of PEP and the 
enzyme is active. The following sections contain detailed results for each motif.  
3.2.1. Evaluation of Tropolone derivatives against E. coli enolase 
The tropolone series didn’t show high potency against enolase. We screened different substituents 
aiming to target this enzyme and inhibit it (Table 3.1).  This motif has a metal binding group that 
can chelate with two metal ions (two magnesium ions for enolase enzyme). Two compounds were 
relatively having a noticeable activity T2 and T8 at 10 µM. The molecule T2 has a benzyl 
substituent and T8 cyclopropyl methyl group.  Since this new amide group didn’t result in an 
increase in the activity, we decided to install a different group that mimic the substrate. The 
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substrate 2-PGA has a phosphate and a carboxylic acid group. The goal was to install a phosphonic 
acid group on tropolone and evaluate its activity against enolase enzyme. The synthesis of this new 
motif was achieved and the molecule (T12) was screened against enolase. Unfortunately, this new 
motif didn’t increase the activity against enolase. This series didn’t give valuable information to 
help in building and design new derivatives. The next step was to evaluate another motif with a 
metal binding group.  
Table 3.1. Evaluations of tropolone derivatives against E. coli enolase enzyme.  
Identifier Compound structure  %inhibition at 10 µM 
T2  46 
T4 
 
37 
T6  68% at 20 µM 
T8 
 
56 
T10 
 
38 
T12 
 
50% at 20 µM 
 
3.2.2. Evaluation of pyridone derivatives against E. coli enolase 
This motif has two sites for diversification and it will be valuable to understand if one site can 
affect the activity of these derivatives against enolase enzyme. The first set of pyridone derivatives 
were evaluated while keeping R1 benzyl group and varying R2 (Table 3.2). The results didn’t show 
a significant increase in the activity against enolase. The activity of this set of compounds was 
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similar to tropolone derivatives with average value of 50% at 10  µM. No large variations were 
observed in the activity of these derivatives. This set can’t provide information to design more 
active compounds.  
Table 3.2. Evaluation of pyridone derivatives against enolase enzyme at 10 µM.   
Identifier Compound structure %inhibition Identifier Compound structure  %inhibition 
P3 
 
65 P5 
 
59 
P7 
 
54 P9 
 
49 
P11 
 
56 P12 
 
51 
 
Another set of compounds was prepared and evaluated against enolase. This new set contains a 
smaller substituent (cyclopropyl group) at R1. In this new set, the R2 substituents were selected to 
be more polar to increase H-bonding with the active site residues (Table 3.3). The molecule P26 
was prepared with pyrazole ring to maximize H-bonding and to chelate with Mg2+ ion. It has an 
extra chelating group guanidine that can coordinate through the nitrogen to a metal ion and at the 
same time can serve as H-bond donor. This molecule was further modified by removing the 
pyrazole ring which resulted in P27. This new molecule can form multiple H-bonds with the active 
site residues and chelate with metal ions. All of these modifications were designed to probe any 
information about the active site functionality and catalytic activity. The results again were 
consistent with the first set of molecules. All values were around 50% inhibition at 10 µM. 
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Removing the pyrazole ring from P26 resulted in only 8% increase in the activity of this 
compound. No lead compound was observed in this series.  
Table 3.3. Evaluation of pyridone against enolase enzyme at 10 µM.  
Identifier Compound structure %inhibition Identifier  Compound structure  %inhibition 
P18 
 
53  P20 
 
29 
P22 
 
55 P26 
 
40 
P27 
 
48 P29 
 
41 
P31 
 
40 P32 
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3.2.3. Evaluation of 8-hydroxyquinoline-7-carboxamide derivatives against E. coli enolase 
Derivatives of the third motif were prepared to probe additional information about the active site 
residues. These derivatives were designed to target any hydrophobic interactions in the active site. 
One derivative was prepared with R = benzyl as in H1 with a methylene spacer link between the 
amide nitrogen and the phenyl ring (Scheme 3.2). This derivative had 48% inhibitory value against 
enolase (Table 3.4). Replacing the benzyl group with the morpholine H2 resulted in 49% 
inhibition.  
 
Scheme 3.2. General motif of the 8-hydroxyquinoline-7-carboxamide. 
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Morpholine can form H-bonding and it is not planer compared the benzyl group. There was no 
effect of changing the benzyl with a morpholine substituent on the activity of this molecule. 
Additional derivative H3 was prepared where the benzyl has a methoxy group at C2 of the ring. 
The 2-methoxy benzyl caused an increase of 17% in the activity of this molecule compared to H1 
derivative. Additional derivatives were prepared by varying the groups and the position at the 
benzyl ring. The derivatives H4 and H5 didn’t increase the potency against enolase. Interestingly, 
replacing the bromide in H6 with fluoride atom in H7 resulted in a significant decrease in the 
activity of H7. Overall, the inhibitory values of these derivatives were similar to the tropolone and 
pyridone motifs.  
Table 3.4. Evaluation of hydroxyquinoline derivatives against enolase enzyme at 10 µM.  
Identifier Compound structure  %inhibition 
H1  48% 
H2 
 
49% 
H3  65% 
H4 
 
67% at 20 µM 
H5 
 
35% 
H6 
 
49% 
H7 
 
26% 
 
3.3. Crystal structure of E. coli enolase complexed with the substrate-product  
The crystal structure of E. coli enolase co-crystallized with the substrate (2-PGA) was determined 
in our lab at resolution of 1.8 Å (Figure 3.4). The substrate has multiple interactions with the active 
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site residues. First, it chelates through the carboxylic group to Mg1 and the phosphate group to 
Mg2. The distance between these two metal ions is 4.09 Å calculated using the software Maestro, 
Schrödinger Suite.13 The substrate has several H-bonding with the active site residues. It forms H-
bonding with Glu167, Glu208 through the hydroxyl group. This group is removed when 
phosphoenolpyruvate (PEP) is formed. The other H-bonding is formed between Lys392, Lys341 
and the carboxylic group. Additional H-bonding is shown between His158, Ser371, Arg370 and 
the phosphate group. These interactions provide this substrate with strong binding affinity to the 
active site of enolase. Docking of selected derivatives synthesized in this study didn’t show 
multiple interactions like the substrate. An inhibitor can be active if it overcomes these strong 
interactions between the substrate and the active site residues.  
 
Figure 3.4. Crystal structure of E. coli enolase active site co-crystallized with substrate (2-PGA, PDB code 6BFY). 
H-bonding is shown in dashed yellow line, ligand in caped sticks.  
 
The crystal structure of enolase complexed with the product (PEP) was fortunately determined in 
our lab (Figure 3.5). This structure reveals more information about the catalytic activity of this 
enzyme. The product PEP coordinates with only one Mg2+ ion in the active site. Interestingly, the 
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enzyme undergoes conformational changes in the active site upon reaction completion. The 
distance between Mg1 and the loop with Ser41 is 9.23 Å compared to 6.84 Å in the substrate bound 
structure (Figure 3.4). His158 does not coordinate to the ligand and the active site is in the open 
form compared to the closed form with the substrate bound.  
 
Figure 3.5. Crystal structure of E. coli enolase active site complexed with product (PEP, PDB code 6BFZ). H-
bonding is shown in dashed yellow line, ligand in caped sticks 
 
These two structures provide valuable information about the active site catalytic activity in 
transforming 2-PGA into PEP. Designing an inhibitor to bind in the presence of the substrate (2-
PGA) needs to have the following properties. First, it needs to form multiple interactions with the 
active site residues to overcome the binding strength of substrate into the active site. Second, the 
ligand is required to fit in the active site pocket and possibly coordinates with two Mg2+ ions in 
order for the enzyme to be in the closed form. Third, it should possess metal binding group that 
can chelate the active site metal ions. Finally, the presence of groups (carboxylic, phosphonic acid) 
that mimic the substrate is preferred. 
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3.4. Targeting E. coli enolase with the natural product SF-2312 
The natural product SF-2312 was a good fit for the enolase inhibition based on the above analysis. 
This molecule contains a phosphonic acid group which mimics the substrate phosphate group (2-
PGA, Figure 3.6). In addition, it has the hydroxamic acid group that can coordinate with Mg2+ ion 
in the active site. This compound was evaluated and the IC50 was determined to be 33 nM. 
Previously, it was reported that this compound inhibited the human enolase. We here determined 
the crystal structure of E. coli enolase complexed with SF-2312 (Figure 3.7).  
 
Figure 3.6. The structure of SF-2312. 
 
Figure 3.7. Crystal structure of E. coli enolase active site co-crystallized with SF-2312 (PDB code 6D3Q). H-
bonding is shown in dashed yellow line, ligand in caped sticks. 
 
The crystal structure shows that this molecule mimics the substrate in that it chelates to the two 
Mg2+ ions in the active site. The distance between Mg1 and the loop with Ser41 is 7.67 Å compared 
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to 6.84 Å in the substrate bound structure. This distance is between the substrate and the product 
bound structure. Although the active site didn’t close tightly on SF-2312 compared to the substrate, 
it was active and potent against this enzyme. This molecule forms multiple H-bonds with the 
nearby residues. The hydroxylamine and the carbonyl of the pyrrolidinone ring coordinate to the 
Mg1 forming a 5-membered ring. The formation of this 5-membered ring contributes to the 
stability of this motif in the active site as reported.14 It also forms multiple H-bonding with the 
active site residues. Interestingly, His158 is pointing away from the active site compared to the 
substrate bound structure.  
To further address the affinity of the SF-2312 to the enolase, the thermal stability of this complex 
was evaluated by DSC experiment. Binding of the ligand to the active site results in the 
stabilization of protein which becomes crystal like material compared to the native structure. The 
process of binding a ligand into a protein results in conformational change in the protein structure 
and reorganizational of the solvent molecules around the protein surface. The thermal stability 
result showed a significant increase in the protein melting temperature by 28 ºC (Figure 3.8).  
 
Figure 3.8. DSC data for the enolase enzyme complexed with SF-2312. 
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This high shift in the melting temperature reflects a strong binding of SF-2312 to the active site of 
enolase. It is interesting to compare the thermal shift of the enolase protein complexed with the 
substrate.  In vivo testing of SF-2312 against E. coli showed no significant potency although it has 
high activity against enolase enzyme. This molecule has the phosphonic group that ionizes and 
form a total charge of -2. This might render its ability to penetrate the cell wall of bacteria. 
Replacing this group with a sulfonic acid would result in a decrease of the charge to -1. An analog 
of SF-2312 where the hydroxyl group is oxidized to a keto and phosphonic acid is replaced by 
sulfonic is commercially available (Figure 3.9).  
 
Figure 3.9. Commercially available an analog of SF-2312 (NHS) where the hydroxyl group at C5 is oxidized to a 
keto group and the phosphonic group is replaced by a sulfonic acid.   
 
This molecule was evaluated at 10  µM and resulted in 47% inhibition of enolase enzyme. This is 
a very low activity compared to the SF-2312. The low activity needs to be addressed and 
investigated by two approaches. The first approach was to synthesize an exact analog of SF-2312 
with only one modification, the replacement of the phosphonic group with a sulfonic acid. This 
requires multistep synthesis and a designed synthetic route. The second approach was to oxidize 
the hydroxyl group at C5 of the SF-2312. The second approach was chosen first and the analog 
was prepared. Surprisingly, this new analog has very low activity compared to SF-2312. The IC50 
of this motif was 9.1 µM which interestingly very close to the NHS compound (Table 3.5). This 
suggests that the sulfonic analog with C5 having a hydroxyl group might be very potent like the 
SF-2312.  
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Table 3.5. Evaluations of SF-2312 analogs against E. coli enolase.  
Compound Structure %inhibition 
 
47% at 10 µM 
 
50% at 9.1 µM 
 
3.5. Crystal structure of E. coli enolase with the tartaric acid 
An attempt to co-crystallize the enolase enzyme with NHS wasn’t successful. However, a new 
structure was determined with the tartaric acid bound in the active site (Figure 3.10). Tartaric acid 
is used as a component in the crystallization method with a concentration of 0.2 M. This high 
concentration caused the co-crystallization of the tartaric acid with the protein.  
 
Figure 3.10. Crystal structure of E. coli enolase active site cocrystallized with tartaric acid. Ligand is shown in 
caped sticks. 
 
We thought about modifying this native ligand by installing a hydroxamic acid in one side and 
keep one carboxylic acid unchanged (Figure 3.11). The hydroxamic group was chosen carefully 
to bind the Mg2+ ion and form a 5-membered ring similar to SF-2312. Both of these molecules 
N
O
O
S
OH
O
O
HO
N
O
OH
O
P
O OH
HO
 64 
 
 
were evaluated against enolase enzyme. The IC50 of tartaric acid was 30 mM and for its analog 
400 µM which results in 75-fold an increase in the potency. This result supports the analysis 
obtained from the crystal structures of SF-2312 (Figure 3.7).  The formation of 5-membered ring 
provides stability of the ligand in the ligand active site. 
 
Figure 3.11. The structures of tartaric acid and its analog with hydroxamic group.  
3.6. Molecular modeling 
The crystal structure of the enolase co-crystallized with SF-2312 was used for molecular docking. 
The goal of this experiment was to investigate the interactions between the weakly active 
compounds and compare it with the SF-2312. The crystal structure has six chains (A-F) with each 
one has SF-2312 co-crystallized in. All of these chains are equivalent and the docking experiment 
was carried out on chain A. The ligand SF-2312 was removed from the active site and docked 
again into the same chain to validate the docking process. The calculated root mean square 
deviation (RMSD) between the native ligand and the docked ligand was 3.78 Å (Figure 3.12).  
 
Figure 3.12. (a) Binding view of the native ligand, (b) and the docked ligand SF-2312. H-bonding is shown in yellow 
dashed lines, ligands in caped sticks.  
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The docked ligand and the native have similar interactions with the active site residues. It forms 
H-bonding with Arg370 and Ser41. The hydroxyl group at C5 interacts with Lys392 and Glu167. 
These similar interactions of the docked ligand support the validity of molecular docking. The next 
experiment was to dock the weakly binding ligands to visualize the interactions with the active 
site residues. The aim was to understand the reason why converting the hydroxyl group at C5 into 
a carbonyl resulted in a significant decrease in the activity of this motif.  
Both analogs of SF-2312 were docked in the active site of enolase. The analysis of this docking 
reveals that both molecules lack the interactions between C5 residue and Lys392. The native ligand 
has this interaction in addition to Glu167. None of these interactions exit in the analogs of SF-
2312 (Figure 3.13). This indicates that this of type of interaction is essential for the activity of this 
motif against E. coli enolase.  
  
Figure 3.13. View pose of SF-2312 analog with C5 is a carbonyl group (a) and the sulfonic acid analog (b). H-bonding 
is shown in dashed yellow lines, ligand in caped sticks.  
 
The substrate 2-PGA was docked into the enolase active site. This experiment was carried out to 
find if there are similarities between the interactions of 2-PGA in the active site with that SF-2312. 
The docking result reveals similar interactions with the active site residues. Importantly, it shows 
H-bonding interactions with Lys392 through the carbonyl oxygen of the carboxylic acid group 
(Figure 3.14).  
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It can be concluded that the formation of H-bonding with Lys392 is essential in the activity of a 
designed molecule against E. coli enolase. Any molecule that lacks this interaction would result in 
a low potency against enolase enzyme.  
 
Figure 3.14. Binding view of the substrate (2-PGA) in the active site of enolase. H-bonding is shown in yellow and 
pink dashed lines, ligands in caped sticks.  
 
3.7. Conclusion: 
The three motifs (tropolone, pyridone and hydroxyquinoline) were screened against E. coli 
enolase. The in vitro assays showed low activity of the derivatives of these motifs. The natural 
product SF-2312 was found to be potent against enolase with IC50 of 33 nM. Two analogs of SF-
2312 where the C5 is a carbonyl group had low activity against enolase. Molecular modeling 
indicates that the hydroxyl group at C5 is essential in the activity of SF-2312. The presence of this 
group forms H-bonding with Lys392 which results in the stabilization of the protein and increase 
the binding affinity of the ligand.  
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3.8. Materials and methods. 
3.8.1. Enolase activity and inhibition assay 
The activity of recombinant tagged and untagged enolase was determined by direct monitoring of 
the increase in PEP absorbance at 240 nm, using DU 640 spectrophotometer (Beckman). The 
standard assay contained 50 mM Tris pH 8.0, 0.1 M KCl, 0.5 mM 2-phosphoglycerate (as the 
glycolysis substrate) and 1 mM MgSO4. The reactions were carried out at 25 °C, at a final volume 
of 500 µL. One unit of enolase activity was defined as the amount of protein which catalyzes the 
synthesis formation of 1 µmol PEP from 2-PGA in 1 minute under these standard conditions. The 
concentration of PEP was determined using a molar extinction coefficient (Ɛ240 nm= 1,300  
M-1 cm-1).  
Inhibition of enolase activity by tropolones was performed at a constant enolase concentration of 
40 nM and inhibitor concentrations close to the MICs values. The compounds supplied in 50 mM 
Tris pH 8.0 and 5% DMSO were preincubated with the protein sample for 5 minutes in the assay 
buffer consisting of 50 mM Tris pH 8.0, 0.1 M KCl and 1 mM MgSO4. The reaction was initiated 
by the addition of 2-PGA substrate at 1.0 mM final concentration. The decrease in enolase activity 
upon inhibition was monitored at 15 second intervals for a period of 4 minutes at 240 nm. The 
measurements were repeated and the average half maximal inhibitory concentrations (IC50) were 
calculated from initial rates of absorbance increase. Baker’s yeast enolase (Sigma-Aldrich) served 
as a positive control in the assay. 
3.8.2. Molecular modeling  
Molecular modeling was carried out using Schrödinger Small-Molecule Drug Discovery and 
Biologics Suites 2017-4.13 The crystal structure of E. Coli enolase (PDB code 6D3Q) co-
crystallized with 2-PGA and determined in herein was used. The structure was prepared for 
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docking using Protein Preparation Wizard (Schrödinger 2017-4). Missing hydrogen atoms were 
added, heteroatoms states were generated using Epik15 with pH 7.0 ± 2.0 and zero-order bonds to 
metals created, followed by the generation of metal binding states. Sample water orientations using 
PROPKA with pH 7.0, waters less than 3 H-bonds to non-waters were removed and the protein 
was minimized using OPLS316 to converge heavy atoms to an RMSD of 0.3 Å.  
The active site was defined using the receptor grid generation tool by picking the native ligand 
(SF-2312). Ligands with length less than or equal to 15 Å were allowed for docking. Metal 
coordination constraint was selected in the grid generation. All other parameters were used as is. 
All compounds were constructed using Maestro’s building tool17 and energetically minimized, 
LigPrep18 was used to generate different ionization states at pH 7.0 ± 2.0 using Epik.15 The ligands 
were desalted and different tautomers were generated. All dockings were carried out using Glide 
SP18 (version 7.7) and all other parameters kept with the default values.  
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Chapter 4 
Developing inhibitors for the human acyl protein thioesterases 
APT1  
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4.1. Introduction 
Ras are membrane bound proteins that are encoded by Ras genes. These proteins act as 
molecular switches that control signal transduction from cell to cell. They convert the signals 
from the cell membrane to the nucleus. These signals lead to protein synthesis and regulation of 
cell survival and proliferation.1 Activation of the Ras protein occurs through the palmitoylation 
and depalmitoylation cycle. The palmitoylation of Ras involves the attachment of a long chain 
fatty acid (palmitic acid) to the cysteine residue of Ras. This process which involves the 
localization of this protein in the plasma membrane is a reversible modification for Ras protein.2  
Hyperactivation of Ras leads to uncontrolled cell proliferation and formation of tumors. 
Therefore, regulation of Ras has become a focus in drug development for cancer therapy.3 The 
depalmitoylation of Ras involves the hydrolysis of the thioester linkage by the enzyme acyl 
protein thioesterase 1 (APT1). This enzyme has a serine residue that acts as a nucleophile in the 
hydrolysis of this bond. Regulation of the palmitoylation cycle can be achieved by the inhibition 
of the APT1 enzyme.4,5 
 
Figure 4.1. Palmitoylation cycle and the role of APT1 enzyme in this cycle.5 
 
Acyl protein thioesterase inhibit rs as probe of
dynamic S-palmitoylation
Dahvid Davdaa and Brent R. Martin*ab
Prote n palmitoylation describes the hydrophobic post-translational modification of cy teine residues in
certain proteins, and is required for the spatial organization and composition of cellular membrane
environments. Certain palmitoylated proteins are processed by acyl protein thioesterase (APT) enzymes,
which catalyze thioester hydrolysis of palmitoylated cysteine residues. Inhibiting APT enzymes disrupts
Ras trafficking and attenuates oncogenic growth signaling, highlighting these enzymes as potential
t erapeutic targ ts. As members of the serine hydrolase enzyme family, APT enzymes can be assayed by
fluorophosphonate activity-based protein profiling (ABPP) methods, allowing rapid profiling of inhibitor
selectivity and potency. In this review, we discuss recent progress in the development of potent and
selective inhibitors to APT enzymes, including both reversible and irreversible inhibitor chemotypes.
These examples highlight how ABPP methods integrate with medicinal chemistry for the discovery and
optimization of inhibitors in complex proteomes.
Introduction
Protein palmitoylation describes the post-translational attach-
ment of a long-chain fatty acid to a cysteine residue.1 This
hydrophobicmodication is critical for the function, trafficking,
and localization of diverse proteins with central roles in adhe-
sion, signaling, and organelle structure. Recent proteomics
studies have annotated hundreds of palmitoylated proteins,2–8
uncovering a widespread role for such a hydrophobic modica-
tion. Due to the unstable thioester linkage, protein palmitoyla-
tion undergoes steady hydrolysis in cells, generally with a half-
life of less than a few hours. Unlike static modications like
protein prenylation or myristoylation, protein palmitoylation
provides a unique mechanism to reversibly regulate the
membrane association of modied proteins. Indeed, dynamic
palmitoylation of oncogenic HRas is required to mediate cell
transformation.9 Furthermore, activation of Ras or the G-protein
Gas stimulates palmitoylation turnover,10,11 suggesting palmi-
toylation dynamics may be an essential trigger in the activation
or deactivation of distinct signaling pathways. In this model,
protein palmitoyl thioesterases catalyze the de-palmitoylation
and release of certain proteins from the plasma membrane,
potentially attenuating membrane-coupled signaling pathways
(Fig. 1). The released proteins can then undergo re-palmitoyla-
tion by endomembrane-bound DHHC palmitoyl-transferas s,
restoring palmitoylation and resetting the cycle.
Given the evidence that HRas participates in an acylation/
deacylation cycle,12 a putative HRas thioesterase termed acyl
protein thioesterase (APT1) was identied from soluble rat liver
Fig. 1 A dynamic S-palmitoylation cycle regulates the membrane
association and activity of certain palmitoylated proteins. Certain
stimuli cause an acyl protein thioesterase to catalyze thioester hydro-
lysis of palmitoylated cysteine residues. De-palmitoylation liberates the
protein from the plasma membrane, allowing it to segregate to the
cytosol disrupting interactions with membrane-associated signaling
complexes. The protein can then undergo re-palmitoylation by Golgi-
resident DHHC palmitoyl transferases, transport back to the plasma
membrane, and re-associate with signaling partners.
aProgram in Chemical Biology, University of Michigan, 930. N. University Ave., Ann
Arbor, MI 48109, USA. E-mail: brentrm@umich.edu
bDepartment of Chemistry, University of Michigan, 930. N. University Ave., Ann Arbor,
MI 48109, USA
Cite this:Med. Chem. Commun., 2014,
5, 268
Received 30th October 2013
Accepted 25th November 2013
DOI: 10.1039/c3md00333g
www.rsc.org/medchemcomm
268 | Med. Chem. Commun., 2014, 5, 268–276 This journal is © The Royal Society of Chemistry 2014
MedChemComm
REVIEW
Pu
bli
sh
ed
 on
 02
 D
ec
em
be
r 2
01
3. 
Do
wn
loa
de
d b
y U
niv
ers
ity
 of
 C
on
ne
cti
cu
t o
n 2
3/0
5/2
01
8 1
9:2
6:2
3. 
View Article Online
View Journal  | View Issue
 73 
Studying human tumor cells showed that oncogenic Ras contributed to 30% of human cancer. 
Mutation in the Ras protein results in a yearly death toll similar to tuberculosis and other 
infectious diseases.5,6 A startegy to inhibit Ras was to regulate the palmitoylation cycle. The 
depalmitoylation step of Ras has been targeted by nonspecific inhibitors of palmitic acid. It was 
found that global inhibition of  the depalmitoylation cycle caused cell damage including healthy 
cells. However, another approach to regulate the palmitoylation cycle is to target a specifc 
protein that activates this cycle. Researchers then focused on the enzyme APT1 and studied its 
enzymatic activity.7,8  
Data from literature for targeting APT1 showed that the Ras protein was localized in the plasma 
membrane. This localization resulted in regulating the palmitoylation and depalmitoylation 
cycle. This was a promising result where this approach can be used in developing probes for 
cancer therapy. This strategy lacks selectivity, leads to impaired localization of Ras and shuts 
down the signaling between cells.9 Another approach to the development of APT1 inhibitors was 
based on protein structural similarity. The APT1 was screened for structural similarities with 
other proteins. The result of this sreening showed that dog gastric lipase enzyme has structural 
similarities to APT1. The overlay of the two structures revealed similarities with the acive site 
residues of dog gastric lipase. The active site has three amino acids that are involved in the 
catalytic activity of the lipase. These amino acids were identified as Ser153, His353 and Asp324. 
The analogs of these amino acids in APT1 were found to be Ser114, His203 and Asp169. This 
similarity suggests that molecules that inhibit dog gastric lipase enzyme might inhibit the APT1 
(Figure 4.2).10 
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Figure 4.2. Crystal structure of gastric lipase enzyme with the phosphonate inhibitor (caped sticks). (b) Overlay of 
the gastric lipase enzyme (blue color) and APT1 enzyme (orange) showing the overlap of active site residues. 
 
 
The drug tetrahydrolipstatin is marketed as inhibitor for pancreatic lipase. It also inhibits dog 
gastric lipase and the bile-salt stimulated lipase of human milk.11 Tetrahydrolipstatin has a  
β-lactone core with an aliphatic linear chain at C3 and a polar residue at C4. The lactone ring 
acts as an electrophilic moiety for the nucleophilic attack of the amino acid Ser153 of gastric 
lipase. The initial approach to target APT1 was to screen molecules with a b-lactone motif for 
potential inhibition of this enzyme. The result of the screening revealed a lead compound that 
had activity against this enzyme.  The compound was identified as palmostatin B, which has 
structural similarities with tetrahydrolipstatin. Both structures have an aliphatic chain at C3 and a 
more polar group at C4 of the b-lactone core in tetrahydrolipstatin. In vitro assays showed that 
this lead compound lacked selectivity and potency against APT1 enzyme (Figure 4.3).12  
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Figure 4.3. Structure of tetrahydrolipstatin and Palmostatin B as inhibitor for APT1.12 
Another approach used to identify possible APT1 inhibitors was based on substrate structure 
design. In this approach the structure of the native APT1 substrate (lysophospholipid, 1) was 
analyzed for the binding groups (Figure 4.4). Investigating the substrate revealed that the 
molecule has a negatively charged phosphate group and a positively charged residue (trimethyl 
ammonium group). In addition, a detailed structure investigation of 1 showed that the phosphate 
group is 5 bonds from the ester and 10 bonds away from the positively charged group (trimethyl 
ammonium). Another native APT1 substrate is the H-Ras C-terminus protein 2.  The structure of 
2 has similarities with lysophospholipid 1.  Both of these substrates have three distinct moieties: 
ammonium, (thio-)ester and phosphate/amide.13 
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Figure 4.4. Known APT1 substrates used in the substrate structure design.13 
Based on this analysis a new motif was proposed. The phosphate ester in the native substrate was 
replaced with a sulfone group and the ammonium residue with a dimethylamine with a distance 
of 3 carbons from the sulfur atom. An aliphatic chain was chosen at C3 of the b-lactone, and the 
lactone was selected as the electrophile that Ser114 of APT1 can react with. The importance of 
the β-lactone residue was investigated by replacing it with a methyl ester. The half maximal 
inhibitory concentration (IC50) values were shifted by a factor of 1000 less potent. This indicates 
the importance of this moiety in inhibiting APT1 (Figure 4.5).14,15 
 
                            Figure 4.5. The structure of palmostatin M with the residues labeled. 
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In this study, we aimed to synthesize analogs of palmostatin M and study the effect of changing 
the chains at C3 and C4 of the b-lactone. In palmostatin M, the chain at C4 of the b-lactone has 
an amine and a sulfone group. In order to study the effects of changes at C3, it would be more 
straightforward if a simpler chain at C4 could be used to determine the feasibility of this 
synthesized analog where both chains at C3 and C4 of the b-lactone are all carbons. In addition, 
we wanted to modify the chain at C4 removing the sulfone and the amine separately. Two groups 
in Howell’s lab were working on modifying the chain at C4 of the b-lactone. One group 
modified the C4 by removing the sulfone and keeping the amine. I removed the amine and kept 
the sulfone. In all of these changes, the chain at C3 of the b-lactone was all carbons. In these 
modifications we wanted to study the effect of each group of the chain at C4 on the activity of 
this motif.  
The ultimate goal of our initial studies was to synthesize analogs similar to palmostatin M. 
However, in preparing these analogs we screened the intermediates to get a complete set of 
information about the effect of each chain on the activity of this motif. If one of the C4 modified 
analogs, all of which are more readily accessible than palmostatin M, showed reasonable 
inhibition of APT1, that would allow us to examine the effect of various groups at C3 using a 
methodology previously developed in our group. This method involves the formation of a-
methylene-b-hydroxy ester using Morita Baylis Hillman reaction and the construction of a-
methylene-b-lactone. Diversification of C3 is achieved by cross-metathesis and 1,4-redcution to 
afford analogs similar to palmostatin M (Figure 4.6).  
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Figure 4.6. General method for preparation of palmostatin M. 
4.2. Chemistry  
4.2.1 Synthesis of the first set of analogs 
The proposed modifications at C4 of the b-lactone were carried out and a series of analogs have 
been synthesized. In these analogs the chain first has all carbons at C4 and C3 of the b-lactone. 
The synthesis of this series was achieved in multistep reaction. The commercially available 
undecanal was reacted with methyl acrylate using 3-hydroxyquinuclidinol as a catalyst to 
provide Baylis-Hillman reaction product 1, which was hydrolyzed under basic conditions to give 
2 in 46% two steps (Scheme 4.1).  
 
Scheme 4.1. Preparation of intermediate 2. 
Acid (2) was used to prepare a-alkylidene-b-lactone. Lactone 3 was synthesized by the 
activation of the carboxylic acid using 2-nitrobenzenesulfonyl chloride in the presence of 
Na2CO3. Cross metathesis of lactone 3 with undecene was carried out using Grubbs 2nd 
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generation catalyst to install a hydrophobic chain at C3 (Scheme 4.2). Both isomers (E/Z) were 
separable by column chromatography with the ratio of Z/E (2:1) as found from 1H NMR spectra. 
        
Scheme 4.2. Synthetic route for the lactone formation (3) and the cross-metathesis product (4).  
 
The reduction of the the (Z/E)-4 was chosen to provide both diastereomers of lactone 5 for 
biological assays. The 1,4-reduction was achieved using NaBH4 as the stoichiometric reduction 
and CoCl2(PPh3)2 as the catalyst in an alcoholic solution. This catalyst gave a mixture of isomers 
trans/cis (2:1) where the trans isomer was the major (Scheme 4.3). Reduction using H2 (Pd/C) 
would result mainly in the cis isomer as reported in our lab.  The use of CoCl2(PPh3)2 has been 
reported in the isomerization of terminal alkenes into substituted alkenes.16   
 
Scheme 4.3. 1,4-Reduction of the a-alkylidene-b-lactone using CoCl2(PPh3)2. 
4.2.2 Synthesis of the second set of analogs 
The second set of analogs (13-21) were prepared with the chain at C4 of the b-lactone containing 
a thioether. The chain with the thioether group was synthesized before Baylis-Hillman reaction. 
Commercially available 1,5-pentanediol was brominated to provide 5-bromo-1-pentanol 6. The 
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thioether was installed by SN2 reaction between 6 and 1-pentanethiol to give 7. Formation of 7 
was clean, and 7 was used without purification. Selective oxidation of 7 was carried out using 
Swern oxidation to afford 7 (scheme 4.4).  
 
                                              Scheme 4.4. General method for the synthesis of 7. 
 
Aldehyde 8 was reacted with methyl acrylate using Baylis-Hillman reaction conditions. The 
product of this reaction was hydrolyzed into acid 10 which was used to form b-lactone 11. 
Diversification of the b-lactone at C3 was achieved by the cross-metathesis reaction using 
Hoveyda-Grubbs (II) catalyst (Scheme 4.5).   
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Scheme 4.5. General method for the formation of 12. 
Undecene was crossed coupled with a-methylene-b-lactone 11 to provide a mixture of isomers 
12 Z/E (2:1). These isomers were separable by column chromatography and were used for 
additional modifications. The thioether group of the separated isomers (Z/E) was converted into 
sulfoxide by using H2O2. This reagent was selected since it will stop at the sulfoxide oxidation 
state. Then, they were further oxidized to the sulfone using peroxyacetic acid (CH3COOOH).  
Oxidation was carried out on pure isomers to facilitate the separation of these two isomers 
(Scheme 4.6).  
 
Scheme 4.6. Synthetic route for the sulfoxide and sulfone of Z/E isomers of 11. 
The alkene at C3 of 12 was reduced by CoCl2(PPh3)2 and NaBH4 to provide 17 as a mixture of 
cis and trans isomers (Scheme 4.7). Fortunately, these isomers were separable using column 
chromatography on silica gel. The identity of each isomer was assigned based on what was 
reported in the literature.17  
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Scheme 4.7. Reduction of the alkene at C3 of the b-lactone. 
These two isomers were modified by converting the thioether into sulfoxide and sulfone groups. 
The reaction was conducted on each isomer separately to facilitate the purification (Scheme 4.8).  
 
Scheme 4.8. The conversion of 17 into sulfoxide and sulfone. 
4.2.3 Synthesis of the third set of analogs 
The third modification of the b-lactone motif was carried out by changing the chain at C3 of the 
b-lactone. This chain was replaced with a polar residue containing sulfonamide group.  The 
chain with sulfonamide group was prepared according to a literature method.17 The first step in 
the synthesis was the conversion of 7-bromo-1-heptene to the corresponding sulfonate by 
treatment with Na2SO3. The sulfonate salt was converted to a sulfonyl chloride by using POCl3; 
addition of NH4OH to this intermediate provided the sulfonamide 22. This chain was installed 
into the lactone 11 through cross-metathesis. In this reaction Hoveyda-Grubbs (II) was used. The 
reaction didn’t go to completion after 3 d of reflux, some of the starting material was recovered. 
Product 23 was isolated as a mixture of two isomers Z/E (2:1), Scheme 4.9.  
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Scheme 4.9. Synthesis of 23 with sulfonamide chain at C3 of the b-lactone.  
The Z-isomer was isolated successfully and was used for further modifications. The thioether 
group was converted into the corresponding sulfoxide and sulfone (Scheme 4.10). The identity of 
these compounds was confirmed by NMR spectra and HRMS. The protons adjacent to the 
thioether group were shifted downfield upon the oxidation of sulfur. The protons in the sulfoxide 
compound appeared at 2.73 ppm, and they were shifted to 2.98 ppm in the sulfone.  
 
                                Scheme 4.10. Synthesis of the sulfoxide and sulfone of 23. 
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4.3 Results and discussion 
Analogs of Palmostatin M were screened against APT1. The screening protocol was developed 
by Cravat’s lab for similar analogs.18 The N-ras protein was incubated with the inhibitors at 25 
µM for 30 min at 37 °C. Then, it was incubated with the fluorescent probe FP-rhodamine at 2 
µM for 30 min at 37°C. The samples were analyzed by bel-based activity-based protein profiling 
(ABPP). The inhibitory activity of palmostatin analogs was detected by the loss of FP-rhodamine 
fluorescence.   
The first set of analogs, where the C4 and C3 chains of the b-lactone are all carbons, were 
biologically evaluated. The biological assays showed that these compounds were inactive at 25 
µM (Figures 4.6, 4.7). This result indicates that the presence of a polar chain might be required 
for the activity of this motif against APT1.  
 
 
Figure 4.6. Analogs of Palmostatin M with non-polar chain at C4 and C3 of the β-lactone. 
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 Figure 4.7. In vitro screening of the b-lactone analogs. Compounds KL2-147-3 and KL2-150-30 were synthesized 
by another member of the Howell lab.19 
 
The second set of analogs where the chain at C4 of the b-lactone contains thioether was also 
screened at 25 µM. Both isomers Z/E and their corresponding sulfoxide and sulfone didn’t show 
significant activity against APT1 enzyme (Figures 4.6, 4.8, 4.9). These results provide structural 
information about the activity of the b-lactone motif. This would help in building structural 
activity relationship (SAR) of the b-lactone.  
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Fugure 4.8. Second set of analogs of Palmostatin M with a polar chain at C4 of the β-lactone. 
 
 
Figure 4.9. Screening of the b-lactone series at 25 µM. KL2-164-30 was prepared by a member of Howell’s lab.11  
 
The next set of analogs of this series were evaluated. In this series the carbon at C3 of the b-
lactone was reduced to mimic the motif of Palmostatin M (Figure 4.10). Interestingly, the trans-
isomer with the sulfoxide group was active at 25 µM (compound 9 in Figure 4.7). On the other 
hand, the sulfone analog with the same motif was not active (Figure 4.9). This result was useful 
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since it suggests that the presence of a chain at C4 with a sulfoxide group is required for the 
activity of this motif.  
 
Figure 4.10. Analogs of palmostatin M where C3 of the b-lactone being reduced to Csp3.  
The next modification was to change the chain at C3 of the b-lactone. The first modification was 
explored by combing the sulfur-based modification at C4 with a sulfonamide at C3. The goal of 
this modification was to study the effect of this polar chain on the activity of this motif against 
APT1. The biological assay of b-lactone analogs where C3 has the sulfonamide residue is still in 
progress (Figure 4.10).  
 
Figure 4.10. Analogs of b-lactone with polar group at C3 and C4.  
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4.4 Conclusion 
 
A series of palmostatin analogs was prepared by modifying the chains at C3 and C4 of the b-
lactone. Initially, the chain at C4 was non-polar with all carbon atoms. It was then modified by 
introducing a thioether group 4 bonds away from C4 of the b-lactone. This thioether group was 
converted into sulfoxide and sulfone. Following these modifications, the chain at C3 was 
modified by installing a polar chain with a sulfonamide. Screening of these analogs against 
APT1 was carried out at 25 µM.  Results showed that one analog with the chain at C4 of the b-
lactone containing sulfoxide group and C3 is Csp3 was active. The rest of the analogs didn’t have 
significant activity. The biological values of the sulfonamide analoges are still in progress.  
4.5. Experimental section 
4.5.1. Reagents/Chemicals and instruments 
All chemicals were purchased from commercial sources and used without further purifications. 
CH2Cl2 was distilled over CaH2 and stored over Molecular Sieves 4 Å. Thin-layer 
chromatography (TLC) was conducted using glass TLC plates coated with 0.2 mm silica gel with 
fluorescent indicator. Phosphomolybdic acid was used for staining the TLC plates. Column 
chromatography purification was done using 60 Å porosity, 32-63 Å µm silica gel. 1H,13C and 
NMR spectra were collected on a Bruker DRX-400 (400.144 MHz 1H, 100.65 13C MHz) or 
Bruker Avance 500 (500.13 MHz 1H, 125.65 13C) spectrometer. Chemical shifts are reported in 
ppm downfield from tetramethylsilane (TMS) or using the residual peak of CHCl3 (7.26 ppm) 
for 1H NMR or 77.16 ppm for 13C NMR. All coupling constants are reported in Hertz (Hz). The 
following abbreviations were used to explain the multiplicities: s = singlet, brs = broad singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet. IR spectra were recorded on a Nexus 670 FTIR. 
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High resolution mass spectra (HRMS) were obtained from the University of Connecticut MS 
facility. 
 
3-Hydroxy-2-methylenetridecanoic acid (1). Undecanal (5.0 g, 0.029 mol) and methyl acrylate 
(5.3 mL, 0.059 mol) were transferred to a round bottom flask equipped with a stir bar. 3-hydroxy 
quinuclidinol (940 mg, 7.4 mmol) and MeOH (0.9 mL) were added, and the mixture was stirred 
at rt for 4 d. Then, excess methyl acrylate was removed in vacuo to provide 3-Hydroxy-2-
methylenetridecanoic acid as a yellow oil which was used for the next step without purification. 
1H NMR (300 MHz, CDCl3) d 6.21 (s, 1H), 5.79 (s, 1H), 4.37 (dd, J = 6.5, 6.5 Hz, 1H), 3.77 (s, 
1H), 1.25 (brs, 18H), 0.87 (t, J = 6.3 Hz, 3H).  A solution of 3-Hydroxy-2-methylenetridecanoic 
acid in MeOH (100 mL) and (3.81g, 68 mmol) of KOH dissolved in H2O (50 mL) stirred for 2 d 
at rt. MeOH was removed, and aqueous 2M HCl (100 mL) was added to the residue. It was then 
extracted with Et2O (200 mL), followed by additional extraction with Et2O (2 ´ 100 mL) of the 
aqueous layer. The combined organic extracts were washed with brine (2 ´ 100 mL) and dried 
(MgSO4). The solvent was removed and the crude yellow oil was purified by column 
chromatography on silica gel (petroleum ether/EtOAc 80:20) to provide 1 as a pale-yellow oil 
(3.3 g, 46%): IR (neat) 3321 (br), 2917, 2849, 1690, 1634, 1284 cm-1; 1H NMR (500 MHz, 
CDCl3) d 6.39 (s, 1H), 5.91 (s, 1H), 4.42 (dd, J = 6.6, 6.6 Hz, 1H), 1.67 (m, 2H), 1.43 (m, 1H), 
1.26 (brs, 15H), 0.87 (t, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 171.5, 142.1, 127.7, 
71.8, 36.4, 32.1, 29.8, 29.8, 29.6, 29.5, 26.0, 22.9, 14.3; HRMS (ESI) calcd for C14H27O3  
(M + H)+ m/z  225.1855, found 225.1837. 
OH
OOH
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4-Decyl-3-methyleneoxetan-2-one (2). 3-Hydroxy-2-methylenetridecanoic acid 1 (1.33 g, 5.49 
mmol) was transferred to a round bottom flask and dissolved in CH2Cl2 (50 mL). Anhydrous 
Na2CO3 (3.0 g, 0.028 mol) was added, and the mixture was stirred at rt for 15 min, followed by 
the addition of 2-nitrobenzenesulfonyl chloride (1.74 g, 7.85 mmol). The mixture was stirred for 
5 d at rt, then it was diluted with CH2Cl2 (50 mL) and H2O (50 mL). The solution was stirred 
until two clear layers formed. The layers were separated, and the aqueous layer was extracted 
with CH2Cl2 (3 ´ 50 mL). The combined organic extracts were washed with H2O (100 mL) and 
brine (3 ´ 50 mL) and dried (MgSO4). The solvent was removed resulting in a yellow oil. This 
crude oil was purified by column chromatography on silica gel (petroleum Ether/EtOAc 90:10) 
to afford the product as pale-yellow oil (0.94 g, 76%): 1H NMR (500 MHz, CDCl3) d 5.90 (t, J = 
1.9 Hz, 1H), 5.41 (t, J = 1.7 Hz, 1H), 5.06-4.85 (m, 1H), 1.87-1.81 (m, 2H), 1.51-1.41 (m, 2H), 
1.26 (brs, 14H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 163.8, 146.7, 115.0, 
79.8, 33.5, 32.1, 29.7, 29.8, 29.6, 29.5, 29.4, 24.8, 22.9, 14.3; HRMS (ESI) calcd for C14H25O2 
(M + H)+ m/z  225.1855, found 225.1850.  
 
(E/Z)-4-Decyl-3-decylideneoxetan-2-one (3). 4-Decyl-3-methyleneoxetan-2-one (2) (509 mg, 
2.3 mmol) and undecane (0.70 mL, 3.4 mmol) were transferred to a round bottom flask and 
dissolved in CH2Cl2 (12 mL). Grubbs (II) catalyst (43 mg, 0.069 mmol) was added, and the 
solution was heated at 40 °C for 12 h. It was then concentrated, and the crude product was 
purified by column chromatography on silica gel (petroleum ether/EtOAc 98:2) to provide a 
O
O
O
O
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mixture of isomers Z/E (2:1) as a pale-yellow oil (613 mg, 77%). The two isomers were 
separated using the same chromatographic conditions. Z-isomer: IR (neat) 2924, 2855, 1803, 
1465, 1215, 752 cm-1; 1H NMR (500 MHz, CDCl3) d 5.84 (t, J = 7.9 Hz, 1H), 4.84 (dd, J = 6.3, 
6.3 Hz, 1H), 2.55-2.41 (m, 2H), 1.82-1.77 (m, 2H), 1.47-1.41 (m, 4H), 1.26 (brs, 26H), 0.88 (t, J 
= 6.6 Hz, 6H); 13C NMR (125 MHz, CDCl3) d 164.4, 137.7, 136.4, 78.8, 33.9, 32.1, 32.1, 29.8, 
29.7, 29.7, 29.6, 29.5, 29.5, 29.2, 29.1, 29.1, 24.8, 22.9, 14.3; HRMS (ESI) calcd for C23H43O2 
(M + H)+ m/z 351.3263, found 351.3271. E-isomer: IR (neat) 2922, 2853, 1813, 1464, 1117, 
1044, 818, 721 cm-1; 1H NMR (500 MHz, CDCl3) d 6.38 (td, J = 7.9, 1.7 Hz, 1H), 5.03 (m, 1H), 
2.16 (q, J = 7.6 Hz, 2H), 2.01-1.94 (m, 1H), 1.86-1.78 (m, 1H), 1.56-1.48 (m, 4H), 1.32 (brs, 
26H), 0.93 (m, 6H); 13C NMR (125 MHz, CDCl3) d 164.4, 137.6, 134.0, 79.2, 33.3, 31.9, 31.9, 
29.6, 29.6, 29.5, 29.5, 29.5, 29.4, 29.3, 29.3, 29.2, 28.9, 28.4, 24.7, 22.7, 22.6, 14.1; HRMS 
(ESI) calcd for C23H43O2 (M + H)+ m/z  351.3263, found 351.3236. 
 
(cis/trans)-3,4-Didecyloxetan-2-one (4). 4-Decyl-3-decylideneoxetan-2-one (3) a mixture of 
E/Z-isomers (124 mg, 0.35 mmol) were dissolved in a mixture of THF/MeOH (1.7/0.4 mL) and 
immersed in a cooling bath at -10 °C. CoCl2(PPh3)2 (47 mg, 0.072 mmol) was added, followed 
by the addition of NaBH4 (18 mg, 0.48 mmol) in portions over 10 min. A dark brown mixture 
formed which was stirred at -10 °C for 2 h. It was then filtered through a pad of celite, and the 
celite was washed with CHCl3 (10 mL). The organic layer was washed with 2 M HCl (2 ´ 5 mL) 
and brine (3 ´ 5 mL) and dried (MgSO4). The solvent was removed, and the residue was purified 
by column chromatography on silica gel (petroleum ether/EtOAc 100:4) to provide a mixture of 
isomers (cis/trans, 1:2) as a white solid (58 mg, 46%). The mixture was carefully purified using 
O
O
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the same chromatographic conditions to obtain pure isomers. Trans-isomer: IR (neat) 2918, 
2851, 1794, 1467, 1140, 857, 816, 721 cm-1; 1H NMR (500 MHz, CDCl3) d 4.21 (ddd, J = 7.3, 
6.0, 3.9 Hz, 1H), 3.16 (ddd, J = 10.5, 6.5, 3.9 Hz, 1H), 1.89-1.78 (m, 2H), 1.75-1.67 (m, 2H), 
1.26 (brs, 32H), 0.88 (t, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCl3) d 171.7, 78.2, 56.2, 34.5, 
31.9, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 29.2, 27.9, 27.0, 25.0, 22.7, 14.1. Cis-isomer: IR (neat) 
2918, 2850, 1795, 1467, 1132, 1066, 814, 722 cm-1; 1H NMR (500MHz, CDCl3) d (ppm) 4.53 
(ddd, J = 10.0, 6.4, 4.0 Hz, 1H), 3.59 (ddd, J = 8.9, 7.0, 7.0 Hz, 1H), 1.81-1.70 (m, 2H), 1.68-
1.57 (m, 2H), 1.26 (brs, 32H), 0.88 (t, J = 6.7 Hz, 6H); 13C NMR (125 MHz, CDCl3) d 172.4, 
75.8, 52.7, 31.9, 30.2, 29.6, 29.5, 29.5, 29.4, 29.4, 29.3, 27.6, 25.6, 24.0, 22.7, 14.1.  
 
5-Bromo-1-pentanol (5). 1,5-Pentanediol (5.20 g, 49.9 mmol) was transferred to a round bottom 
flask equipped with a magnetic stir bar. Toluene (120 mL) was added, and the solution was 
stirred. HBr 48% in H2O (6.0 mL) was diluted with H2O (10 mL) and added, and a Dean-Stark 
apparatus was connected. The mixture was heated to reflux for 2 h; during this time ~ 15 mL of 
H2O was collected. The light orange solution was allowed to cool to rt. It was then transferred to 
a separatory funnel and washed with 1.0 M aqueous NaOH (2 × 50 mL), H2O (50 mL) and brine 
(50 mL) and dried (MgSO4). The organic solvent was removed, resulting in a pale yellow oil 
(7.17 g). This crude product was purified by flash column chromatography on silica gel 
(petroleum ether/ EtOAc 90:10) to remove 1,5-dibromopentane; then, (petroleum ether/EtOAc = 
50:50) to give 5-bromo-1-pentanol as a pale yellow oil (6.24 g, 75%): 1H NMR (300 MHz, 
CDCl3) 3.66 (t, J = 6.2 Hz, 2H), 3.42 (t, J = 6.8 Hz, 2H), 1.97-1.81 (m, 2H), 1.67-1.44 (m, 4H); 
13C NMR (75 MHz, CDCl3) δ 62.7, 33.9, 32.7, 31.9, 24.6. The spectra were consistent with 
literature.17 
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5-(Pentylthio)pentan-1-ol (6). 5-Bromo-1-pentanol (5) (5.20 g, 31.1 mmol) was transferred to a 
round bottom flask and dissolved in CH3OH (100 mL). The solution was bubbled with N2 for 15 
min, followed by the addition of Cs2CO3 (10.1 g, 31.0 mmol). 1-Pentanethiol (4.1 mL, 33.1 
mmol) was added dropwise under positive N2 and at rt. The mixture was then heated to reflux 
overnight under N2. It was then gravity filtered, and CH3OH was removed, resulting in a yellow 
oil. H2O (100 mL) and Et2O (200 mL) were added to the residue, and the layers were separated. 
The aqueous layer was extracted with Et2O (2 × 100 mL). The combined organic extracts were 
washed with H2O (2 × 50 mL) and brine (2 × 50 mL) and dried (MgSO4). The solvent was 
removed to provide 6 as a yellow oil (5.5 g, 93%): IR (neat) 3336, 2921, 2852, 1691, 1459, 1274, 
1054 cm-1; 1H NMR (500 MHz, CDCl3) δ 3.64 (t, J = 6.5 Hz, 2H), 2.52 (t, J = 7.3 Hz, 2H), 2.50 
(t, J = 7.4 Hz, 2H), 1.65-1.55 (m, 7H), 1.49-1.43 (m, 2H), 1.39-1.30 (m, 4H), 0.90 (t, J = 7.0 Hz, 
3H); 13C NMR (125 MHz, CDCl3) d 62.7, 32.3, 32.2, 32.1, 31.1, 29.5, 29.4, 25.1, 22.3, 14.0; 
HRMS (ESI) calcd for C10H22OS (M + H)+ m/z 191.1470, found 191.1485.  
 
5-(Pentylthio)pentanal (7). Oxalyl chloride (1.8 mL, 21 mmol) was added to CH2Cl2 (20 mL) at 
rt and under N2. The solution was immersed in a cooling bath at -78 °C. Then, a solution of 
DMSO (2.7 mL, 38 mmol) in CH2Cl2 (10 mL) was added dropwise over a period of 10 min. The 
solution was stirred for 20 min at -78 °C. Then, 5-(pentylthio)pentan-1-ol 6 (3.31 g, 17.4 mmol) 
was dissolved in CH2Cl2 (10 mL), and added dropwise over 10 min. Stirring was continued for 
20 min at -78 °C. Et3N (8.7 mL, 62 mmol) dropwise over 10 min, and a white suspension was 
formed. The mixture was stirred for 10 min at -78 °C. The cooling bath was removed, and 
S OH3 4
S
3 3
O
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stirring was continued for 45 min. The reaction was diluted with CH2Cl2 (50 mL), and H2O (50 
mL) was added. The mixture was stirred at rt until two clear layers formed. The layers were 
separated, and the aqueous layer was extracted with CH2Cl2 (3 × 30 mL). The combined organic 
extracts were washed with H2O (2 × 50 mL) and brine (2 × 50 mL) and dried (MgSO4). The 
organic solvent was removed, resulting in a yellow oil. It was purified by column 
chromatography on silica gel (petroleum ether/EtOAc 95:5) to give 7 as a yellow oil (2.02 g, 
62%): 1H NMR (300 MHz, CDCl3) δ 9.75 (t, J = 1.7 Hz, 1H), 2.55-2.38 (m, 6H), 1.80-1.49 (m, 
6H), 1.42-1.18 (m, 4H), 0.87 (t, J = 7.1 Hz, 3H).  
 
Methyl 3-hydroxy-2-methylene-7-(pentylthio)heptanoate (8). 5-(Pentylthio)pentanal (7) (4.7 
g, 25 mmol) was transferred to a round bottom flask. Methyl acrylate (4.5 mL, 50 mmol) and 3-
quinuclidinol (0.79 g, 6.2 mmol) were added. Methanol (1.0 mL, 25 mmol) was added, and the 
mixture was stirred for 3 d. Then, excess methyl acrylate was removed in vacuo, and the residue 
was purified by column chromatography on silica gel (petroleum ether/EtOAc = 90:10) to give 8 
as a light yellow oil (4.22 g, 62%): IR (neat) 3400, 2927, 2857, 1717, 1438, 1260, 1194, 1157, 
1075, 954 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.23 (s, 1H), 5.81 (s, 1H), 4.40 (ddd, J = 6.4, 6.4, 
6.4 Hz, 1H), 3.78 (s, 3H), 2.57 (d, J = 6.7 Hz, 1H), 2.51 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 
2H),  1.74-1.51 (m, 8H), 1.51-1.40 (m, 1H), 1.34-1.29 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ 167.0, 142.4, 125.1, 71.6, 51.9, 35.8, 32.2, 32.0, 31.1, 29.5, 29.4, 
25.1, 22.3, 14.0. 
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3-Hydroxy-2-methylene-7-(pentylthio)heptanoic acid (9). Methyl-3-hydroxy-2-methylene-7-
(pentylthio)heptanoate (8) (4.0 g, 15 mmol) was transferred to a round bottom flask equipped 
with a stir bar. CH3OH (50 mL) was added. Then, 1.3 M aqueous NaOH (25 mL) was added, and 
the solution left stirring at rt for 1 d. The reaction mixture was concentrated in vacuo and diluted 
with 2M aqueous HCl (100 mL). It was then extracted with Et2O (3 × 100 mL), and the 
combined organic extracts were washed with H2O (100 mL) and brine (2 × 50 mL), dried 
(MgSO4) and concentrated to give a yellow, viscous oil. It was purified by column 
chromatography on silica gel (petroleum ether/EtOAc 70:30) to provide 9 as a light yellow oil 
(2.44 g, 64%): IR (neat) 2927, 2858, 1694, 1627, 1250, 1169, 1071, 1047, 960, 736 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 6.39 (s, 1H), 5.93 (s, 1H), 4.44 (dd, J = 7.7, 5.1 Hz, 1H), 2.51 (t, J = 
9.0 Hz, 2H), 2.50 (t, J = 10 Hz, 2H), 1.80-1.54 (m, 6H), 1.53-1.28 (m, 5H), 0.90 (t, J = 6.0 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 171.0, 142.0, 127.6, 71.4, 35.9, 32.4, 32.2, 31.3, 29.6, 29.6, 
25.2, 22.5, 14.1; HRMS/ESI calcd for C13H25O3S (M + H)+ m/z 261.1524, found 261.1499. 
 
3-Methylene-4-(4-(pentylthio)butyl)oxetan-2-one (10). 3-Hydroxy-2-methylene-7-
(pentylthio)heptanoic acid (9) (1.13 g, 4.34 mmol) dissolved in CH2Cl2 (50 mL). Na2CO3 (4.01 
g, 37.8 mmol) was added, and the mixture was stirred for 30 min. Then, 2-nitrobenzenesuflonyl 
chloride (1.47 g, 6.63 mmol) was added, and the mixture was stirred for 1 d, resulting in a white 
suspension. It was gravity filtered, and the solvent was removed, resulting in a yellow oil. It was 
purified by column chromatography on silica gel (hexanes/EtOAc 95:5) giving 10 as a colorless 
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oil (0.363 g): IR (neat) 2928, 2858, 1816, 1080, 816 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.92 
(dd, J = 2.0, 2.0 Hz, 1H), 5.44 (dd, J = 1.8, 1.8 Hz, 1H), 4.97 (tt, J = 6.4, 1.7 Hz, 1H), 2.57 (t, J = 
7.0 Hz, 2H), 2.53 (t, J = 7.5 Hz, 2H), 1.95-1.81 (m, 2H), 1.64-1.59 (m, 4H), 1.43-1.33 (m, 4H), 
0.90 (t, J = 6.9 Hz, 3H);  13C NMR (125 MHz, CDCl3) d163.6, 146.4, 115.2, 79.5, 33.1, 32.4, 
31.9, 31.3, 29.5, 29.3, 24.0, 22.5, 14.1; HRMS/ESI calcd. For C13H23O2S (M + H)+ m/z 
243.1419, found 243.1407.  
                                       
(E/Z)-3-Decylidene-4-(4-(pentylthio)butyl)oxetan-2-one (11). 3-Methylene-4-(4-(pentylthio)-
butyl)oxetan-2-one and Hoveyda catalyst (34.3 mg, 0.0548 mmol) and undecene (0.50 mL, 2.4 
mmol) were added. A green solution resulted. It was heated at 40 °C under N2 overnight. The 
resulting brown solution was allowed to cool to rt and was filtered through celite. The filtrate 
was concentrated and the residue purified by column chromatography on silica gel (petroleum 
ether/EtOAc 100:4) resulting in 11 as a colorless oil (287 mg, 76%). The two isomers were 
separated by column chromatography using the same conditions. E-isomer 11-E: IR (neat) 2923, 
2853, 1810, 1458, 731cm-1; 1H NMR (500 MHz, CDCl3) δ 6.35 (td, J = 8.0, 1.8 Hz, 1H), 4.99 
(m, 1H), 2.53 (t, J = 7.0 Hz, 2H), 2.50 (t, J = 6.0 Hz, 2H), 2.11 (m, 2H), 1.99-1.92 (m, 1H), 1.83-
1.76 (m, 1H), 1.71-1.52 (m, 7H), 1.47 (p, J = 7.5 Hz, 2H), 1.38-1.27 (m, 17H), 0.90 (t, J = 7.5 
Hz, 3H), 0.89 (t, J = 7.0, 3H); 13C NMR (125 MHz, CDCl3) δ 164.2, 137.4, 134.2, 78.8, 32.9, 
32.2, 31.9, 31.1, 29.5, 29.4, 29.3, 29.3, 29.3, 29.2, 28.9, 28.4, 24.0, 22.7, 22.3, 14.1, 13.9; 
HRMS/ESI calcd for C22H41O2S (M + H)+ m/z 369.2827, found 369.2805. Z-isomer 11-Z: IR 
(neat) 2922, 2853, 1805, 1464, 1066, 815 cm-1; 1H NMR (400 MHz, CDCl3) d 5.87 (td, J = 7.9, 
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1.4 Hz, 1H), 4.85 (td, J = 6.4, 1.3 Hz, 1H), 2.54-2.48 (m, 6H), 1.82 (dt, J = 8.5, 8.5 Hz, 2H), 
1.68-1.62 (m, 2H), 1.60-1.54 (m, 4H), 1.47-1.42 (m, 2H), 1.38-1.26 (m, 16H), 0.90 (t, J = 9.0 
Hz, 3H), 0.88 (t, J = 9.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 164.0, 137.3, 136.5, 78.3, 33.4, 
32.2, 31.9, 31.8, 31.1, 29.5, 29.4, 29.3, 29.3, 29.0, 28.9, 28.8, 23.9, 22.7, 22.3, 14.1, 14.0; HRMS 
(ESI) calcd for C22H41O2S (M + H)+ m/z 369.2827, found 369.2805.  
General procedure for the preparation of R2SO (dialkyl sulfoxide): The thioether (0.03 
mmol) was transferred into an NMR tube and MeOH-d4 (~0.6 mL) was added. H2O2 (30% in 
H2O, 0.062 mmol) was added. The reagents were mixed and left overnight. The next day, the 
reaction was complete based on NMR. The solution was concentrated, and the residue was 
purified by a short column chromatography (Pasteur pipette) on silica gel.  
 
(Z)-3-Decylidene-4-(4-(pentylsulfinyl)butyl)oxetan-2-one (12). The products 12 (8 mg, 73%) 
was obtained as a light-yellow oil after purification using (CH2Cl2/MeOH 99:1). IR (neat) 2923, 
2854, 1807, 1459, 1407,1080, 908, 816, 729 cm-1; 1H NMR (500 MHz,CDCl3) d 5.87 (td, 6.2, 
1.8 Hz, 1H), 4.89-4.85 (m, 1H ), 2.73-2.59 (m, 4H), 2.53-2.45 (m, 2H), 1.94-1.82 (m, 4H), 1.80-
1.73 (m, 2H), 1.49-1.35 (m, 6H), 1.33-1.26 (m, 12H), 0.92 (t, J = 6.2 Hz, 3H), 0.88 (t, J = 6.9 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.0, 137.3, 137.2, 137.1, 137.0, 78.2, 78.1, 52.9, 52.8, 
52.2, 52.2, 33.6, 33.5, 32.1, 31.2, 29.7, 29.5, 29.5, 29.2, 29.2, 29.0, 24.3, 24.1, 22.9, 22.7, 22.6, 
22.5, 22.5, 14.3, 14.0; HRMS (ESI) calcd for C22H41O3S (M + H)+ m/z 385.2776, found 
385.2746. 
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 (E)-3-Decylidene-4-(4-(pentylsulfinyl)butyl)oxetan-2-one (13). Product 13 (9 mg, 67%) was 
obtained as a colorless oil after purification using (CH2Cl2/MeOH 100:1). IR (neat) 2922, 2853, 
1804, 1459, 1015, 813 cm-1; 1H NMR (500 MHz, CDCl3) d 6.29 (t, J = 7.8 Hz, 1H), 4.93 (m, 
1H), 2.70-2.50 (m, 4H), 2.12 (ddd, J = 7.6, 7.6, 7.6 Hz, 2H), 2.05-1.99 (m, 1H), 1.88-1.76 (m, 
5H), 1.48-1.35 (m, 7H), 1.32-1.25 (m, 15H), 0.85 (t, J = 7.1, 3H), 0.81 (t, J = 6.8 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 164.2, 137.5, 137.4, 134.8, 134.7, 78.7, 78.6, 52.9, 52.8, 52.3, 52.2, 
33.1, 33.1, 32.1, 31.2, 29.9, 29.7, 29.5, 29.4, 29.1, 28.6, 24.4, 24.3, 22.8, 22.6, 22.6, 22.5, 22.5, 
14.3, 14.0; HRMS (ESI) calcd for C22H41O3S (M + H)+ m/z 385.2746, found 385.2787. 
General procedure for the preparation of R2S2O (dialkyl sulfone): The corresponding 
thioether was transferred into an NMR tube and MeOH-d4 (~0.6 mL) was added. Peroxyacetic 
acid (32% in acetic acid, 2.2 eq). was added, mixed and left overnight. The next day, the reaction 
was complete based on 1H NMR. It was evaporated under vacuum, and the residue was purified 
by a short column (Pasteur pipette) on silica gel.  
 
(E)-3-Decylidene-4-(4-(pentylsulfonyl)butyl)oxetan-2-one (14). Product 14 (4 mg, 59%) was 
obtained as colorless oil after purification using (CH2Cl2/MeOH 100:1): IR (neat) 2954, 2919, 
2851, 1798, 1106, 808, 572, 503 cm-1; 1H NMR (500 MHz, CDCl3) d 6.37 (td, J = 8.0, 2.0 Hz, 
1H), 5.01-4.98 (m, 1H), 2.97 (t, J = 5.0 Hz, 2H), 2.95 (t, J = 7.5 Hz, 2H), 2.13-2.08 (m, 2H), 
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1.96-1.89 (m, 2H), 1.88-1.78 (m, 3H), 1.70-1.64 (m, 2H), 1.48-1.35 (m, 7H), 1.32-1.25 (m, 12H), 
0.93 (t, J = 7.5 Hz, 3H), 0.88 (t, J = 6.5 Hz, 3H); 13C NMR (125 MHz,CDCl3) δ 164.1, 137.4, 
134.9, 78.4, 53.3, 52.5, 32.9, 32.1, 30.8, 29.7, 29.6, 29.5, 29.1, 28.6, 24.1, 22.9, 22.4, 21.9, 21.8, 
14.3, 13.9; HRMS (ESI) calcd for C22H41O4S (M + H)+ m/z 401.2726, found 401.2749.  
 
 
(Z)-3-Decylidene-4-(4-(pentylsulfonyl)butyl)oxetan-2-one (15). Product 15 (8 mg, 64%) was 
obtained as colorless oil after purification using (CH2Cl2/CH3OH 100:2): IR (neat) 2954, 2916, 
2850, 1800, 1780, 1465, 1126, 804, 767, 593, 498 cm-1; 1H NMR (500 MHz, CDCl3) d 6.37 (td, 
J = 7.9, 1.5 Hz, 1H), 4.88-4.85 (m, 1H), 2.96 (t, J = 6.5 Hz, 2H), 2.95 (t, J = 8.0 Hz, 2H), 2.55-
2.43 (m, 2H), 1.94-1.79 (m, 6H), 1.69-1.61 (m, 2H), 1.47-1.35 (m, 6H), 1.31-1.25 (m, 13H), 0.93 
(t, J = 7.5 Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 163.7, 137.0, 137.0, 
77.8, 53.1, 52.2, 33.2, 31.9, 30.6, 29.7, 29.5, 29.3, 29.3, 29.1, 29.0, 28.8, 23.8, 22.7, 22.2, 21.7, 
21.6, 14.1, 13.7; HRMS (ESI) calcd for C22H41O4S (M + H)+ m/z 401.2726, found 401.2718.  
 
 General method for preparation of (cis/trans)-3-Decyl-4-(4-(pentylthio)butyl)oxetan-2-one 
(16). (E/Z)-3-Decylidene-4-(4-(pentyl-thio)butyl)oxetan-2-one (11) (174 mg, 0.472 mmol) was 
transferred to a round bottom flask, and THF/MeOH (2/0.5 mL) was added. The solution was 
then immersed in a cooling bath at -10 °C, and CoCl2(PPh3)2 (63.2 mg, 0.0966 mmol) was 
added. Then, NaBH4 (21.4 mg, 0.566 mmol) was added in portions for 10 min, resulting in a 
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dark brown mixture. It was stirred at -10 °C for 2 h. The mixture was then filtered through a pad 
of celite, and the celite was washed with CHCl3 (10 mL). The filtrate was then washed with 2M 
HCl (2 × 5 mL), H2O (5 mL) and brine (3 × 5 mL) and dried (MgSO4). It was concentrated and 
purified by column chromatography on silica gel (petroleum. ether/EtOAc 100:4) to give 16 as a 
clear oil, mixture of (cis/trans 2:1, 83 mg, 48%). The two isomers were separated by column 
chromatography on silica gel (petroleum. ether/EtOAc 100:4). Trans-isomer 16-t (colorless oil): 
IR (neat) 2923, 2854, 1819, 1460, 1116 cm-1; 1H NMR (500 MHz, CDCl3) d ) 4.23-4.19 (m, 1H), 
3.19-3.15 (m, 1H),  2.52 (t, J = 7.0 Hz, 2H), 2.49 (t, J = 7.0 Hz, 2H), 1.89-1.69 (m, 4H), 1.66-
1.62 (m, 2H), 1.59-1.55 (m, 2H), 1.38-1.26 (m, 22H), 0.89 (t, J = 7.5 Hz, 3H), 0.88 (t, J = 7.0 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 171.6, 78.1, 56.4, 34.3, 32.4, 32.1, 32.0, 31.3, 29.8, 
29.7, 29.6, 29.5, 29.5, 29.4, 28.1, 27.2, 24.5, 22.9, 22.5, 14.3, 14.2; HRMS (ESI) calcd for 
C22H43O2S (M + H)+ m/z 371.2984, found 371.2982. Cis-isomer 16-c (colorless oil): IR (neat) 
2923, 2854, 1819, 1461, 1125, 826 cm-1; 1H NMR (400 MHz, CDCl3) d  4.53 (ddd, J = 9.4, 3.8, 
3.7 Hz, 1H), 3.62 (ddd, J = 8.8, 6.8, 6.8 Hz, 1H), 2.53 (t, J = 8.5 Hz, 2H), 2.50 (t, J = 9.5 Hz, 
2H),  1.82-1.48 (m, 12H), 1.39-1.26 (m, 18H), 0.89 (m, 6H); 13C NMR (101 MHz, CDCl3) d 
172.1, 75.5, 52.8, 32.2, 31.9, 31.9, 31.1, 29.9, 29.6, 29.5, 29.4, 29.3, 29.3, 27.6, 24.9, 24.0, 22.7, 
22.3, 14.1, 14.0; HRMS (ESI) calcd for C22H43O2S (M + H)+ m/z 371.2984, found 371.2993. 
 
(trans)-3-Decyl-4-(4-(pentylsulfinyl)butyl)oxetan-2-one (17). Product 17 (17.4 mg, 58%) was 
isolated as a white solid after purification on silica gel (CH2Cl2/MeOH 99:1): IR (neat) 2921, 
2853, 1806, 1465, 1136, 1015 cm-1; 1H NMR (500 MHz, CDCl3) d 4.23 (ddd, J = 7.8, 7.8, 4.2 
Hz, 1H), 3.19 (ddd, J = 8.7, 6.6, 3.9 Hz, 1H), 2.74-2.66 (m, 2H), 2.65-2.60 (m, 2H), 1.88-1.58 
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(m, 10H), 1.49-1.35 (m, 6H), 1.34-1.26 (m, 14H), 0.92 (t, J = 7.1 Hz, 3H), 0.88 (t, J = 6.9 Hz, 
3H); 13C NMR (125 MHz, CDCl3) d 171.2, 77.6, 77.5, 56.3, 56.3, 52.7, 52.0, 34.2, 34.1, 31.9, 
31.0, 29.6, 29.5, 29.3, 29.3, 27.8, 27.0, 24.6, 24.5, 22.7, 22.4, 22.4, 22.3, 22.3, 14.1, 13.8; HRMS 
(ESI) calcd for C22H43O3S (M+H)+ m/z 387.2855, found 387.2905. 
 
 
(trans)-3-Decyl-4-(4-(pentylsulfonyl)butyl)oxetan-2-one (18). Product 18 (12 mg) was isolated 
as a white solid after purification on silica gel (pet. ether/ethyl acetate 80:20): IR (neat) 2917, 
2849, 1793, 1467, 1325, 1125, 814, 769, 601cm-1; 1H NMR (400 MHz, CDCl3) d 4.27-4.23 (m, 
1H), 3.22 (ddd, J = 8.7, 6.6, 3.9 Hz, 1H), 2.99 (t, J = 6.5 Hz, 2H), 2.97 (t, J = 7.0 Hz, 2H), 1.99-
1.81 (m, 6H), 1.78-1.59 (m, 3H), 1.50-1.29 (m, 20H), 0.95 (t, J = 7.1 Hz, 3H), 0.91 (t, J = 6.7 
Hz, 3H); 13C NMR (101 MHz, CDCl3) d 171.3, 77.5, 56.6, 53.3, 52.4, 34.2, 32.1, 30.8, 29.8, 
29.7, 29.5, 28.0, 27.2, 24.5, 22.9, 22.4, 21.9, 21.7, 14.3, 13.9; HRMS (ESI) calcd for C22H43O4S 
(M + H)+ m/z 403.2882, found 403.2864.  
 
(cis)-3-Decyl-4-(4-(pentylsulfinyl)butyl)oxetan-2-one (19). Product 19 (1.5 mg) was isolated as 
a white solid after purification on silica gel (CH2Cl2/MeOH 100:2): IR (neat) 2921, 2851, 1803, 
1466, 1152, 1132, 1015 cm-1; 1H NMR (400 MHz, CDCl3) d 4.63-4.51 (m, 1H), 3.65 (dd, J = 6.7 
Hz, 1H), 2.77-2.61 (m, 4H), 1.95-1.86 (m, 2H), 1.84-1.59 (m, 7H), 1.51-1.29 (m, 19H), 0.95 (t, J 
= 7.1 Hz, 3H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 171.9, 75.2, 75.1, 52.9, 
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52.7, 52.0, 31.9, 31.0, 29.9, 29.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.6, 25.1, 25.0, 24.0, 22.7, 22.4, 
22.4, 22.3, 14.1, 13.8; HRMS (ESI) calcd for C22H43O3S (M + H)+ m/z 387.2855, found 
387.2910.  
 
(cis)-3-Decyl-4-(4-(pentylsulfonyl)butyl)oxetan-2-one (20). Product 20 (7 mg) was isolated as 
colorless oil after purification on silica gel (petroleum ether/EtOAc 80:20): IR (neat): 2921, 
2853, 1803, 1460, 1277, 1129, 816 cm-1; 1H NMR (400 MHz, CDCl3) d 4.53 (ddd, J = 8.9, 6.4, 
3.9 Hz, 1H), 3.67-3.58 (ddd, J = 8.8, 6.8, 6.8 Hz, 1H), 2.96 (t, J = 9.5 Hz, 2H), 2.94 (t, J = 9.5 
Hz, 2H), 1.98-1.89 (m, 2H), 1.86-1.79 (m, 2H), 1.77-1.71 (m, 2H), 1.64-1.58 (m, 2H), 1.44-1.34 
(m, 6H), 1.29-1.25 (m, 16 H), 0.92 (t, J = 7.1 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (101 
MHz, CDCl3) d 171.9, 75.1, 53.2, 53.1, 52.4, 32.0, 30.8, 29.9, 29.9, 29.7, 29.7, 29.5, 29.5, 27.7, 
24.9, 24.1, 22.8, 22.3, 21.8, 21.7, 14.3, 13.9; HRMS (ESI) calcd for C22H43O4S (M + H)+ m/z 
403.2882, found 403.2861.  
 
Hept-6-ene-1-sulfonamide (21). 7-Bromo-1-heptene (1.0 g, 5.6 mmol) was transferred to a 
round bottom flask. Na2SO3 (1.31 g, 10.4 mmol) and H2O (6.0 mL) were added. The mixture 
was heated overnight. Then it was cooled to rt and washed with Et2O (3.0 mL). Then, the 
aqueous layer was concentrated to dryness on a rotary evaporator, and the residue was dried in 
an oven at 130 °C overnight to provide a white solid. POCl3 (3.0 mL) was added, and the 
mixture was heated at 130 °C for 5 h. The mixture was then concentrated to dryness, and CH3CN 
(5.0 mL) was added. The mixture was immersed in an ice bath, and a solution of NH4OH (28% 
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in H2O, 10 mL) and CH3CN (3.0 mL) was added dropwise. It was stirred at 0 °C for 1 h, 
followed by extraction with CH2Cl2 (2 ´ 25 mL). The combined organic extracts were washed 
with brine (30 mL) and dried (MgSO4). The solvent was removed, and the residue was purified 
by column chromatography on silica gel (Hexanes/EtOAc 80:20 to 60:40) to provide 21 a white 
solid (0.30 g, 40%): 1H NMR (400 MHz, CDCl3) d 5.79 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.04-
4.95 (m, 2H), 4.81 (brs, 2H), 3.15-3.08 (m, 2H), 2.10-2.05 (m, 2H), 1.91-1.83 (m, 2H), 1.49-1.42 
(m, 4H). The NMR spectrum is consistent with the literature.10 
 
(Z)-6-(2-Oxo-4-(4-(pentylthio)butyl)oxetan-3-ylidene)hexane-1-sulfonamide (22). 3-Methy-
lene-4-(4-(pentylthio)butyl)oxetan-2-one (10) (242 mg, 0.99 mmol) and hept-6-ene-1-
sulfonamide (21) (265 mg, 1.5 mmol) were transferred to a round bottom flask. Dry CH2Cl2 (10 
mL) was added, followed by Hoveyda-Grubbs (II) catalyst (52 mg, 0.083 mmol). The solution 
was heated for 3 d at 45 °C and then concentrated. The residue was purified by column 
chromatography on silica gel (CH2Cl2/MeOH 100:1) to give 22 as a mixture of isomers (Z/E 2:1, 
56 mg, 14%). This mixture was purified again using the same conditions: Z-isomer (colorless 
oil): IR (neat) 3351 (br), 3279 (br), 2926, 2857, 1800, 1714, 1574, 1326, 1143 cm-1; 1H NMR 
(500 MHz, CDCl3) d 5.87 (td, J = 8.0, 1.4 Hz, 1H), 4.88 (dd, J = 6.0, 6.0 Hz, 1H), 4.72 (brs, 2H), 
3.14-3.11 (m, 2H), 2.55-2.49 (m, 6H), 1.93-1.87 (m, 2H), 1.86-1.82 (m, 2H), 1.69-1.49 (m, 10H), 
1.39-1.29 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 164.2, 138.0, 135.5, 
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78.6, 55.0, 33.3, 32.2, 31.8, 31.1, 29.4, 29.2, 28.1, 28.0, 27.2, 23.8, 23.4, 22.3, 14.0; HRMS 
(ESI) calcd for C18H34NO4S2 (M + H)+ m/z 392.1929, found 392.1916.  
 
(Z)-6-(2-Oxo-4-(4-(pentylsulfinyl)butyl)oxetan-3-ylidene)hexane-1-sulfonamide (23). (Z)-6-
(2-Oxo-4-(4-(pentylthio)butyl)oxetan-3-ylidene)hexane-1-sulfonamide (22) (8 mg, 0.02 mmol) 
was transferred to a NMR tube and dissolved in MeOH-d4 (0.6 mL). H2O2 30% in H2O (4.8 µL, 
0.04 mmol) was added, and the solution was left on the bench overnight. The 1H NMR spectrum 
showed complete reaction; so it was then purified by short column (Pasteur pipette) on silica gel 
(CH2Cl2/MeOH 98:2) to provide 23 as colorless oil (5 mg, 60%): IR (neat ) 2927, 2859, 1797, 
1713, 1461, 1327, 1144, 1085, 1007, 812 cm-1; 1H NMR (500 MHz, CDCl3) d 5.89 (ddd, J = 8.5, 
4.0, 1.5 Hz, 1H), 4.94-4.92 (m, 2H), 3.11 (t, J = 7.5 Hz, 2H), 2.76-2.69 (m, 2H), 2.68-2.55 (m, 
3H), 2.54-2.46 (m, 1H), 1.93-1.84 (m, 6H), 1.79-1.73 (m, 2H), 1.68-1.49 (m, 4H), 1.56-1.50 (m, 
4H), 1.41-1.35 (m, 3H), 0.92 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 164.1, 137.8, 
137.6, 136.0, 135.9, 78.2, 78.1, 55.0, 54.9, 52.6, 52.5, 51.9, 51.9, 33.1, 33.0, 31.0, 29.7, 28.2, 
27.9, 27.8, 27.1, 27.1, 23.8, 23.6, 23.5, 22.6, 22.5, 22.3, 22.3, 13.8; HRMS (ESI) calcd for 
C18H34NO5S2 (M + H)+ m/z 408.1878, found 408.1869.  
 
(Z)-6-(2-Oxo-4-(4-(pentylsulfonyl)butyl)oxetan-3-ylidene)hexane-1-sulfonamide (24). (Z)-6-
(2-Oxo-4-(4-(pentylthio)butyl)oxetan-3-ylidene)hexane-1-sulfonamide (22) (8 mg, 0.02 mmol) 
O
O
S
S
O
O
NH2
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O
NH2
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was transferred to a NMR tube and dissolved in MeOH-d4 (0.6 mL). CH3COOOH 32% in acetic 
acid (15 µL, 0.06 mmol) was added, and the solution was left on the bench overnight. The 1H 
NMR spectrum showed complete reaction; so it was then purified by short column (Pasteur 
pipette) on silica gel (CH2Cl2/MeOH 98:2) to provide 24 as colorless oil (7 mg, 79%): IR (neat) 
3351 (br), 3264 (br), 2931, 2861, 1798, 1318, 1288, 1124, 1086 cm-1; 1H NMR (500 MHz, 
CDCl3) d 5.88 (td, J = 8.0, 1.4 Hz, 1H), 4.91 (dd, J = 6.5, 6.5 Hz, 1H), 4.71 (s, 2H), 3.12 (t, J = 
7.5 Hz, 2H), 2.99-2.94 (m, 4H), 2.59-2.48 (m, 2H), 1.95-1.81 (m, 10H), 1.68-1.62 (m, 2H), 1.56-
1.51 (m, 2H), 1.45-1.34 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 164.0, 
137.7, 136.0, 78.0, 54.9, 53.1, 52.1, 33.0, 30.6, 29.7, 28.2, 27.9, 27.1, 23.6, 23.5, 22.2, 21.7, 21.5, 
13.7; HRMS (ESI) calcd for C18H37N2O6S2 (M + NH4)+ m/z 441.2093, found 441.2095.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
4.6. References 
 
1. Adjei, A. “Blocking oncogenic Ras signaling for cancer therapy.” J. Natl. Cancer Inst. 
2001, 93, 1062-1074.  
2. Won, S.; Kit, M.; Martin, B. “Protein depalmitoylases.” Crit. Rev. Biochem. Mol. Biol. 
2018, 53, 83-98.  
3. Hancock, J.F. “RAS Proteins: Different Signals from Different Locations.” Nature 
Reviews, 2003, 4, 373-384.  
4. Rajasekharan, S.; Raman, T. “Ras and Ras mutations in cancer.” Cent. Eur. J. Biol. 2013, 
8, 609-624.   
5. Davda, D.; Martin, B.R. “Acyl Protein Thioesterase Inhibitors as Probes of Dynamic S-
palmitoylation.” Med. Chem. Comm. 2014, 5, 268-276. 
6. Bhattacharjee, A.; Gurung, A. “Significance of Ras signaling in cancer and strategies for 
its control.” Oncol. Hematol. Rev. 2015, 11, 147-152. 
7. Fernández-Medarde, A.; Santos, E. “Ras in cancer and development diseases.” Genes 
Cancer, 2011, 2, 344-358.  
8. 3-Downward, J. “Targeting Ras Signalling Pathways in Cancer Therapy.”  Nature 
Reviews, 2003, 3, 11-22.  
9. Hattum, H.V.; Waldmann, H. “Chemical Biology Tools for Regulating RAS Signaling 
Complexity in Space and Time.” Chem. Biol. 2014, 21, 1185-1195. 
10. 4-Balamurugan, R.; Bastiaens, P.; Brunsveld, L.; Coates, G.W.; Dekker, F.J.; Gerauer, 
M.; Hedberg, C.; Kramer, J.W.; Menninger, S.; Rauh, D.; Renner, S.; Rocks, O.; Rusch, 
M.; Scholermann, B.; Vartak, N.; Waldmann, H. “Small-Molecule Inhibition of APT1 
Affects Ras Localization and Signaling.” Nature Chem.Biol. 2010, 6, 449-455.  
 107 
11. Harvey, P.; Silder, W.; Meister, W.; Vetter, W.; Wolfer, H. “The lipase inhibitor 
tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase.” 
J. Biol. Chem.1991, 266, 2021-2027. 
12. Dekker, F.; Hedberg, C. “Small molecule inhibition of protein depalmitoylation as a new 
approach towards downregulation of oncogenic Ras signaling.” Bioorganic Med. Chem. 
2011, 19, 1376-1380. 
13. Bastiaens, P.I.H.; Bon, S.R.; Dekker, F.J.; Gerding-Reimers, C.; Hedberg, C.; Renner, S.; 
Rusch, M.; Vartak, N.; Waldmann, H.; Wetzel, S. “Development of Highly Potent 
Inhibitors of the Ras-Targeting Human Acyl Protein Thioesterases Based on Substrate 
Similarity Design.” Angew. Chem. Int. Ed. 2011, 50, 9832-9837.  
14. Vujic, I.; Sanlorenzo, M.; Puig, R.; Vujic, M.; Kwong, A.; Tsumura, A.; Murphy, R.; 
Moy, A.; Posch, C.; Monshi, B.; Rappersberger, K.; Urda, S. “Acyl protein thioesterase 1 
and 2 (APT-1, APT-2) inhibitors Palmostatin B, ML348 and ML349 have different 
effects on NRAS mutant melanoma cells.” Oncotarget, 2016, 7, 7297-7306.  
15. Rusch, M.; Zimmermann, T.; Bürger, M.; Dekker, F.; Görmer, K.; Triola, G.; 
Brockmeyer, A.; Janning, P.; Böttcher, T.; Sieber, S.; Vetter, I.; Hedberg, C.; Waldmann, 
H. “Identification of Acyl Protein Thioesterases 1 and 2 as the Cellular Targets of the 
Ras-Signaling Modulators Palmostatin B and M.” Angew. Chem. Int. Ed. 2011, 50, 9838-
9842.  
16. Satyanarayana, N.; Periasamy, M. “Isomerization of olefins catalyzed by a 
CoCl2/Ph3P/NaBH4 system.” J. Organomet. Chem. 1987, 319, 113-117.  
 108 
17. Bird, T. D.; Camara, K.; Chen, D. H.; Cravat, B, F.; Dix, M. M.; Howell, A. R.; Kamat, 
S. S.; Parsons, W. H. “Immunomodulatory lysophosphatidylserines are regulated by 
ABHD16A and ABHD12 interplay.” Nat. Chem. Biol. 2015, 2, 164. 
18. Leung, D.; Hardonin, C.; Boger, D.; Cravatt, B. “Discovering potent and selective 
reversible inhibitors of enzymes in complex proteomes.” Nature Biotechnol. 2003, 21, 
687-691. 
19. Data not published from Dr. Cravatt’s lab. The Scripps Research Institute.  
 
 
 
 
 
 
 
 109 
Chapter Five 
Experimental Section 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 110 
5.1. Synthesis of tropolone derivatives  
The installation of amide moiety into tropolone was done using aminocarbonylation method. Our 
interest was to construct this group in one step in order to synthesize a quick library of tropolone 
derivatives for SAR study. Buchwald group1 reported a method for the formation of Weinreb 
amide via Pd-catalyzed aminocarbonylation using CO gas (scheme 5.1). 
 
Scheme 5.1. Aminocarbonylation of aryl bromides to form Weinreb amide.1 
Applying this method to tropolone requires bromination of tropolone and protection of the 
hydroxyl group using iodomethane. This protocol was established in our lab and used for cross 
coupling reactions (scheme 5.2).  
 
Scheme 5.2. Protection and bromination of tropolone.  
Applying the aminocarbonylation conditions to bromotropone didn’t give a clean product. The 1H 
NMR showed the formation of the product in a low yield. Several attempts were made to modify 
the reaction conditions. The temperature was increased to 100 °C and the reaction time was varied 
between (1-16 h). The product was still minimum and it didn’t give a clean reaction.   However, 
switching to the solvent to dioxane and using Cs2CO3 gave a cleaner reaction but with a low yield. 
Interestingly, the other product that formed was the conjugate addition of amine into tropolone 
before the aminocarbonylation took place. Initially, 1.5 equivalent of the corresponding amine was 
Br
R + NH
CH3
H3CO HCl
2 mol% Pd(OAc)2
2 mol% XantPhos
CO (1 atm)
3.0 equiv Na2CO3
PhCH3, 80 ºC, 5-22 h
R
N
O
OCH3
CH3
O
OH 1) CH3I, K2CO3    CH3CN, 80 °C, 16 h
2) NBS, Benzene
    80 ºC, 1 h
O
OCH3Br
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used where 1.0 equivalent was consumed for the conjugate addition. The other 0.5 equivalent was 
only available to undergo aminocarbonylation (Scheme 5.3).  
 
 Scheme 5.3. Aminocarbonylation of 2-bromo-7-methoxytropone using 1.5 and 2.2 equivalent of amine.  
Monitoring the reaction by TLC and 1H NMR showed that the formation of the conjugate addition 
of amine into tropone occurred first. Fortunately, the addition of 2.2 equivalent of the amine 
resulted in the formation of the desired product I. The aminocarbonylation cycle of tropolone is 
shown in Scheme 5.4. The pre-catalyst Pd(OAc)2 is reduced to the active form L2Pd(0) by 
XantPhos ligand as reported before with similar phosphine ligands.2 Addition of amine to 2-
bromo-7-methoxytropone would result in the formation of 1. This intermediate undergoes 
aminocarbonylation reaction. The oxidative addition of L2Pd(0) to 1  provides 2 a 16e species (i). 
Palladium catalyzed carbonylation of 2 gives the acylpalladium complex 3 16e (ii). Nucleophilic 
attack of the amine to palladium resulted in 4 16e (iii).  The acid produced from this step is 
neutralized by the base Cs2CO3. Reductive elimination generates the catalyst and provides the 
desired product 5 (iv).  
O
OCH3Br
5 mol% Pd(OAc)2
6 mol% XantPhos
3 eq. Cs2CO3
1.5 eq RNH2, CO (1 atm)
dioxane, 80 ºC, 16 h
O O
N
H
RHNR
O
Br
H
NR
+
Initially formed
5 mol% Pd(OAc)2
6 mol% XantPhos
3 eq. Cs2CO3
2.2 eq RNH2, CO (1 atm)
dioxane, 80 ºC, 16 h
O O
N
H
RHNR
I
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Scheme 5.4. Aminocarbonylation cycle of 2-bromo-7-methoxytropone. 
The conversion of the amine to a hydroxyl group was achieved under basic conditions. However, 
the molecule contains two symmetrical amine groups and removing either one can result with the 
same molecular weight. Mass spectrometry was not the proper characterization method to 
distinguish between these constitutional isomers (Scheme 5.4). 
 
Scheme 5.5. Possible products for the conversion of amine into hydroxyl group under basic conditions. 
Two methods were used to elucidate the correct structure. The first method was 2D NMR 
experiment (NOESY) to identify any coupling between methylene protons (a, b) of I and the 
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adjacent aromatic protons (c, d), Figure 5.1. The proton with a chemical shift at 6.60 ppm was 
assigned to d-proton since it is adjacent to the amine and it is expected to appear upfield in the 
spectrum. The NOESY spectrum shows that the methylene protons (a) with a chemical shift of 
3.22 ppm has a strong NOE with the d-proton. No NOE signal was observed for the c-proton. This 
confirmed that the peak at 3.22 ppm was for the a-protons. These protons disappeared after the 
hydrolysis, suggesting that the amide moiety was intact and the hydrolysis of this group didn’t 
occur.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. NOESY spectrum of I in CDCl3. 
The method used to confirm the identity of the product after base treatment was X-ray 
crystallography. Fortunately, the product after the hydrolysis was solid. Crystals of this compound 
were formed by the slow evaporation method using methanol as a solvent. Methanol gave crystals 
OH
N N
H
H2
C
O
C
H2a
b
H Hcd
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large enough to diffract on the X-ray diffractometer compared to THF. Other solvents (CHCl3 and 
CH3CN) were used but they gave small crystals. 
The crystal structure showed intramolecular and intermolecular H-bonding interactions. 
Intramolecular H-bonding was formed between the amide proton and the carbonyl oxygen of 
tropolone. Additional interaction exists between the hydroxyl group and the carbonyl oxygen of 
the tropolone ring. These interactions allow this molecule to adapt this conformation in the absence 
of metal ion that coordinates with both carbonyl and amide groups. The second type of interactions 
(intermolecular) facilitates the growth of crystals in 2D and stabilizes them. This interaction was 
formed between the carbonyl oxygen from one tropolone and the hydroxyl group from the other 
molecule (Figure 5.2).  
 
 
 
 
 
Crystal system: Triclinic  
Space group: P-1 
a: 5.1029(3)     α: 95.624(5)° 
b: 9.6604(6)     β: 95.659(5)° 
c: 10.7216(7)   γ: 92.232(5)° 
R1: 2.98% 
Figure 5.2. ORTEP view of tropolone carboxamide (left), crystal packing showing H-bonding interactions (right). 
 
So, the crystal structure confirmed the formation of the desired product and it was consistent with 
the NMR analysis for the compound before the hydrolysis. Both methods led to the same 
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conclusion that the desired product tropolone carboxamide was prepared. A library of tropolone 
derivatives were prepared by changing the amine substituent (aryl, linear or cyclic) (Table 5.1).  
Table 5.1. tropolone derivatives with their yield.  
Compound Yield Compound Yield 
 
76% 
 
51% 
 
39% 
 
60% 
 
77% 
 
52% 
 
76% 
 
47% 
 
75% 
 
27% 
 
5.2. Synthesis of tropolone phosphonic acid 
Tropolone has been further modified by installing a phosphonic acid group. 2-bromo-7-
methoxytropone was used as the starting material for the cross coupling with diethyl phosphite. In 
the reaction of aminocarbonylation, XantPhos ligand gave a clean reaction with a moderate yield. 
This ligand was used again to install the phosphite group into tropolone. After optimizing the 
reaction conditions, the use of toluene with 1.5 equivalent of diethyl phosphite gave a complete 
conversion of tropolone into product in 1 h (Scheme 5.5). Characterization of this compound was 
performed using 1H, 13C and 31P NMR (Figures S.22-S.24). 31P NMR was calibrated using a 
capillary of H3PO4 inserted in the NMR tube and H3PO4 was assigned a value of 0.00 ppm. The 
glass capillary was prepared in the lab by using a melting point capillary with both ends open. The 
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acid was filled in the capillary by applying vacuum so as no bubbles were formed. The two ends 
were sealed by a flame and it was used as a reference for all 31P NMR measurements.  
 
Scheme 5.6. Synthetic method of tropone phosphite. 
The hydrolysis of tropone phosphite was conducted under acidic conditions. Under these 
conditions both the phosphite group and methoxy were hydrolyzed and the desired product was 
formed in a quantitative yield (Scheme 5.7). The product was highly polar and any attempt to 
purify it on silica gel would result in losing the compound on silica. The preparatory HPLC was 
used to purify the compound using gradient elution mode H2O/CH3CN (90/10 to 10/90%) and a 
reversed phase C18 column. The yield from this purification was low since the column is old and 
gave broad peak. The fragments collected were chosen carefully so no impurities exist. This 
resulted in a loss of the compound that was contaminated with impurities. NMR spectra of this 
product were consistent with the formation of tropolone phosphonic acid (Figures S.25, S.26 and 
S.27).  
 
Scheme 5.7. Formation of tropolone phosphonic acid. 
5.3. Synthesis of 8-hydroxyquinoline-7-carboxamide derivatives 
These derivatives were synthesized in one step using organic coupling reagent. The coupling 
reagent, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) with 
O
BrH3CO Pd(OAc)2 (5 mol%)XantPhos (6 mol%)
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          PhCH3, 100 ºC, 1 h
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O
OO EtOH: 6 M HCl (1:1) 
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Hydroxybenzotriazole (HOBt) was used as reported in literature for analogous derivatives.2 The 
product from this coupling was solid so recrystallization method was used for purification (Scheme 
5.8, Table 5.2).  
 
Scheme 5.8. General method for the synthesis 8-hydroxyquinoline-7-carboxamide derivatives. 
Two solvents were used in recrystallization (ethyl acetate and isopropanol) and pure products were 
obtained using this method. However, different trials were attempted to recrystallize compound 
H2 but without success. This compound was purified by column chromatography on silica gel. 
Compound H4 wasn’t soluble in hot isopropanol (IPA) but when it was filtered and the solid was 
collected; a pure sample was obtained. The yield from this technique was low for this compound 
(H4), which might be due to the loss during heating it with hot IPA. This heating will cause part 
of this molecule to dissolve and be lost while filtering it hot. At least, this technique gave pure 
sample and enough material for the biological testing.  
Table 5.2. 8-Hydroxyquinoline-7-carboxamide derivatives with their yields.  
Identifier Compound Yield 
H1  28% 
H2 
 
20% 
H3  27% 
H4 
 
8% 
H5 
 
42% 
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H6 
 
19% 
H7 
 
34% 
 
5.4. Synthesis of pyridone derivatives 
This motif was constructed in multi-step reaction analogous to a reported method.3,4 The synthesis 
started by the reaction of ethyl(E)-3-(dimethylamino) acrylate with benzyloxyacetyl chloride to 
form 1. The next step in the synthesis was modified for the reproducibility of the method. The 
synthesis of 2 following a method that was previously published resulted in very low yield (~20%) 
and sometimes no product formed. The method was changed by reverse the order of reagent 
addition; the base (NaOtBu) was transferred to the vial first followed by the addition of dry THF. 
Compound 1 was then added at room temperature followed by the addition of ethylformate 
dropwise. The addition of ethylformate as the last step was critical in this reaction. If ethylformate 
was added first then compound 1 second; it resulted in a low to no yield. The crude product was 
purified by column chromatography on silica to provide a colorless solid in a moderate yield. This 
compound (2) has been synthesized by this method several times and the yield was reproducible 
(Scheme 5.9).   
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Scheme 5.9. General synthetic method for pyridone derivatives. 
The next two steps were carried out according to a reported method.3 Two methods were used for 
the synthesis of 4. The method was chosen based on the yield of 4. Coupling using HATU required 
leaving the reaction for at least 12 h. However, using ethyl chloroformate would provide the 
product in a moderate yield in less than 2 h. The purification of these intermediates was carried 
out using a recrystallization technique. This method was quick and provided a clean product. It 
has the advantage of minimizing the generation of waste by eliminating the use of silica gel and 
organic solvents if the products were purified by column chromatography. In addition, it allowed 
the formation of a pyridone library in a reasonable time which facilitated a high throughput 
screening in a moderate time frame.  
The last step in the synthesis was removing the protecting group (benzyl group). Depending on the 
substrate, this step was achieved by using trifluoracetic acid (TFA) or the hydrogenolysis 
conditions. Interestingly, the compound P25 provided different products depending on which 
method was used. When P25 was treated with TFA it resulted in a compound P27 where pyrazole 
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and benzyl groups were cleaved. It appeared that when pyrazole was cleaved the product 
underwent rearrangement/tautomerized to form a new amide group. A source of water can exist 
from the trituration step with MeOH and diethyl ether. However, under hydrogenolysis conditions 
only the benzyl group was cleaved (Scheme 5.10). A list of the pyridone derivatives are shown in 
table 5.3.  
 
Scheme 5.10. Debenzylation with two different reaction conditions resulted in two different products. 
Compound P34 has a different amide substituent. This wasn’t commercially available and it was 
prepared in the lab through Suzuki cross coupling (Scheme 5.11). The yield for this reaction after 
column purification was low. One method to increase the yield is by protecting the amine with di-
tert-butyl dicarbonate or using high concentration of boronic ester. 
 
Scheme 5.11. Synthetic method for the 4-(1-methyl-1H-pyrazole-4-yl) aniline.  
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Table 5.3. Pyridone derivatives with their corresponding yield.  
Identifier Compound Yield Identifier Compound Yield 
P3 
 
34% P5 
 
41% 
P7  61% P9  56% 
P11  42% P12  85% 
P14 
 
63% P16  51% 
P18  77% P20  82% 
P22  63% P24  70% 
P26  34% P27  69% 
P29  67% P31  64% 
P32  76% P34  60% 
P36  73% P38  32% 
P39 
 
65% P41 
 
83% 
P42 
 
45%  
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5.5. Synthesis of tartaric acid analog 
The goal of the synthesis was to prepare an analog by replacing one of the carboxylic acid group 
with a hydroxamic acid. The starting material was tartaric acid which was cyclized to form the 
anhydride. This step was carried out according to a reported method.5 There was no need to purify 
the sample since 1H NMR showed a pure sample (Scheme 5.12). 
 
Scheme 5.12. Synthetic method of 2,5-dioxotetrahydrofuran-3,4-diyl diacetate. 
The next step was to introduce O-benzylhydroxylamine group which later can be deprotected to 
provide the desired product. In this reaction a solvent (CH2Cl2) was chosen so that nucleophilic 
addition reaction is preferred. The compound was purified by recrystallization from EtOAc which 
eliminates the use of column chromatography. The compound has a carboxylic group which can 
be hard to purify using silica gel. The recrystallization step was chosen carefully so as to result in 
a pure compound and minimize the use of silica gel and other organic solvents (Scheme 5.13).  
 
Scheme 5.13. Synthesis of 2,3-diacetoxy-4-((benzyloxy)amino)-4-oxobutanoic acid. 
The next two steps involved the deprotection of the benzyl and acetyl groups. These two steps 
were selected so as to facilitate the purification of the intermediates. The decision was made to 
deprotect the acetyl group since this would keep the benzyl group. Keeping this group can facilitate 
the extraction with organic solvent. The hydrolysis conditions were chosen such that the 
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byproducts can either be volatile or water soluble. So, sodium methoxide was used with slightly 
excess to hydrolyze the acetyl group. This reaction provided a product that was clean and it was 
used for next step. The final step was the debenzylation under hydrogenolysis conditions. This 
reaction resulted in a complete conversion and the desired product was formed (Scheme 5.14).  
 
Scheme 5.14. Deprotection of the acetyl and benzyl groups to provide the tartaric analog. 
5.6. Synthesis of SF-2312 analog  
SF-2312 compound was synthesized according to a reported method.6 Both compounds have 
similar route, only the method for the analog will be mentioned here. The first step in the synthesis 
was the formation of an enolate from triethyl phosphonoacetate a commercially available reagent. 
The enolate was formed using sodium hydride (NaH) and the solvent THF (Scheme 5.15). This 
reaction provided two products: the desired intermediate (1) and the disubstituted intermediate 
where the two a-hydrogens are replaced by the allyl group. Isolating these intermediates on silica 
gel wasn’t successful and required multiple purification cycles. The interest was to get the 
compound as quick as we can so prep. HPLC was used for isolating these intermediates. 
Lyophilization of the desired intermediate (1) was achieved by removing the solvent under 
vacuum.  
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Scheme 5.15. General method for the synthesis of the oxidized form of SF-2312 analog. 
The second step in the synthesis provided 2 which was clean and no purification was needed. 
Coupling of 2 with O-benzyloxy hydroxylamine and cyclization through hemiacetal provided the 
intermediate 4 as two isomers. The intermediate was oxidized using pyridinium chlorochromate 
(PCC) in the presence of molecular sieves to provide diethyl (1-(benzyloxy)-2,5-dioxopyrrolidin-
3-yl) phosphonate 5 in a quantitative yield. When 1.0 or 2.0 equivalents of PCC was used, the 
reaction was slow and it didn’t go for complete conversion.  
Removing excess chromium from the product was achieved by using a mixture of 30% of cysteine 
on silica gel. The presence of cysteine provided a chelation for chromium which slowed the elution 
of PCC and resulted in a cleaner product. Cleavage of the phosphonic ester was achieved by 
trimethylsilyl iodide and then hydrogenolysis to afford the desired product (1-hydroxy-2,5-
dioxopyrrolidin-3-yl) phosphonic acid 7.  
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5.7. Synthesis of sulfonic acid analog of SF-2312 
The goal of this synthesis was to prepare an analog of SF-2312 with sulfonic acid that replaces 
phosphonic acid group. The synthetic route was designed to be quick and it was analogous to the 
SF-2312 method. The starting material S0 was prepared according to a reported method.7 The next 
steps were optimized to give the desired product. The synthesis was planned to add a protecting 
group for sulfonic acid that was stable in the subsequent steps. In addition, the reaction conditions 
for deprotection of this group shouldn’t affect the stability of the final product oxopyrrolidine. The 
phenol compound was selected to protect the sulfonic acid group. It was reported that phenyl 
sulfonate ester required two equivalents of 2 N NaOH for 16 h in order to be cleaved.8 Protection 
of sulfonic acid was performed in the presence of TEA base. Changing the ratios between phenol 
and S0 didn’t increase the yield. Several reaction conditions were carried out to increase the yield 
but no increase was observed. The optimized reaction conditions of this step provided a yield of 
34% and compound S1 was used for the next step (Scheme 5.16). Installing the allyl residue was 
achieved by the use of NaH in THF to provide S1 in a quantitative yield. The byproduct from this 
reaction was the substitution of the two a-hydrogens of S0 with two allyl residues.  Hydrolysis of 
the ester group was carried out and fortunately the phenol ester was still intact. No hydrolysis was 
observed under these conditions. This was a critical step in the synthesis, it was the step where the 
protection strategy could have failed. Coupling of the acid with O-benzylhydroxylamine 
hydrochloride was performed using a general coupling procedure to provide S4.  
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Scheme 5.16. General method for the synthesis SF-2312 analog. 
Cyclization of S4 through hemiacetal provided the intermediate S5 as two isomers. The two 
isomers were identified using 2D NOESY NMR experiment. The assigment was carried out by 
investigating the NOE signal of the diastereotopic protons (Hc and Hb). It was found that Hc has a 
strong NOE with Hd and Ha. This occurs if the these three protons all in cis-conformation where 
all on the same face of oxopyrrolidone ring (Figure 5.3).  In this experiment the cis-isomer was 
the minor and the trans-isomer was the major. The assigment of protons Hd and Ha was based on 
the chemical shift and HSQC NMR experiment (Figure S160). The proton at C5 is attached to a 
carbon with two heteroatoms (N, O) which casued this proton to be deshielded and appears 
downfield at 5.10 ppm. The other proton Hd is adjacent to the carbonyl and it is connected to a 
carbon that is atatched to the sulfonate ester group. The chemical shift for this proton was either 
4.27 or 4.05 ppm. The peak at 4.05 ppm has NOE signal with Hc so this concludes that it belongs 
to one isomer.  
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Figure 5.3. NOESY spectrum of intermediate S5 showing the important peaks. 
It is worth to note that the multiplicity of the benzylic protons follows the AB quartet (ABq) 
pattern. The method for the analysis of those peaks was carried out using a reported method.9  
The chemical shift and J couplings were calculated as shown in table 5.4 and Figure 5.4. The ABq 
pattern was chosen since the value of nAB / JAB < 4.  
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Figure 5.4. 1H NMR for the S5 showing the benzylic protons of the cis and trans isomers. 
Table 5.4. ABq calculations results for the benzylic protons of S5. 
Parameter  Cis-isomer Trans-isomer 
JAB 10.2 Hz 10.9 Hz 
ncenter 2588.75 Hz 2536.88 Hz 
DnAB 27.67 Hz 22.19 Hz 
nA 2602.58 Hz 2547.98 Hz 
nB 2588.75 Hz 2525.78 Hz 
dA 5.21 ppm 5.09 ppm 
dB 5.15 ppm 5.05 ppm 
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The following step was planned to deprotect the phenol sulfonate ester to form sulfonic acid. The 
reaction conditions were chosen to deprotect the phenol sulfonic ester by keeping the 
oxopyrrolidine ring intact. The first attempt was to use a mixture of CH2Cl2/MeOH (9:1) and 1.2 
eq. of 2 N KOH. This reaction didn’t give a clean product and resulted in multiple byproducts. 
Solubility of S5 limited the solvent choice, this compound was not soluble in MeOH or EtOH. 
However, this compound was soluble in a hot methanol, so a mixture of MeOH/H2O (4:1) was 
used with 1.2 eq. of 2 N KOH. The reaction didn’t give complete conversion even after adding 
additional 1.0 eq. of base. 
It was reported in the literature10 that phenol sulfonate ester can be hydrolyzed into sulfonic acid 
using hydrogenolysis conditions using MeOH/H2O mixture. This approach was very interesting 
since the two deprotection steps can be done in one step. However, the compound was not soluble 
in the reported solvent mixture (MeOH/H2O) but the target molecule was expected to be very 
soluble. An attempt was made where the sample S5 was mixed in MeOH/H2O (4:1) and underwent 
hydrogenolysis conditions. Interestingly, this reaction was successful in that both groups were 
cleaved. Purification of the residue by prep. HPLC resulted in the desired product. Since the C18 
column does not give better separation, only few fractions were collected which resulted in a low 
yield (15%). The 1H NMR spectrum (Figure S166) showed the desired product but the multiplicity 
wasn’t clear and there was a water peak in the spectrum. Replacing MeOH-d4 with D2O is expected 
to give a better resolution. Since the mass of sample was only 6 mg the decision was made to 
proceed with the enzymatic assay to evaluate its activity against E. coli enolase. If the compound 
is active then the synthesis can be repeated.  
 
 
 130 
5.8. References: 
1. Martinelli, J.R.; Freckmann, D.M.M.; Buchwald S.L. “Convenient method for the preparation 
of Weinreb amides via Pd-catalyzed aminocarbonylation of aryl bromides at atmospheric 
pressure.” Org. Lett. 2006, 8, 4843-4846.  
2. Amatore, C.; Jutand, A.; Thuilliez, A. “Formation of palladium (0) complexes from Pd(OAc)2 
and bidentate phosphine ligand (dppp) and their reactivity in oxidative addition.” 
Organometallic, 2001, 20, 3241-3249. 
3. Fuji, M.; Mikamiyama, H.; Murai, H. “Nitrogen-containing heteroaryl compounds having HIV 
integrase inhibitory activity.” U.S. Patent 2004/0127708 A1, 2004.  
4. Kankanala, E.; Kirby, K.A.; Liu, F.; Miller, L.; Nagy, E.; Parniak, M.A.; Sarafianos, S.G.; 
Wang, Z.; Wilson, D.J. “Design, synthesis, and biological evaluations of hydroxypyridone-
carboxylic acids as inhibitors of HIV reverse transcriptase associated    
      RNase H.” J. Med. Chem. 2016, 59, 5051-5062.  
5. Fujishita, T.; Mikamiyama, M. Kawai, M.; Akiyama, T. “Substituted 3-hydroxy-4-pyridone 
derivative.”  U.S. Patent 2012/002225 5A1, 2012. 
6. Liu, X.; Meng, Z.; Li,C.; Lou, H.; Liu, L. “Organocatalytic Enantioselective Oxidative C-
H Alkenylation and Arylation of N-Carbamoyl Tetrahydropyridines and Tetrahydro-β-
carbolines.” Angew. Chem. Int. Ed. 2015, 54, 6012-6015. 
7. Hanaya, T.; Itoh, C. “An effective synthesis of antibiotic SF-2312 (3-dihydroxyphosphoryl-
1,5-dihydroxy-2-pyrrolidone.” Heterocycles 2011, 82, 1675-1683.  
8. Cao, L.; Weidner, K.; Renand, P. “Metal-Free Radical Addition to Alkenes via Desulfonylative 
Chlorine Atom Transfer.” Adv. Synth. Catal. 2011, 353, 3467-3472.   
 131 
9. Miller, S.C. “Profiling sulfonate ester stability: identification of complementary protecting 
groups for sulfonates.” J. Org. Chem. 2010, 75, 4632-4635. 
10. Reich, H.J. “5-HMR-10 AX and AB spectra.” 2018. < https://www.chem.wisc.edu/-
areas/reich/nmr/05-hmr-10-ax-ab.htm> (accessed 05/02/2018).  
11. Schedel, H.; Sieler, J.; Hennig, L.; Burger, K. “New Conformationally Restricted Phosphorus- 
and Sulfur-Containing Structure Mimetics of Glutamic Acid – Pro-Glu Chimeras.” Synthesis. 
1999, 1, 152-156.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 132 
Chapter Six  
 
 
Experimental Procedure and NMR Spectra 
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6.1. Reagents and instruments used  
 
All chemicals were purchased from commercial sources and used without further purifications. 
Thin-layer chromatography (TLC) was conducted using glass TLC plates coated with 0.2 mm 
silica gel with fluorescent indicator. Column chromatography purification was done using 60 Å 
porosity, 32-63 Å µm silica gel. C18 silica gel spherical, 200-400 mesh (40-75 µm), 70 Å,	was 
purchased from Sigma-Aldrich. 1H,13C and 31P NMR spectra were collected on Bruker DRX-400 
(400.144 MHz 1H, 100.65 13C MHz) or Bruker Avance 500 (500.13 MHz 1H, 125.65 13C, 202.404 
MHz, 13P). Chemical shifts are reported in ppm downfield from tetramethylsilane (TMS). All 
coupling constants are reported in Hertz (Hz). The following abbreviations were used to explain 
the multiplicities: s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet. 
IR spectra were recorded on Nexus 670 FTIR. All melting point (uncorrected) were recorded to 
upper limit 260  °C using a Digimelt MPA160. X-ray crystallography was recorded in Yale X-ray 
facility By Dr. Brandon Mercado using Low-temperature diffraction data (ω-scans) were collected 
on a Rigaku MicroMax-007HF diffractometer coupled to a Saturn994+ CCD detector with Cu Kα 
(λ = 1.54178 Å). The diffraction images were processed and scaled using Rigaku Oxford 
Diffraction software (CrysAlisPro; Rigaku OD: The Woodlands, TX, 2015). High resolution mass 
spectra (HRMS) was obtained from the University of Connecticut MS facility.  
6.2. Tropolone derivatives 
 
General method for the aminocarbonylation of tropolone: 2-Bromo-7-methoxytropone (1.0 
eq.), Pd(OAc)2 (5 mol%), Xantphos (6 mol%) and Cs2CO3 (3.0 eq.)  were transferred into a vial 
with rubber septum equipped with stir bar. Dioxane was added to make a solution of 0.15 M in 
tropone which then was degassed by bubbling argon through the solution for 10 min. The 
corresponding amine (2.2 eq.) was added and the mixture is bubbled with CO gas for 1.0 min. The 
 134 
mixture was heated at 80 °C for 16 h under CO. It was then cooled to room temperature and 
filtered. The filtered solid was washed with EtOAc and the filtrate was concentrated under vacuum. 
It was purified by column chromatography using silica gel and EtOAc/hexanes (1:1) to provide 
the desired aminocarbonylation product.  
General Procedure For converting α-amino into α-hydroxy-2-substituted tropone: the 
product from aminocarbonylation (1.0 eq) was dissolved in EtOH (0.2 M) and 2N KOH (20 eq) 
was added. The reaction was heated to 90°C while stirring for 16 h. The reaction was cooled room 
temperature and EtOH was removed under vacuum. The resulting residue was acidified to pH = 2 
with 2 N HCl. It was then filtered and purified by preparatory HPLC to afford the desired product.  
 
N-Benzyl-6-(benzylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T1). Orange solid 
(76%); Rf value 0.26 (Hexanes/EtOAc = 70:30); mp 125-126 °C ; IR (neat) n max: 3292,3228, 
2921, 1640, 1600, 1439 cm-1; 1H NMR (CDCl3, 400 MHz) d (ppm) 10.87 (brs, 1H), 8.94 (dd, J = 
10.4, 1.2 Hz, 1H), 8.17 (s, 1H), 7.45 – 7.28 (m, 10H), 6.93 (t, J = 10.0 Hz, 1H), 6.69 (d, J = 10.4 
Hz, 1H), 4.71 (d, J = 5.6 Hz, 2H), 4.59 (d, J = 5.7 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 
174.6, 166.9, 158.5, 142.2, 140.7, 138.9, 135.6, 129.1, 128.6, 128.2, 127.7, 127.4, 127.1, 126.9, 
121.9, 110.3, 47.5, 44.3; HRMS (ESI) (m/z) calcd for [C22H20N2O2 + H]+, 345.1592, observed 
345.1486. 
 
N-Benzyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T2). Yellow solid (51 %); 
Rf value 0.38 (EtOAc/MeOH = 10:1); mp 92-93 °C; IR (neat) n max:  3254, 3197, 3032, 2919, 
1647, 1609, 1411,1229 cm-1;  1H NMR (CDCl3, 500 MHz) d (ppm) 10.39 (s, 1H), 9.88 (s, 1H), 
OH
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9.11 (dd, J = 10.1, 1.2 Hz, 1H), 7.60 (td, J = 10.0, 1.2 Hz, 1H), 7.46 (dd, J = 9.9, 1.0 Hz, 1H), 7.41 
– 7.32 (m, 5H), 7.33 – 7.26 (m, 1H), 4.73 (d, J = 5.6 Hz, 2H); 13C NMR (CDCl3, 125 MHz) d 
(ppm) 176.1, 168.6, 165.0, 144.5, 141.2, 138.3, 130.7, 128.7, 128.0, 127.7, 127.4, 117.4, 44.4; 
HRMS (ESI) (m/z) calcd for [C15H13NO3 + Na]+, 278.0782, observed 278.0796.  
 
N-Cyclohexyl-6-(cyclohexylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T3). 
Orange solid (39%); Rf value 0.40 (Hexanes/EtOAc = 70:30); mp 70-71 °C; IR (neat) n max: 3258, 
2926, 1644, 1599, 1494, 1446 cm-1; 1H NMR (CDCl3, 500 MHz) d (ppm) 10.50 (d, J = 5 Hz, 1 H), 
8.85 (dd, J = 10.5, 1.0 Hz, 1 H), 7.95 (d, J = 5 Hz, 1 H), 7.41 (t, J = 10.0 Hz, 1 H), 6.86 (t, J = 10 
Hz, 1 H), 6.70 (d, J = 10 Hz, 1 H), 4.04 (m, 1 H), 3.58 (m, 1H), 2.03 (m, 4 H), 1.83 (m, 2 H), 1.60-
1.76 (m, 4 H), 1.38-1.61 (m, 10 H); 13C NMR (CDCl3, 125 MHz) d (ppm) 173.9, 165.9, 157.8, 
141.6, 140.3, 126.4, 121.1, 51.6, 48.6, 33.0, 32.0, 25.9, 25.5, 24.8, 24.6; HRMS (ESI) (m/z) calcd 
for [C20H28N2O2 + H]+, 329.2218, observed 329.2199. 
 
N-Cyclohexyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T4). Yellow solid 
(60%); Rf value 0.26 (EtOAc/MeOH = 10:1); mp 150-151 °C; IR (neat) n max: 3228, 2921, 2849, 
1645, 1609, 1523, 1470, 1414, 1226 cm-1; 1H NMR (CDCl3, 400 MHz) δ (ppm) 9.95 (s, 2H), 9.08 
(dd, J = 10.1, 1.3 Hz, 1H), 7.58 (td, J = 9.9, 1.2 Hz, 1H), 7.45 (dd, J = 9.9, 1.1 Hz, 1H), 7.32 (td, 
J = 10.1, 1.1 Hz, 1H), 4.05 (dd, J = 7.8, 3.9 Hz, 1H), 2.07 – 1.95 (m, 2H), 1.76 (dt, J = 8.4, 3.9 Hz, 
2H), 1.62 (d, J = 3.7 Hz, 1H), 1.58 – 1.23 (m, 6H); 13C NMR (CDCl3, 101) MHz) δ (ppm) 176.1, 
168.5, 163.7, 144.3, 140.8, 131.2, 130.0, 117.4, 48.8, 32.8, 25.7, 24.6; HRMS (ESI) (m/z) calcd 
for [C14H17NO3 + Na]+, 270.1095, observed 270.1129.  
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N-Hexyl-6-(hexylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T5). Yellow oil 
(77%); Rf value 0.73 (Hexanes/EtOAc = 1:1); IR (neat) n max: 3238, 2925, 1647, 1502, 1451, 
1329 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 10.52 (brs, 1H), 8.86 (d, J = 10 Hz, 1H), 7.91 
(brs, 1H), 7.44 (t, J = 10 Hz 1H), 6.88 (t, J = 10 Hz, 1H), 6.65 (d, J = 10 Hz, 1H), 3.48 (q, J = 6.7 
Hz, 2H), 3.37 (q, J = 6.7 Hz, 2H), 1.79 (p, J = 7.3 Hz, 2H), 1.65 (p, J = 7.3 Hz, 2H), 1.32-1.48 (m, 
12H), 0.90 (m, 6H); 13C NMR (CDCl3, 125) MHz) δ (ppm) 174.1, 166.9, 158.8, 141.7, 140.5, 
126.3, 121.2, 110.0, 109.9, 43.4, 40.2, 31.6, 31.4, 29.5, 28.4, 26.9, 26.8, 22.6, 22.5, 14.1, 14.0; 
HRMS (ESI) (m/z) calcd for [C20H32N2O2 + H]+, 333.2531, observed 333.2576.  
 
N-Hexyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T6). Yellow solid (52%); Rf  
value 0.27 (EtOAc/MeOH = 9:1); mp 49-50 °C; IR (neat) n max: 3276, 3172, 3047, 2925, 1652, 
1521, 1412 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 10.00 (brs, 1H); 9.08 (dd, J = 10.1, 1.2 Hz, 
1H), 7.58 (td, J = 10.0, 1.2 Hz, 1H), 7.46 (dd, J = 9.9, 1.1 Hz, 1H), 7.32 (td, J = 10.1, 1.1 Hz, 1H), 
3.51 (q, J = 10 Hz, 2H), 1.66 (p, J = 7.3 Hz, 2H), 1.46 – 1.39 (m, 2H), 1.37 – 1.31 (m, 4H), 0.93 – 
0.87 (m, 3H); 13C NMR (CDCl3, 125) MHz) δ (ppm) 176.1, 168.5, 164.7, 144.3, 140.9, 130.9, 
128.0, 117.4, 40.4, 31.5, 29.3, 26.8, 22.6, 14.0; HRMS (ESI) (m/z) calcd for [C14H19NO3 + Na]+, 
272.1252, observed 272.1224.   
 
N-(Cyclopropylmethyl)-6-((cyclopropylmethyl)amino)-7-oxocyclohepta-1,3,5-triene-1-
carboxamide (T7). Orange solid (76%); Rf value 0.48 (EtOAc/Hexanes = 1:1); mp 88-89 °C; IR 
(neat) n max: 3284, 3221, 3080, 2994, 1651, 1603, 1495, 1454, 1495, 1454, 1319 cm-1; 1H NMR 
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(CDCl3, 500 MHz) δ (ppm) 10.58 (brs, 1H), 8.87 (d, J = 10 Hz, 1H), 8.01 (brs, 1H), 7.42 (t, J = 
10 Hz, 1H), 6.88 (t, J = 10 Hz, 1H), 6.61 (d, J = 10 Hz, 1H), 3.38 (dd, J = 7.0, 5.3 Hz, 2H), 3.22 
(dd, J = 7.1, 5.1 Hz, 2H), 1.23 (m, 1H), 1.13 (m, 1H), 0.69 (dd, J = 9.6, 3.9 Hz, 2H), 0.56 (dd, J = 
9.6, 3.9 Hz, 2H), 0.36 (dd, J = 10.5, 5.5 Hz, 2H), 0.31 (dd, J = 10.0, 5.0 Hz, 2H); 13C NMR (CDCl3, 
125) MHz) δ (ppm) 174.2, 166.9, 158.7, 141.9, 140.5, 126.6, 121.4, 110.0, 48.5, 45.0, 10.8, 9.9, 
4.0, 3.6; HRMS (ESI) (m/z) calcd for [C16H20N2O2 + H]+, 273.1592, observed 273.1546. 
 
N-(Cyclopropylmethyl)-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T8). 
Yellow solid (47%); Rf value 0.12 (EtOAc/MeOH = 9:1); mp 94-95 °C; IR (neat) n max: 3269, 
3159, 2997, 1653, 1612, 1528, 1474, 1416, 753 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 10.07 
(brs, 1H), 9.98 (sb, 1H), 7.59 (t, J = 10 Hz, 1H), 7.46 (d, J = 10 Hz, 1H), 7.32 (t, J = 10 Hz, 1H), 
3.39 (appt, J = 5 Hz, 2H), 1.12 (m, 1H), 0.58 (brd, J = 10 Hz, 2H), 0.31 (brd, J = 5 Hz, 2H); 13C 
NMR (CDCl3, 125) MHz) δ (ppm) 176.1, 168.6, 164.7, 144.3, 141.0, 130.9, 127.9, 117.4, 45.1, 
10.6, 3.5; HRMS (ESI) (m/z) calcd for [C12H13NO3 + Na]+, 242.0782, observed 242.0718.  
 
N-Cyclopropyl-6-(cyclopropylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T9). 
Yellow sloid (75%); Rf value 0.38 (EtOAc/Hexanes = 1:1); mp 109.5-111 °C; IR (neat) n max: 
3260, 3071, 2992, 1649, 1597, 1447, 1323, 1197 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 10.50 
(brs, 1H), 8.89 (dd, J = 10.4, 1.2 Hz, 1H), 7.82 (brs, 1H), 7.48 (t, J = 10 Hz, 1H), 7.17 (d, J = 10 
Hz, 1H), 6.95 (t, J = 10.0 Hz, 1H), 3.02 (tq, J = 7.7, 4.0 Hz, 1H), 2.65 (tq, J = 6.8, 3.6 Hz, 1H), 
1.01 (td, J = 6.9, 5.1 Hz, 2H), 0.84 (td, J = 7.0, 5.0 Hz, 2H), 0.74 – 0.67 (m, 2H), 0.66 – 0.59 (m, 
2H); 13C NMR (CDCl3, 125) MHz) δ (ppm) 174.3, 168.3, 160.2, 141.7, 140.6, 126.8, 122.2, 
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111.51, 24.7, 23.1, 7.6, 6.6; HRMS (ESI) (m/z) calcd for [C14H16N2O2 + H]+, 245.1279, observed 
245.1287.  
 
N-Cyclopropyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide (T10).  Yellow solid 
(27%); Rf value 0.21 (EtOAc/MeOH = 9:1); mp 103.5-104.5 °C; IR (neat) n max: 3138, 3082, 
2999, 1645, 1536, 1415, 1305, 754 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 10.03 (brs, 2H), 
9.08 (d, J = 9.9 Hz, 1H), 7.59 (t, J = 9.9 Hz, 1H), 7.45 (d, J = 9.9 Hz, 1H), 7.33 (t, J = 10.1 Hz, 
1H), 3.03 (tq, J = 7.7, 4.0 Hz, 1H), 0.88 (m, 2H), 0.67 (m, 2H); 13C NMR (CDCl3, 125) MHz) δ 
(ppm) 176.0, 168.5, 166.2, 144.2, 141.1, 130.6, 128.0, 117.4, 23.3, 6.7; HRMS (ESI) (m/z) calcd 
for [C11H11NO3 + Na]+, 228.0626, observed 228.0611.  
 
Diethyl (6-methoxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonate (T11). 7-Methoxy-2-
bromotropone (100 mg, 0.465 mmol), Pd(OAc)2 (6 mg, 0.0267 mmol, 6 mol%), Xantphos (17 mg, 
0.0294 mmol, 6 mol%) were transferred to a vail and toluene (2.0 mL) was added. The mixture 
was bubbled with Ar for 10 min followed by the addition of triethyl amine (97 µL, 0.696 mmol, 
1.5 eq.) and diethyl phosphite (90 µL, 0.698 mmol, 1.5 eq.). The mixture was heated at 100 °C for 
1 h. It was then brought to room temperature and concentrated under vacuum. The residue was 
purified using silica gel and EtOAc/Hexanes (1:1) followed by EtOAc/MeOH (10:0.5) to provide 
yellow oil (110 mg, 86%). Rf value 0.18 (EtOAc/MeOH = 100:0.5); IR (neat) n max: 2981, 1596, 
1493, 1360, 1281, 1218, 1167, 1106, 1017, 956, 795, 563 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
(ppm) 20.25 (ddd, J = 23.7, 8.8, 1.1 Hz, 1H), 17.91 – 17.68 (m, 1H), 17.07 (ddd, J = 11.0, 8.8, 2.7 
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Hz, 1H), 16.54 (d, J = 9.7 Hz, 1H), 10.80 – 10.34 (m, 4H), 9.77 (s, 3H), 3.33 (t, J = 7.1 Hz, 6H); 
8.20 (ddd, J = 23.8, 8.8, 1.1 Hz, 1H), 7.20 (ddt, J = 10.8, 9.7, 1.2 Hz, 1H), 6.91 (ddd, J = 10.9, 8.8, 
2.7 Hz, 1H), 6.69 (d, J = 9.7 Hz, 1H), 4.37 – 4.20 (m, 4H), 3.95 (s, 3H), 1.35 (t, J = 7.1 Hz, 1H); 
13C NMR (CDCl3, 125) MHz) δ (ppm) 179.2 (d, J = 7.5 Hz), 166.2 (d, J = 16.2 Hz), 144.4 (d, J = 
6.2 Hz), 136.6 (d, J = 2.5 Hz), 136.2, 134.8, 126.3 (d, J = 21.5 Hz), 111.4, 63.2 (d, J = 6.2 Hz), 
56.7, 16.4 (d, J = 7.5 Hz); 31P NMR (CDCl3, 200 MHz) ) δ (ppm) 16.8; HRMS (ESI) (m/z) calcd 
for [C12H17O5P + H]+, 273.0881, observed 273.0762. 
 
(6-Hydroxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonic acid (T12). Diethyl (6-methoxy-7-
oxocyclohepta-1,3,5-trien-1-yl) phosphonate T11 (90 mg, 0.33 mmol) was transferred to a vial. 
To this was added EtOH (0.50 mL) and 6 M HCl (0.50 mL) and then it was heated at 100 °C for 
12 h. It cooled to room temperature and EtOH removed under vacuum. The residue was neutralized 
with 2 N NaOH and purified by prep HPLC providing the title compound as pale-yellow solid (13 
mg, 20%). Rf value 0.36 (MeOH/H2O = 1:1); mp 185-186 °C; IR (neat) n max: 3217, 2993, 1732, 
1650, 1601, 1518, 1499, 1460, 1370, 1326, 1191, 817, 739, 689, 617, 541, 472 cm-1; 1H NMR 
(D2O, 500 MHz) δ (ppm) 8.20 (dd, J = 19.9, 9.8 Hz, 1H), 7.68 (t, J = 10.2 Hz, 1H), 7.48 (d, J = 
10.7 Hz, 1H), 7.33 (t, J = 9.9 Hz, 1H); 13C NMR (MeOH-d4, 125) MHz) δ (ppm) 177.8, 169.7, 
144.0 (d, J = 6.2 Hz), 141.4, 133.7 (d, J = 172 Hz), 128.3 (d, J = 20 Hz), 119.5; 31P NMR (MeOH-
d4, 200 MHz) ) δ (ppm) 14.4; HRMS (ESI) (m/z) calcd for [C7H7O5P +H]+, 203.0109, observed 
203.0175.  
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6.3. (8-Hydroxyquinoline)-7-carboxamide derivatives 
General method for the preparation of hydroxyquinoline derivatives: 8-hydroxyquinoline-7-
carboxylic acid (1.0 eq.) was dissolved in DMF (0.15 M). EDC.HCl (1.2 eq.) and HOBt (1.2 eq.) 
were added at room temperature and the mixture was stirred for 30 min. Then, it was cooled in an 
ice bath to which amine (1.0 eq.) was added and the solution was stirred for 1 h at room 
temperature. After that, it was diluted with H2O and extracted with EtOAc (3 ´) followed by 
washing the organic layer with brine. It was dried over Na2SO4 and the solvent was removed under 
vacuum. The residue was recrystallized from the proper solvent or purified using silica gel to yield 
the desired product.  
 
N-Benzyl-8-hydroxyquinoline-7-carboxamide (H1). Recrystallized from isopropanol provided 
a pale yellow solid (28%); Rf value 0.38 (EtOAc/MeOH = 90:10); mp 140-141; IR (neat) n max: 
3228, 3063, 2926, 1716, 1636, 1560, 1460, 1324, 1291, 1106, 831 cm-1; 1H NMR (CDCl3, 500 
MHz) d (ppm) 8.84 (dd, J = 4.3, 1.6 Hz, 1H), 8.22-8.14 (m, 3H), 7.53 (dd, J = 8.3, 4.3 Hz, 1H), 
7.42 (t, J = 5 Hz, 2H), 7.39 – 7.35 (m, 2H), 7.32 – 7.27 (m, 1H), 4.77 (d, J = 5.8 Hz, 2H); 13C 
NMR (CDCl3, 125 MHz) d (ppm) 165.7, 152.0, 148.5, 138.6, 138.5, 136.2, 130.1, 128.7, 127.8, 
127.5, 127.4, 123.3, 117.7, 113.9, 43.9; HRMS (ESI) (m/z) calcd for [C17H14N2O2 + H]+, 
279.1123, observed 279.1113.  
 
(8-Hydroxyquinolin-7-yl)(morpholino) methanone (H2). Purified using silica gel and 
CH2Cl2/MeOH (95:5) to provide a pale green solid (20%); Rf value 0.34 (EtOAc/MeOH = 90:10); 
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mp 158-159 °C; IR (neat) n max: 3252, 3057, 2988, 2852, 1620, 1497, 1438, 1374, 1279, 1189, 
1104, 1066, 1027, 827, 720, 578 cm-1;  1H NMR (CDCl3, 500 MHz) d (ppm) 8.83 (dd, J = 4.3, 1.5 
Hz, 1H), 8.18 (dd, J = 8.3, 1.5 Hz, 1H), 7.51 (dd, J = 8.4, 3.8 Hz, 2H), 7.39 (d, J = 8.4 Hz, 1H), 
3.82 – 3.72 (m, 4H), 3.68 (s, 4H); 13C NMR (CDCl3, 125 MHz) d (ppm) 167.2, 148.7, 148.5, 138.0, 
136.2, 128.9, 127.0, 122.8, 118.4, 117.1, 67.1; 45.0; HRMS (ESI) (m/z) calcd for [C14H14N2O3 + 
H]+, 259.1072, observed 259.1030.  
 
8-Hydroxy-N-(2-methoxybenzyl)quinoline-7-carboxamide (H3). Recrystallized from EtOAc, 
yellow solid (27%); Rf value 0.23 (EtOAc/MeOH = 90:10); mp 185-186 °C; IR (neat) n max: 3242, 
3076, 2927, 1634, 1615, 1551, 1493, 1459, 1383, 1325, 1292, 1247, 1012, 887, 831, 752, 502 cm-
1; 1H NMR (DMSO-d6, 500 MHz) d (ppm) 9.23 (t, J = 5.8 Hz, 1H), 8.92 (dd, J = 4.2, 1.7 Hz, 1H), 
8.37 (dd, J = 8.3, 1.6 Hz, 1H), 8.06 (d, J = 8.8 Hz, 1H), 7.66 (dd, J = 8.3, 4.2 Hz, 1H), 7.44 (d, J = 
8.8 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.03 (d, J = 8.5 Hz, 1H), 6.92 (t, J = 7.4 Hz, 1H), 4.56 (d, J = 
5.7 Hz, 2H), 3.86 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) d (ppm) 167.2, 156.9, 155.9, 148.9, 
139.0, 136.1, 130.5, 128.3, 127.9, 126.3, 125.6, 123.4, 120.2, 116.9, 113.1, 110.6, 55.4, 38.1; 
HRMS (ESI) (m/z) calcd for [C18H16N2O3 + H]+, 309.1228, observed 309.1209.  
 
Methyl 4-(8-hydroxyquinoline-7-carboxamido) benzoate (H4). Triturated from hot 
isopropanol, orange solid (8%); Rf value 0.28 (EtOAc/MeOH = 90:10); mp 235-236 °C; IR (neat) 
n max: 1717, 1659, 1584, 1530, 1487, 1458, 1408, 1272, 1185, 1112, 1012, 880, 810, 764, 583 
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cm-1; 1H NMR (DMSO-d6, 500 MHz) d (ppm) 11.61 (brs, 1H), 8.93 (dd, J = 4.4, 1.5 Hz, 1H), 8.67 
– 8.43 (m, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.90 (d, J = 8.6 Hz, 2H), 7.76 (dd, J = 8.3, 4.3 Hz, 1H), 
7.39 (d, J = 8.7 Hz, 1H), 3.85 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) d (ppm) 166.3, 165.9, 
156.4, 147.4, 143.8, 139.0, 138.3, 131.5, 130.9, 128.1, 124.7, 124.0, 119.8, 116.3, 115.3, 52.4; 
HRMS (ESI) (m/z) calcd for [C18H14N2O4 + H]+, 323.1021, observed 323.1100.  
 
N-(4-Bromophenyl)-8-hydroxyquinoline-7-carboxamide (H5). Recrystallized from EtOAc, 
pinkish solid (42%); Rf value 0.68 (EtOAc/MeOH = 90:10); mp 203-204 °C; IR (neat) n max: 
3325, 3262, 1649, 1584, 1511, 1432, 1389, 1304, 1236, 1191, 1124, 1070, 1008, 949 cm-1;  1H 
NMR (DMSO-d6, 500 MHz) d (ppm) 11.17 (s, 1H), 8.93 (dd, J = 4.4, 1.6 Hz, 1H), 8.50 (dd, J = 
8.3, 1.6 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.77 – 7.69 (m, 3H), 7.56 (d, J = 8.8 Hz, 2H), 7.41 (d, 
J = 8.7 Hz, 1H); 13C NMR (DMSO-d6, 125 MHz) d (ppm) 165.9, 156.0, 147.9, 138.7, 138.3, 132.2, 
131.3, 127.6, 123.9, 122.5, 116.1, 115.9, 115.8; HRMS (ESI) (m/z) calcd for [C16H11BrN2O2 + 
H]+, 343.0071, observed 343.0042.  
 
8-Hydroxy-N-(4-isopropylbenzyl)quinoline-7-carboxamide (H6). Recrystallized from 
isopropanol, white solid (19%); Rf value 0.40 (EtOAc/MeOH = 90:10); mp 149.5-155.5 °C; IR 
(neat) n max: 3371, 3290, 1639, 1531, 1468, 1433, 1386, 1330, 1294, 1199, 1159, 1097, 1045, 
834, 663 cm-1; 1H NMR (DMSO-d6, 500 MHz) d (ppm) 9.30 (t, J = 6.0 Hz, 1H), 8.91 (dd, J = 4.2, 
1.6 Hz, 1H), 8.35 (dd, J = 8.3, 1.6 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.65 (dd, J = 8.3, 4.2 Hz, 1H), 
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7.43 (d, J = 8.8 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 8.0 Hz, 2H), 4.55 (d, J = 5.9 Hz, 
2H), 1.19 (d, J = 6.8 Hz, 6H); 13C NMR (DMSO-d6, 125 MHz) d (ppm) 168.4, 157.2, 149.6, 147.6, 
136.9, 136.5, 131.2, 128.0, 126.8, 125.6, 124.0, 117.4, 113.1, 42.9, 33.6, 24.4; HRMS (ESI) (m/z) 
calcd for [C20H20N2O2 + H]+, 321.1592, observed 321.1635.  
 
N-(4-Fluorophenyl)-8-hydroxyquinoline-7-carboxamide (H7). Recrystallized from 
isopropanol, red solid (34%); Rf value 0.48 (EtOAc/MeOH = 90:10); mp 200-201 °C; IR (neat) n 
max: 3366, 3262, 1659, 1610, 1543, 1507, 1384, 1212, 1121, 820, 727, 629 cm-1; 1H NMR (CDCl3, 
500 MHz) d (ppm) 9.88 (s, 1H), 8.86 (dd, J = 4.3, 1.5 Hz, 1H), 8.31 (d, J = 8.9 Hz, 1H), 8.22 (dd, 
J = 8.3, 1.5 Hz, 1H), 7.73 (dd, J = 9.0, 4.8 Hz, 2H), 7.57 (dd, J = 8.3, 4.2 Hz, 1H), 7.46 (d, J = 8.9 
Hz, 1H), 7.08 (t, J = 8.6 Hz, 2H); 13C NMR (CDCl3, 125 MHz) d (ppm) 163.2, 160.4, 158.5, 150.8, 
148.5, 138.2, 136.3,134.4 (d, J = 3.8 Hz), 130.1, 127.9, 123.6, 122.2 ( d, J = 8.8 Hz), 118.1, 115.6 
(d, J = 22.5 Hz), 114.6; HRMS (ESI) (m/z) calcd for [C16H11FN2O2 + H]+, 283.0872, observed 
283.0913.  
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6.4 Pyridone Derivatives 
 
--------------------------------------------------------------------------------------------------------- 
 
 
 
Ethyl (E)-4-(benzyloxy)-2-((dimethylamino)methylene)-3-oxobutanoate (1). Ethyl (E)-3-
(dimethylamino)acrylate (1.10 g, 7.68 mmol) were dissolved in CH2Cl2 (8 mL) and cooled in an 
ice bath. A solution of benzyloxyacetyl chloride (1.3 mL, 8.37 mmol, 1.1 eq.) was added dropwise 
to the above solution and left stirring for 30 min at 0 °C. It was then warmed to room temperature 
and left stirring overnight. Then, it was diluted with CH2Cl2 (20 mL) and H2O (20 mL) was added. 
Layers were separated and the aqueous layer was extracted with CH2Cl2 (3 ´ 20 mL), washed with 
brine (40 mL) and dried over sodium sulfate. The solvent was removed under vacuum resulting in 
yellow oil. It was purified by silica gel using EtOAc/Hexanes = 1:1 then 100 % EtOAc which 
provided yellow oil (1.6 g, 72% yield) and the spectra were consistent with the reported values.1 
Rf value 0.43 (EtOAc); IR (neat) n max: 3029, 2978, 1685, 1644, 1577, 1423, 1377, 1278, 1204, 
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1093, 738, 698 cm-1; 1H NMR (CDCl3, 500 MHz) d (ppm) 7.73 (s, 1H), 7.38-7.27 (m, 6H), 4.59 
(s, 2H), 4.45 (s, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.24 (brs, 3H), 2.89 (brs, 3H), 1.25 (t, J = 7.1 Hz, 
3H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 194.6, 167.6, 157.9, 138.1, 128.3, 127.9, 75.1, 73.2, 
69.2, 60.1, 47.7, 42.1, 14.4. 
 
Ethyl 5-(benzyloxy)-4-oxo-4H-pyran-3-carboxylate (2). This compound was prepared by 
modifying a reported method.2 NaOtBu (404 mg, 4.20 mmol) was transferred to a dry vial equipped 
with stir bar and THF (2.0 mL) was added under N2. Ethyl (E)-4-(benzyloxy)-2-
((dimethylamino)methylene)-3-oxobutanoate 1 (620 mg, 2.13 mmol) was dissolved in THF (2.0 
mL) and it was added dropwise to the above solution at room temperature. Then, ethyl formate 
(2.5 mL, 30.9 mmol) was added dropwise and the mixture was stirred overnight. The reaction was 
quenched with 2 N HCl (2.0 mL) and the THF was removed under vacuum. The resulting residue 
was diluted with H2O (15 mL) and extracted with EtOAc (3 ´ 15 mL), combined organics were 
washed with brine (20 mL) and dried over NaSO4. After removing solvent under vacuum and 
purifying the residue using silica gel and EtOAc/Hexanes = 1:1, a colorless solid was obtained 
(400 mg, 69% yield). Rf value 0.60 (EtOAc/Hexanes = 80:20); mp 93.6-94.6 °C; IR (neat) n max: 
3092, 2985, 1725, 1625, 1281, 1087, 1026 cm-1;  1H NMR (CDCl3, 500 MHz) d (ppm) 8.40 (d, J 
= 0.9 Hz, 1H), 7.55 (d, J = 0.9 Hz, 1H), 7.42 – 7.29 (m, 5H), 5.11 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 
1.37 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 170.5, 162.8, 160.0, 148.8, 141.9, 
135.6, 128.7, 128.5, 127.8, 120.4, 72.4, 61.6, 14.2; HRMS (ESI) (m/z) calcd for [C15H14O5 + H]+, 
275.0909, observed 275.0853.  
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General method for the formation of 3 
Ethyl 5-(benzyloxy)-4-oxo-4H-pyran-3-carboxylate 2 (1.0 mmol) is dissolved in EtOH (5.0 mL) 
and the corresponding amine (2.0 mmol) is added and the solution was stirred for 1 h at room 
temp. Then, CH3COOH (4.0 mL) was added and it was heated at 80 °C for 2 h. Afterwards, EtOH 
was removed under vacuum and the residue was diluted with H2O and extracted with EtOAc (3 
´), combined organics were washed with brine, dried over NaSO4 and rotavaped resulting in pale 
yellow oil. This intermediate was dissolved in EtOH (5.0 mL) and 2 N KOH (10.0 mL) was added. 
It was heated at 90 °C for 4 h, then EtOH was removed under vacuum. The residue was acidified 
with 2 N HCl to pH = 2, precipitate was filtered and dried under vacuum in an oven overnight to 
afford the desired product 3 which is used for subsequent reactions without purifications.  
General method for the formation of 4 
Reaction conditions A: compound 3 (1.0 mml) was dissolved in DMF (2.0 mL). HATU (1.2 
mmol) was added followed by DIPEA (1.2 mmol). Then, the amine (1.2 mmol) was added and the 
whole was stirred overnight at room temp. It was then diluted with H2O and extracted with EtOAc 
(3 ´) and combined organics were washed with brine, dried over Na2SO4 and solvent removed 
under vacuum. Recrystallization of the reside from MeOH or EtOAc provides the desired 
compound pure.  
Reaction conditions B: compound 3 (1.0 mmol) was dissolved in DMF (2.0 mL), TEA (5 eq.) 
was added followed by the addition of ethyl chloroformate (2 eq.) at 0 °C and under Ar. The 
mixture was stirred for 10 min at the same temperature then the amine (2.0 eq.) and a catalytic 
amount of DMAP were added. It was then brought to room temperature and stirred for 1 h. It was 
diluted with H2O and extracted with EtOAc (3 ´), combined organics were washed with brine and 
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dried over Na2SO4. The residue either recrystallized from MeOH/EtOAc or it is pure and no further 
purifications were required.  
General procedure for the debenzylation reaction 
Method A: TFA was added to a sample (30-50 mg) in a vial equipped with a stir bar and it was 
heated at 80 °C for 1 h. It was then cooled to room temp. and the TFA was removed under vacuum. 
The residue was triturated with a mixture of MeOH/diethyl ether = 1:1 and the precipitate was 
filtered. The solid was washed with diethyl ether and dried to afford the desired molecule pure.  
Method B:  The sample is dissolved in MeOH (5.0 mL) and bubbled with Ar. It was then subjected 
to the hydrogenolysis conditions. The residue was filtered through a plug of celite to remove Pd/C.  
 
1-Benzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (P1). White solid (60%); 
mp 209-210 °C; Rf  value 0.53 (EtOAc/MeOH = 90:10); IR (neat) n max: 3064, 1712, 1631, 1547, 
1438, 1275, 1141, 1051, 702 cm-1; 1H NMR (CDCl3, 500 MHz) d (ppm) 15.40 (s, 1H), 8.44 (d, J 
= 2.2 Hz, 1H), 7.44 – 7.36 (m, 3H), 7.32-7.40 (m, 5H), 7.08 (dd, J = 7.5, 1.5 Hz, 2H), 7.05 (d, J = 
2.3 Hz, 1H), 5.15 (s, 2H), 5.01 (s, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 173.3, 166.5, 150.0, 
141.7, 135.1, 132.8, 129.7, 129.6, 128.8, 128.6, 127.8, 126.1, 115.6, 72.2, 62.2; HRMS (ESI) (m/z) 
calcd for [C20H17NO4 + H]+, 336.1225, observed 336.1169.  
 
N,1-Dibenzyl-5-(benzyloxy)-N-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P2). 
Reaction conditions A, recrystallized from MeOH provides white solid (40%); Rf value 0.74 
(EtOAc/MeOH = 9:1); mp 167-168 °C; IR (neat) n max: 3612, 3012, 2886, 2846, 1636, 1597, 
1564, 1169 cm-1; 1H NMR (CDCl3, 500 MHz) d (ppm) 11.61 (s, 1H), 8.19 (d, J = 2.4 Hz, 1H), 
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7.44 (d, J = 7.1 Hz, 2H), 7.40 – 7.32 (m, 3H), 7.29 (s, 4H), 7.10 – 7.05 (dd, J = 6,1.5 Hz, 2H), 7.01 
(d, J = 2.3 Hz, 1H), 5.12 (s, 2H), 4.99 (d, J = 6.2 Hz, 4H); 13C NMR (CDCl3, 101 MHz) δ (ppm) 
170.2, 163.9, 149.9, 142.4, 136.3, 135.5, 133.1, 129.6, 129.5, 128.8, 128.5, 128.4, 128.1, 127.8, 
127.8, 127.4, 125.2, 124.2, 72.2, 61.9, 52.6; HRMS (ESI) (m/z) calcd for [C27H24N2O4 + H]+, 
441.1803, observed 441.1604. 
 
N,1-Dibenzyl-N,5-dihydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P3). Method B, 
34% white solid; Rf  value 0.68 (EtOAc/MeOH = 9:1); mp 119-120 °C; IR (neat) n max: 3204, 
3031, 2968, 1644, 1603,1530, 1486, 1147, 696 cm-1; 1H NMR (CDCl3, 400 MHz) d (ppm) 11.30 
(s, 1H), 8.22 (d, J = 2.2 Hz, 1H), 7.43 (m, 5H), 7.39 – 7.28 (m, 4H), 7.00 (s, 1H), 5.10 (s, 2H), 
4.98 (s, 2H); 13C NMR (CDCl3, 101 MHz) δ (ppm) 167.3, 163.8, 149.1, 141.3, 136.3, 133.1, 129.7, 
129.6, 128.6, 128.2, 128.1, 127.5, 120.1, 119.9, 62.5, 52.5; HRMS (ESI) (m/z) calcd for 
C20H18N2O4 [M+H]+, 351.1334, found 351.1353.  
 
             
1-Benzyl-5-(benzyloxy)-N-cyclohexyl-4-oxo-1,4-dihydropyridine-3-carboxamide (P4). 
Reaction conditions A, recrystallized from MeOH, white solid (39%); Rf  value 0.55 (EtOAc); mp 
187-188 °C; IR (neat) n max: 3612, 3045, 2928, 2852, 1654, 1611, 1536, 1267, 731 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ (ppm) 10.28 (d, J = 10.5 Hz, 1H); 8.47 (d, J = 2 Hz, 1H), 7.36-7.28 (m, 8H), 
7.07 (dd, J = 7.5, 2 Hz, 2H), 6.91 (d, J = 2.5 Hz, 1H), 5.07 (s, 2H), 4.96 (s, 2H); (CDCl3, 125 MHz) 
δ (ppm) 171.9, 163.4, 150.2, 141.3, 135.9, 133.9, 129.4, 129.2, 128.6, 128.2, 127.8, 127.5, 124.4, 
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118.7, 71.9, 61.6, 47.7, 32.8, 25.8, 24.5; HRMS (ESI) (m/z) calcd for [C26H28N2O3 + H]+, 
417.2167, observed 417.2181.  
 
1-Benzyl-N-cyclohexyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P5). Method 
A, white solid (41%); Rf value 0.69 (EtOAc/MeOH = 9:1); mp 224-225 °C; IR (neat) n max: 3205, 
3035, 2923, 2846, 1657, 1631, 1539, 1277, 1156 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 9.78 
(d, J = 8.1 Hz, 1H), 8.46 (d, J = 2.3 Hz, 1H), 7.40 (d, J = 5 Hz, 1H), 7.39 (d, 5 Hz, 2H), 7.23 (d, 5 
Hz, 1H), 7.22 (d, J = 2.5 Hz, 2H), 5.06 (s, 2H), 3.99 (m,1H), 2.03 – 1.89 (m, 2H), 1.74 (m, 2H), 
1.60 (m, 1H), 1.49 – 1.22 (m, 6H); 13C NMR (CDCl3, 125 MHz) δ (ppm)169.3, 163.1, 149.3, 
140.2, 133.8, 129.5, 129.4, 127.8, 119.2, 115.6, 62.1, 47.8, 32.9, 25.7, 24.6; HRMS (ESI) (m/z) 
calcd for [C19H22N2O3 + H]+, 327.1698, observed 327.1611.  
 
1-Benzyl-5-(benzyloxy)-4-oxo-N-(pyridin-2-yl)-1,4-dihydropyridine-3-carboxamide (P6). 
Reaction conditions A, recrystallized from MeOH, pale yellow solid (43%); mp 183-184 °C; IR 
(neat) n max: 3647, 3028, 2998, 1670, 1626, 1531, 1432, 1288, 1164, 734,699 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ (ppm) 12.87 (s, 1H), 8.52 (d, J = 2.4 Hz, 1H), 8.38 (dd, J = 5.0, 1.8 Hz, 1H), 
8.26 (d, J = 8.3 Hz, 1H), 7.68 (td, J = 10, 5 Hz, 1H), 7.38-7.29 (m, 8H), 7.09 (dd, J = 7.3, 2.2 Hz, 
2H), 7.01 (dd, J = 10, 5 Hz, 2H), 5.19 (s, 2H), 4.98 (s, 2H); (CDCl3, 125 MHz) δ (ppm) 172.1, 
163.0, 152.1, 150.3, 148.5, 141.8, 137.8, 136.1, 129.5, 129.3, 128.6, 128.3, 128.0, 127.6, 126.1, 
119.5, 118.3, 114.9, 72.3, 61.7, 50.9; HRMS (ESI) (m/z) calcd for [C25H21N3O3 + H]+, 412.1650, 
observed 412.1598. 
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1-Benzyl-5-hydroxy-4-oxo-N-(pyridin-2-yl)-1,4-dihydropyridine-3-carboxamide (P7). 
Method A, white solid (61%); Rf value 0.63 (EtOAc/MeOH = 9:1); mp 235-236 °C; IR (neat) n 
max: 3299, 3023, 1668, 1643, 1524, 1435, 1297, 1135 cm-1; 1H NMR (DMSO-d6, 500 MHz) δ 
(ppm) 12.93 (s, 1H), 9.45 (brs, 1H), 8.65 (d, J = 2.5 Hz, 1H), 8.34 (d, J = 4.5 Hz, 1H), 8.25 (d, J 
= 8.5 Hz, 1H), 7.83 (t, J = 8 Hz, 1H), 7.72 (s, 1H), 7.41 (m, 5H), 7.13 (t, J = 4.5 Hz, 1H), 5.33 (s, 
2H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 170.1, 163.3, 152.2, 150.0, 148.7, 140.6, 138.8, 
136.4, 129.4, 129.0, 128.5, 123.2, 120.0, 115.1, 114.4, 60.3; HRMS (ESI) (m/z) calcd for 
[C18H15N3O + H]+, 322.1181, observed 322.1050.  
 
1-Benzyl-5-(benzyloxy)-4-oxo-N-(pyridin-4-yl)-1,4-dihydropyridine-3-carboxamide (P8). 
Reaction conditions A, recrystallized from MeOH, white solid (56%); Rf value 0.5 (EtOAc); mp 
128-130; IR (neat) n max: 3630, 1692, 1633, 1552, 1633, 1506, 1267, 1154, 831 cm-1; 1H NMR 
(DMSO-d6, 500 MHz) δ (ppm) 13.57 (s, 1H), 8.75 (s, 1H), 8.61 (s, 1H), 8.00 (s, 1H), 7.96 (d, J = 
5 Hz, 2H), 7.41-7.36 (m, 10H), 5.35 (s, 2H), 5.06 (s, 2H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 
170.9, 164.4, 150.3, 146.2, 142.6, 136.5, 136.3, 129.5, 129.0, 128.9, 128.7, 128.5, 128.4, 126.1, 
115.9, 115.2, 79.7, 71.3, 60.5; HRMS (ESI) (m/z) calcd for [C25H21N3O3 + H]+, 412.1650, 
observed 412.1598. 
 
1-Benzyl-5-hydroxy-4-oxo-N-(pyridin-4-yl)-1,4-dihydropyridine-3-carboxamide (P9). 
Method A, yellow solid (56%); Rf value 0.33 (EtOAc/MeOH = 9:1); mp 242-243; IR (neat) n max: 
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3221, 3032, 2952, 1690, 1638, 1558, 1507, 1319, 1133, 824 cm-1; 1H NMR (DMSO-d6, 500 MHz) 
δ (ppm) 13.64 (s, 1H), 9.68 (brs, 1H), 8.72 (d, J = 2 Hz, 1H), 8.66 (d, J = 6.5 Hz, 2H), 8.00 (d, J = 
6 Hz, 2H), 7.76 (d. J = 2.5 Hz, 1H), 7.42-7.36 (m, 5H), 5.36 (s, 2H); 13C NMR (DMSO-d6, 125 
MHz) δ (ppm) 170.4, 164.7, 150.7, 150.1, 145.4, 141.0, 136.3, 129.5, 129.1, 128.6, 123.9, 115.3, 
114.5, 60.5; HRMS (ESI) (m/z) calcd for [C18H15N3O3 + H]+, 322.1181, observed 322.1050.     
 
N,1-Dibenzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxamide (P10). Reaction 
conditions A, recrystallized from methanol, white solid (44%); mp 175-176; Rf value 0.52 
(EtOAc); IR (neat) n max: 3623, 3051, 2953, 1646, 1612, 1547, 1266, 1156, 1068, 731, 695 cm-1; 
1H NMR (CDCl3, 500 MHz) δ (ppm) 10.67 (brs, 1H), 8.50 (d, J = 2.5 Hz, 1H), 7.36-7.30 (m, 13H), 
7.06 (dd, J = 10, 5 Hz, 2H), 6.93 (d, J = 5 Hz, 1H), 5.07 (s, 2H), 4.95 (s, 2H), 4.64 (d, J = 5 Hz, 
2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 171.9, 164.6, 150.3, 141.5, 138.6, 135.8, 133.8, 129.4, 
129.2, 128.6, 128.5, 128.3, 127.8, 127.6, 127.5, 127.0, 124.7, 118.3, 72.0, 61.6, 43.3;  HRMS (ESI) 
(m/z) calcd for [C27H24N2O3 + H]+, 425.1854, observed 425.1762.  
 
N,1-Dibenzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P11). Method A, white 
solid (42%); Rf value 0.50 (EtOAC); mp 178-179 °C; IR (neat) n max: 3649, 3031, 1653, 1632, 
1494, 1274, 1145, 803 cm-1; 1H NMR (CDCl3, 400 MHz) δ (ppm) 10.16 (s, 1H), 8.49 (s, 1H), 
7.39-7.21 (m, 10H), 5.06 (s, 2H), 4.64 (d, J = 5 Hz); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.4, 
164.3, 149.5, 140.3, 138.6, 133.7, 129.5, 129.4, 128.6, 127.8, 127.6, 127.2, 119.4, 115.1, 62.1, 
43.3; HRMS (ESI) (m/z) calcd for [C20H18N2O3 + H]+, 335.1385, observed 335.1269. 
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1-Benzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxylic acid (P12). Method A, pale 
yellow solid (85%); Rf value 0.24 (EtOAc/MeOH = 90:10); mp 242.5-243.5 °C; IR (neat) n max : 
3217, 3088, 2985, 1712, 1643, 1564, 1442, 1138, 754 cm-1, 1H NMR (DMSO-d6, 500 MHz) δ 
(ppm) 16.01 (s, 1H), 10.10 (s, 1H), 8.68 (s, 1H), 7.84 (s, 1H), 7.41 (s, 5H), 5.35 (s, 2H); 13C NMR 
(DMSO-d6, 125 MHz) δ (ppm) 171.5, 166.6, 149.0, 140.6, 136.1, 129.5, 129.2, 128.6, 126.2, 
113.7, 60.5; HRMS (ESI) (m/z) calcd for [C13H10NO4]-, 244.0615, observed 244.0688. 
 
1-Benzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxamide (P13). Ethyl 1-benzyl-5-
(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxylate 3 (53 mg, 0.146 mmol) was mixed with 3.0 
mL of 7 N NH3/MeOH and stirred for 48 h at room temp. The solvent was then removed under 
vacuum and the residue was triturated with diethyl ether and filtered resulting in white solid (26 
mg, 53%); Rf value 0.24 (EtOAc); mp 198-199 °C; IR (neat) n max: 3226, 3104, 2941, 1658, 1625, 
1527, 1625, 1262, 1143 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 9.94 (brs, 1H), 8.48 (d, J = 2.4 
Hz, 1H), 7.37-7.31(m, 8H), 7.07 (dd, J = 7.5, 2 Hz, 2H), 6.92 (d, J = 2.4 Hz, 1H), 5.7 (brs, 1H), 
5.10 (s, 2H), 4.94 (s, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 171.8, 166.3, 150.4, 141.9, 135.8, 
133.7, 129.5, 129.3, 128.7, 128.3, 127.7, 127.5, 124.6, 118.1, 72.0, 61.6; HRMS (ESI) (m/z) calcd 
for [C20H18N2O3 + H]+, 335.1385, observed 335.1269. 
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1-Benzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P14). Method A, pale yellow 
solid (63%); IR (neat) n max: 3292, 3180, 3064, 1655, 1556, 1525, 1439, 1345, 1291, 1145, 1034, 
805, 725, 694, 617, 503 cm-1; 1H NMR (DMSO-d6, 500 MHz) δ (ppm) 9.45 (d, J = 4.8 Hz, 1H), 
9.12 (s, 1H), 8.47 (d, J = 2.3 Hz, 1H), 7.64 (d, J = 2.4 Hz, 1H), 7.48 (d, J = 4.7 Hz, 1H), 7.42-7.35 
(m, 5H), 5.25 (s, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 170.1, 166.0, 149.8, 140.4, 136.7, 
129.4, 128.9, 128.4, 122.6, 116.1,60.1; HRMS (ESI) (m/z) calcd for [C13H12N2O3 +H]+, 245.0926, 
observed 245.0902.  
 
1-Benzyl-5-(benzyloxy)-N-(4-bromophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
(P15). Reaction conditions A, recrystallized from MeOH, grey solid (63%); Rf value 0.83 
(EtOAC/MeOH = 9:1); mp ; IR (neat) n max: 1673, 1626, 1590, 1525, 1168 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ (ppm) 12.61 (s, 1H), 8.52 (dd, J = 2 Hz, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.44 
(d, J = 9 Hz, 2H), 7.38-7.30 (m, 8H), 7.09 (d, J = 9 Hz, 2H), 6.97 (d, J = 2.5 Hz, 1H), 5.11 (s, 2H), 
5.00 (s, 2H);  13C NMR (CDCl3, 125 MHz) δ (ppm) 171.8, 162.5, 150.3, 141.5, 137.8, 135.6, 
133.5, 131.9, 129.6, 129.4, 128.8, 128.4, 127.8, 127.6, 124.6, 122.0, 118.2, 116.4, 72.0, 61.9; 
HRMS (ESI) (m/z) calcd for [C26H21BrN2O3 +H]+, 489.0803, observed 489.0702.  
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1-Benzyl-N-(4-bromophenyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P16). 
Method A, white solid (51%); mp >260 °C; Rf value 0.83 (EtOAc/MeOH = 0.83); IR (neat) n max: 
3216, 3028, 2963, 1643, 1550, 1488, 1415, 1305, 1229, 1147, 821, 699 cm-1; 1H NMR (CDCl3, 
500 MHz) δ (ppm) 12.05 (s, 1H), 8.51 (d, J = 2.5 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.46-7.42 (m, 
5H), 7.28-7.24 (m, 5H), 5.10 (s, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.3, 162.3, 149.5, 
140.3, 137.5, 133.4, 131.9, 129.6, 127.9, 122.0, 119.7, 116.6, 115.3, 62.4; HRMS (ESI) (m/z) calcd 
for [C19H15BrN2O3 +H]+, 399.0344, observed 399.0290. 
 
5-(Benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid (P17). Yellow 
solid (69%); mp 163-164 °C; Rf value 0.25 (EtOAc); IR (neat) n max: ; 1H NMR (CDCl3, 500 
MHz) δ (ppm) 15.35 (s, 1H), 8.46 (d, J = 2.1 Hz, 1H), 7.44 – 7.31 (m, 5H), 7.27 (d, J = 2.2 Hz, 
1H), 5.19 (s, 2H), 3.57 (m, 1H), 1.14 (m, 2H), 1.04 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 
173.4, 166.4, 149.2, 142.4, 135.3, 128.8, 128.7, 127.9, 127.0, 115.3, 72.2, 39.2, 7.3; HRMS (ESI) 
(m/z) calcd for [C18H16N2O3 +H]+, 309.1228, observed 309.1209.  
 
N,1-Dicyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P18). Method B, 
white solid (77%); Rf value 0.48 (EtOAc/MeOH = 90:10); mp 174-176 °C; IR (neat) n max: 3010, 
1640, 1535, 1293, 1157, 802 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 9.75 (s, 1H), 8.47 (d, J = 
2.5 Hz, 1H), 7.39 (d, J = 2.5 Hz, 1H), 3.59 (m, 1H), 2.94 (m, 1H), 1.14 (m, 1H), 0.83 (m, 4H), 
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0.63 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.6, 165.4, 148.8, 140.5, 38.9, 22.4, 7.2, 
6.6; HRMS (ESI) (m/z) calcd for [C12H14N2O3 + H]+, 235.1072, observed 235.1050. 
 
5-(Benzyloxy)-1-cyclopropyl-N-(cyclopropylmethyl)-4-oxo-1,4-dihydropyridine-3-
carboxamide (P19). Reaction conditions B, purified by column using silica gel and EtOAc/MeOH 
= 10:1; white solid (80%); Rf value 0.52 (EtOAc/MeOH = 90:10); mp 110-111 °C; IR (neat) n 
max: 3168, 3006, 2927, 1660, 1620, 1535, 1284, 1219, 1172, 1104, 1050, 832, 753, 699 cm-1; 1H 
NMR (CDCl3, 500 MHz) δ (ppm) 10.29 (brs, 1H), 8.50 (d, J = 2.5 Hz, 1H), 7.43-7.36 (m, 5H), 
7.13 ( d, J = 2.5 Hz, 1H), 5.13 (s, 2H), 3.49 (m, 1 H), 3.31 (dd, J = 7.0, 5.5 Hz, 2H), 1.06 (m, 3H), 
0.99 (m, 1H), 0.52 (dd, J = 13, 6 Hz, 2 H), 0.27 (dd, J = 10.5, 5 Hz, 2H); 13C NMR (CDCl3, 125 
MHz) δ (ppm) 172.1, 164.3, 149.8, 141.8, 136.1, 128.7, 128.3, 127.8, 125.5, 118.4, 72.0, 43.9, 
38.4, 10.8, 7.2, 3.5; HRMS (ESI) (m/z) calcd for [C20H22N2O3 +H]+, 339.1698, observed 339.1656. 
 
1-Cyclopropyl-N-(cyclopropylmethyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide (P20).  Method B, white solid (82%); Rf value 0.58 (EtOAc/MeOH = 90:10); mp 
152-153 °C; IR (neat) n max: 3226, 3048, 2914, 1634, 1537, 1295, 1160, 803 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ (ppm) 9.83 (brs, 1H), 8.48 (d, J = 2.2 Hz, 1H), 7.41 (d, J = 2.3 Hz, 1H), 3.59 
(m, 1H), 3.32 (dd, J = 7.0, 5.5 Hz, 2H), 1.13 (m, 5H), 0.54 (dd, J = 15, 6 Hz, 2H), 0.28 (dd, J = 
10.5, 6 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.6, 164.0, 148.8, 140.7, 120.2, 115.3, 
43.9, 38.9, 10.8, 7.2, 3.5; HRMS (ESI) (m/z) calcd for [C13H16N2O3 + H]+, 249.1228, observed 
249.1140. 
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N-Benzyl-5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxamide (P21). 
Reaction conditions A, recrystallized from EtOAc, white solid (75%); Rf  value 0.34 (EtOAc); mp 
121-122 °C; IR (neat) n max: 3252, 3031, 2934, 1652, 1618, 1567, 1513, 1454, 1284, 1219, 1158, 
1102, 1054, 750, 694, 577 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) δ 10.64 (brs, 1H), 8.52 (d, 
J = 2.6 Hz, 1H), 7.45 – 7.19 (m, 10H), 7.14 (d, J = 2.2 Hz, 1H), 5.11 (s, 2H), 4.64 (d, J = 5.7 Hz, 
2H), 3.48 (m, 1H), 1.03-0.99 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 172.1, 164.5, 149.8, 
141.9, 138.7, 136.0, 128.7, 128.5, 128.3, 127.8, 127.6, 127.0, 125.5, 118.1, 72.0, 43.2, 38.5, 7.2; 
HRMS (ESI) (m/z) calcd for [C23H22N2O3 +H]+, 374.1630, observed 375.1688.  
 
N-Benzyl-1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P22). 
Method B, white solid (63%); Rf value 0.58 (EtOAc/MeOH = 90:10); mp 204-205 °C; IR (neat) n 
max: 3203, 3072, 2920, 1657, 1639, 1538, 1423, 1358, 1298, 1267, 1164, 804, 726 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ (ppm) 10.14 (brs, 1H), 8.50 (d, J = 2.2 Hz, 1H), 7.40 (s, 1H), 7.38 – 7.28 (m, 
4H), 7.24 (d, J = 7.4 Hz, 1H), 4.65 (d, J = 5.7 Hz, 2H), 3.59 (m, 1H), 1.13 (m, 4H); 13C NMR 
(CDCl3, 125 MHz) δ (ppm) 169.6, 164.2, 148.8, 140.8, 138.6, 128.6, 127.6, 127.2, 120.3, 115.1, 
43.3, 38.9, 7.2; HRMS (ESI) (m/z) calcd for [C16H16N2O3 + H]+, 285.1228, observed 285.1188.  
 
5-(Benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxamide (P23). Ethyl 5-
(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxylate (62 mg, 0.198 mmol) was 
mixed with 3.0 mL of 7 N NH3/MeOH and stirred for 48 h. Then, the solvent was removed and 
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the residue was triturated with a mixture of MeOH/diethyl ether = 1:1 and filtered. After drying a 
white solid was formed (29 mg, 52%); Rf value 0.35 (EtOAc/MeOH = 90:10); mp 193-194 °C; IR 
(neat) n max: 3255, 3069, 2872, 1664, 1625, 1551, 1326, 1278, 1238, 1164, 1044, 827, 751, 699, 
646, 579 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 9.92 (brs, 1H), 8.50 (d, J = 2.2 Hz, 1H), 7.43-
7.33 (m, 5H), 7.14 (d, J = 2.2 Hz, 1H), 5.73 (s, 1H), 5.14 (s, 2H), 3.48 (m, 1H), 1.07 (dd, J = 14, 
6.9 Hz, 2H), 1.00 (dd, J = 9.5, 3.5 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 172.0, 166.2, 
150.0, 142.3, 136.0, 128.7, 128.4, 127.8, 125.5, 117.9, 72.0, 38.5, 7.2; HRMS (ESI) (m/z) calcd 
for [C16H16N2O3 +H]+, 285.1228, observed 285.1130.  
 
1-Cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P24). Method A, white 
solid (70%); Rf value 0.31 (EtOAc/MeOH = 90:10); mp > 260 °C; IR (neat) n max: 3292, 3168, 
3081, 3007, 1657, 1628, 1556, 1529, 1483, 1459, 1375, 1298, 1162, 1026, 807, 716, 582 cm-1; 1H 
NMR (DMSO-d6 , 500 MHz) δ (ppm) 9.42 (d, J = 4.8 Hz, 1H), 9.06 (brs, 1H), 8.24 (d, J = 2.4 Hz, 
1H), 7.55 (d, J = 2.3 Hz, 1H), 7.48 (brs, 1H), 3.74 (tt, J = 7.4, 3.9 Hz, 1H), 1.08 (m, 2H), 0.99 (m, 
2H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 170.3, 165.8, 149.4, 140.4, 122.7, 115.7, 38.9, 7.0; 
HRMS (ESI) (m/z) calcd for [C19H10N2O3 + H]+, 195.0759, observed 195.0734.  
 
5-(Benzyloxy)-1-cyclopropyl-N-(imino(1H-pyrazol-1-yl)methyl)-4-oxo-1,4-dihydropyridine-
3-carboxamide (P25). Reaction conditions A, triturated the residue with MeOH, filtered and dried 
provided a white solid (55%); Rf value 0.69 (EtOAc/MeOH = 90:10); mp 221-222 °C; IR (neat) n 
max: 3289, 3153, 3086, 3066, 1695, 1643, 1560, 1485, 1394, 1366, 1336, 1265, 1236, 1216, 1188, 
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1027, 775, 755 cm-1; 1H NMR (DMSO-d6 , 500 MHz) 14.03 (s, 1H), 9.52 (s, 1H), 8.47 (dd, J = 
10.4, 2.4 Hz, 2H), 7.79 (dd, J = 10, 2Hz, 2H), 7.48-7.39 (m, 5H), 6.58 (s, 1H), 5.08 (s, 2H), 3.84 
(tt, J = 7.4, 3.9 Hz, 1H), 1.17 (dd, J = 12, 7 Hz, 2H), 1.06 (dd, J = 12.5, 6 Hz, 2H); 13C NMR 
(DMSO-d6, 125 MHz) δ (ppm) 170.9, 166.5, 150.1, 145.5, 142.8, 142.2, 136.7, 129.0, 128.7, 
128.5, 128.0, 125.2, 114.9, 109.6, 71.3, 7.3; HRMS (ESI) (m/z) calcd for [C20H19N5O3 + H]+, 
378.1555, observed 378.1348. 
 
1-Cyclopropyl-5-hydroxy-N-(imino(1H-pyrazol-1-yl)methyl)-4-oxo-1,4-dihydropyridine-3-
carboxamide (P26). Method B, white solid (34%); Rf value 0.45 (EtOAc/MeOH); mp 214.5-215.5 
°C; IR (neat) n max: 3382, 3286, 3083, 1687, 1657, 1580, 1478, 1393, 1340, 1303, 1236, 1196, 
1101, 1042, 1015, 833, 801, 769, 687, 646, 584 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 13.61 
(s, 1H), 9.58 (s, 1H), 8.50 (d, J = 2 Hz, 1H), 8.47 (d, J = 3 Hz, 1H), 7.80 (d, J = 1.5 Hz, 1H), 7.45 
(d, J = 2.3 Hz, 1H), 7.10 (brs, 1H), 6.46 (dd, J = 4, 1.5 Hz, 1H), 3.66 (tt, J = 7.5, 4.0 Hz, 1H), 1.27 
– 1.10 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.7, 165.4, 149.3, 145.3, 142.0, 141.2, 
127.5, 120.8, 113.8, 108.7, 39.4, 7.3; HRMS (ESI) (m/z) calcd for [C13H13N5O3 +H]+, 288.1097, 
observed 288.1047. 
 
N-Carbamoyl-1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P27). 
Method A, white solid (69%); Rf value 0.18 (EtOAc/MeOH = 90:10); mp 240-241 °C; IR (neat) n 
max: 3382, 3248, 3084, 2972, 1788, 1719, 1669, 1572, 1352, 1302, 1173, 1033, 837, 801 cm-1; 1H 
NMR (DMSO-d6, 500 MHz) d (ppm) 12.16 (s, 1H), 9.48 (brs, 1H), 8.30 (d, J = 2.1 Hz, 1H), 7.84 
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(s, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.38 (brs, 1H), 3.78 (tt, J = 7.2, 3.7 Hz, 1H), 1.13 – 1.06 (m, 2H), 
0.99 (dd, J = 13, 6.0 Hz, 2H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 170.4, 165.4, 154.0, 149.7, 
141.1, 123.6, 113.2, 67.5, 7.1; HRMS (ESI) (m/z) calcd for [C10H11N3O4 + Na]+, 260.0636, 
observed 260.0599.  
 
N-Benzyl-5-(benzyloxy)-1-cyclopropyl-N-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide (P28). Reaction conditions A, recrystallized from EtOAc, pale yellow solid (62%); 
Rf value 0.55 (EtOAc/MeOH = 10:1); mp 153-154 °C; IR (neat) n max: 1632, 1601, 1558, 1451, 
1290, 1226, 1177, 1056, 835, 742, 700 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 11.48 (s, 1H), 
8.22 (d, J = 2.3 Hz, 1H), 7.45-7.32 (m, 10 H), 7.22 (d, J = 2.1 Hz, 1H), 5.16 (s, 2H), 4.99 (s, 2H), 
3.53 (tt, J = 7.2, 3.8 Hz, 1H), 1.09 (dd, J = 14.5, 7.5 Hz, 2H), 1.0 (dd, J = 9.5, 7.5 Hz, 2H); 13C 
NMR (CDCl3, 125 MHz) δ (ppm) 170.4, 164.0, 149.4, 143.0, 136.3, 135.6, 128.8, 128.5, 128.1, 
127.9, 127.4, 126.2, 124.0, 72.2, 52.6, 38.9, 7.2; HRMS (ESI) (m/z) calcd for [C23H22N2O4 +H]+, 
390.1580, observed 391.1654. 
 
N-Benzyl-1-cyclopropyl-N,5-dihydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide (P29). 
Method B, white solid (67%); Rf value 0.34 (EtOAc); mp 191-192 °C; IR (neat) n max: 3204, 
3087, 2917, 1705, 1646, 1603, 1478, 1447, 1307, 1160, 1103, 853, 730 cm-1; 1H NMR (CDCl3, 
500 MHz) δ (ppm) 11.20 (s, 1H), 8.25 (d, J = 2.3 Hz, 1H), 7.50 (d, J = 2.2 Hz, 1H), 7.44 (d, J = 7 
Hz, 2H), 7.35 (dd, J = 8.3, 6.8 Hz, 2H), 7.29 (d, J = 7.3 Hz, 1H), 6.98 (brs, 1H), 4.98 (s, 2H), 3.65 
(tt, J = 7.1, 4.1 Hz, 1H), 1.16 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 167.6, 163.9, 148.6, 
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141.8, 136.3, 128.5, 128.2, 127.5, 121.0, 120.0, 52.5, 39.4, 29.7, 7.2; HRMS (ESI) (m/z) calcd for 
[C16H16N2O4 + H]+, 301.1177, observed 301.1050.  
 
5-(Benzyloxy)-1-cyclopropyl-N-hydroxy-N-methyl-4-oxo-1,4-dihydropyridine-3-
carboxamide (P30). Reaction conditions B, crude product was pure no purification was needed, 
yellow solid (85%); Rf value 0.21 (EtOAc); mp 153.5-154.5 °C; IR (neat) n max: 1628, 1612, 
1555, 1286, 1216, 1193, 1168, 1041, 1025, 827, 749, 697 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
(ppm) 8.20 (s, 1H), 7.39-7.37 (m, 5H), 7.25 (s, 1H), 5.17 (s, 2H), 3.54 (tt, J = 7.4, 3.8 Hz, 1H), 
3.41 (s, 3H), 1.09 (dd, J = 14, 7.5 Hz, 2H), 0.99 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 
170.2, 163.9, 149.3, 142.8, 135.6, 128.8, 128.5, 127.9, 126.3, 123.8, 72.2, 39.0, 36.6, 7.2; HRMS 
(ESI) (m/z) calcd for [C17H18N2O4 +H]+, 315.1334, observed 315.1279. 
 
1-Cyclopropyl-N,5-dihydroxy-N-methyl-4-oxo-1,4-dihydropyridine-3-carboxamide (P31). 
Method B, white solid (64%); Rf value 0.20 (EtOAc/MeOH = 90:10); mp 187-188 °C; IR (neat) n 
max: 3197, 3086, 2920, 1604, 1475, 1367, 1307, 1190, 1101, 1032, 873, 834, 702, 584 cm-1; 1H 
NMR (CDCl3, 500 MHz) δ (ppm) 11.27 (s, 1H), 8.23 (s, 1H), 7.51 (s, 1H), 3.65 (tt, J = 6.6, 3.1 
Hz, 1H), 3.41 (s, 3H), 1.16 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 167.5, 163.8, 148.6, 
141.7, 121.1, 120.2, 39.4, 36.5, 29.7, 7.2; HRMS (ESI) (m/z) calcd for [C10H12N2O4 + Na]+, 
247.0684, observed 247.0682.  
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1-Cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxylic acid (P32). Method A, 
yellow solid (76%); Rf value 0.11 (EtOAc/MeOH = 90:10); mp 250-251 °C; IR (neat) n max: 3070, 
1607, 1560, 1496, 1455, 1331, 1275, 1239, 806 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 14.33 
(s, 1H), 8.45 (s, 1H), 7.53 (s, 1H), 6.84 (brs, 1H), 3.67 (tt, J = 7.3, 3.9 Hz, 1H), 1.18 (m, 4H); 13C 
NMR (CDCl3, 125 MHz) δ (ppm) 171.0, 165.8, 148.4, 141.4, 122.9, 113.0, 39.6, 7.4; HRMS (ESI) 
(m/z) calcd for [C9H8NO4]-, 194.0459, observed 194.0459. 
 
 
 
Synthesis of 4-(1-methyl-1H-pyrazol-4-yl)aniline: 4-Bromoaniline (51 mg, 0.296 mmol), 1-
methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (75 mg, 0.360 mmol, 1.2 
eq.), Cs2CO3 (192 mg, 0.589 mmol, 1.99 eq.), Pd(PPh3)2Cl2 (22 mg, 0.030 mmol, 10 mol%) were 
transferred into vial. A mixture of dioxane/H2O (0.8:0.2 mL) was added and it was heated at 120 
°C for 16 h. It was cooled to room temperature and diluted with H2O (10 mL). It was extracted 
with EtOAc (3 ´ 15 mL), washed organics with brine (20 mL), dried and solvent was removed 
under vacuum. It was purified by silica gel using EtOAc/Hexanes = 1:1 to provide the desired 
product yellow solid (21 mg, 41%). Rf value 0.20 (EtOAc/Hexanes = 1:1); mp 165-166 °C; IR 
(neat) n max: 3402, 3318, 3221, 3107, 2931, 2879, 1643, 1615, 1569, 1508, 1407, 1361, 1274, 
1195, 992, 953, 829, 795, 661, 524 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 7.67 (s, 1H), 7.50 
(s, 1H), 7.28 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.5 Hz, 2H), 3.92 (s, 3H), 3.67 (brs, 2H); 13C NMR 
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(CDCl3, 125 MHz) δ (ppm) 145.0, 136.3, 126.6, 123.4, 123.3, 115.5, 39.0; HRMS (ESI) (m/z) 
calcd for [C10H11N3 +Na]+, 196.0840, observed 196.0871. 
 
5-(Benzyloxy)-1-cyclopropyl-N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide (P33). Reaction conditions A, recrystallized from EtOAc, 
yellow solid (34%); Rf value 0.56 (EtOAc/MeOH = 90:10); IR (neat) n max: 1674, 1606, 1533, 
1455, 1406, 1283, 1213, 1063, 821, 739 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 12.53 (s, 1H), 
8.59 (d, J = 2.2 Hz, 1H), 7.76 (s, 1H), 7.74 (d, J = 2.1 Hz, 2H), 7.57 (s, 1H), 7.44 (d, J = 8.5 Hz, 
4H), 7.40 (t, J = 8.5 Hz, 2H), 7.35 (t, J = 7 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 5.16 (s, 2H), 3.94 (s, 
3H), 3.54 (tt, J = 7.3, 3.8 Hz, 1H), 1.12 (dd, J = 14.5, 7.5 Hz, 2H), 1.04 (dd, J = 8.5, 5 Hz, 2H); 
13C NMR (CDCl3, 125 MHz) δ (ppm) 172.0, 162.3, 149.8, 141.9, 137.1, 136.6, 135.8, 128.7, 128.4, 
128.3, 127.9, 126.6, 126.0, 125.4, 123.1, 120.8, 118.3, 72.1, 39.1, 38.7, 7.2; HRMS (ESI) (m/z) 
calcd for [C26H24N4O3 + H]+, 441.1916, observed 441.1803.  
 
1-Cyclopropyl-5-hydroxy-N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide (P34). Method A, brown solid (60%); Rf value 0.30 
(EtOAc/MeOH = 90:10); mp > 260 °C; IR (neat) n max: 3236, 3105, 1667, 1550, 1401, 1346, 
1307, 1214, 798, 526 cm-1; 1H NMR (DMSO-d6 , 500 MHz) δ (ppm) 12.67 (s, 1H), 9.39 (brs, 1H), 
8.37 (d, J = 2.3 Hz, 1H), 8.08 (s, 1H), 7.82 (s, 1H), 7.66 (s, 1H), 7.65 (d, J = 9 Hz, 2H), 7.54 (d, J 
= 9 Hz, 2H), 3.86 (s, 3H), 3.82 (tt, J = 7.5, 3.7 Hz, 1H), 1.14 (dd, J = 12, 7 Hz, 2H), 1.04 (dd, J = 
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13, 5.5 Hz, 2H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 170.3, 162.6, 149.4, 140.3, 137.1, 136.3, 
128.6, 127.9, 126.0, 123.5, 122.1, 120.4, 115.4, 39.4, 39.1, 7.1; HRMS (ESI) (m/z) calcd for 
[C19H18N4O3 + H]+, 351.1446, observed 351.1425. 
 
5-(Benzyloxy)-1-cyclopropyl-N-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-
carboxamide (P35). Reaction conditions A, recrystallized from MeOH, yellow solid (60%); Rf 
0.67 (EtOAc); mp 194-195 °C; IR (neat) n max: 1678, 1623, 1553, 1391, 1337, 1284, 1256, 1219, 
1102, 1049, 817, 756, 704, 476; 1H NMR (CDCl3, 500 MHz) δ (ppm) 12.70 (s, 1H), 8.62 (d, J = 
2.4 Hz, 1H), 8.49 (d, J = 2.0 Hz, 1H), 7.84 – 7.76 (m, 3H), 7.67 (dd, J = 8.7, 2.2 Hz, 1H), 7.46-
7.33 (m, 7H), 7.20 (d, J = 2.3 Hz, 1H), 5.18 (s, 2H), 3.55 (tt, J = 7.3, 3.8 Hz, 1H), 1.12 (m, 2H), 
1.05 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 172.1, 162.6, 149.9, 142.0, 136.2, 135.9, 
134.1, 130.6, 128.8, 128.6, 128.4, 127.9, 127.8, 127.5, 126.2, 125.5, 124.7, 120.8, 118.3, 117.1, 
72.1, 38.8, 7.2;  
 
1-Cyclopropyl-5-hydroxy-N-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
(P36). Method A, white solid (45%); Rf  value 0.31 (EtOAc); mp 228-230; IR (neat) n max: 1666, 
1644, 1557, 1533, 1350, 1306, 1269, 1144, 801; 1H NMR (CDCl3, 500 MHz) δ (ppm) 12.15 (s, 
1H), 8.59 (d, J = 2.3 Hz, 1H), 8.45 (d, J = 2.1 Hz, 1H), 7.82 (dd, J = 8.6, 2.7 Hz, 2H), 7.79 (d, J = 
8.1 Hz, 1H), 7.48 (d, J = 2.3 Hz, 1H), .46 – 7.43 (m, 1H), 7.39 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H), 3.65 
(td, J = 6.9, 3.5 Hz, 1H), 1.18 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.6, 162.3, 148.8, 
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140.8, 135.9, 134.0, 130.7, 128.6, 127.8, 127.6, 126.3, 124.8, 120.6, 117.1, 115.4, 39.2, 29.7, 7.3; 
HRMS (ESI) (m/z) calcd for [C19H16N2O3 +H]+, 321.1228, observed 321.1139.  
 
5-(Benzyloxy)-1-(cyclopropylmethyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (P37). 
White solid (79%); Rf value 0.32 (EtOAc); mp 189-190 °C; IR (neat) n max: 1713, 1632, 1547, 
1397, 1272, 1147, 1059, 1031, 875, 807, 744, 696, 626, 492 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
(ppm) 15.53 (s, 1H), 8.38 (d, J = 2.2 Hz, 1H), 7.42-7.34 (m, 5H), 7.19 (d, J = 2.2 Hz, 1H), 5.23 (s, 
2H), 3.74 (d, J = 7.1 Hz, 2H), 1.11 (tt, J = 7.6, 4.8 Hz, 1H), 0.71 (dd, J = 13.5, 6 Hz, 2H), 0.33 
(dd, J = 10.5, 5.5 Hz, 2H);  13C NMR (CDCl3, 125 MHz) δ (ppm) 173.2, 166.7, 149.6, 141.0, 
135.4, 128.9, 128.6, 127.7, 126.0, 115.5, 72.3, 63.2, 11.1, 4.3; HRMS (ESI) (m/z) calcd for 
[C17H17NO4 +H]+, 300.1225, observed 300.1134. 
 
N-Benzyl-1-(cyclopropylmethyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide 
(P38). Method B, white solid (73%); Rf value 0.53 (EtOAc); mp 161.5-162.5 °C; IR (neat) n max: 
3244, 3175, 2921, 1654, 1628, 1537, 1404, 1334, 1276, 1142, 1040, 802, 716 cm-1;  1H NMR 
(CDCl3, 500 MHz) δ (ppm) 10.21 (brs, 1H), 8.40 (d, J = 2.4 Hz, 1H), 7.37-7.31 (m, 5 H), 7.25 (d, 
J = 10 Hz, 1H), 4.66 (d, J = 5.9 Hz, 2H), 3.79 (d, J = 7.3 Hz, 2H), 1.25 (m, 1H), 0.77 (dd, J = 
13.5, 5.5 Hz, 2H), 0.43 (dd, J = 10.5, 5 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.3, 
164.4, 149.3, 139.5, 138.6, 128.6, 127.6, 127.1, 119.1, 115.1, 63.2, 43.3, 11.3, 4.3; HRMS (ESI) 
(m/z) calcd for [C17H18N2O3 + H]+, 299.1385, observed 299.1304.  
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5-Hydroxy-1-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (P39). Method 
A, brown solid (65%); mp > 260 °C; IR (neat) n max: 1552, 1269, 1249, 1224, 1093, 808, 761, 
475 cm-1, 1H NMR (DMSO-d6, 500 MHz) δ (ppm) 15.76 (brs, 1H), 10.25 (brs, 1H), 8.63 (d, J = 
2.3 Hz, 1H), 8.33 (d, J = 2.3 Hz, 1H), 8.19 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.07 (d, J 
= 7.2 Hz, 2H), 7.84 (dd, J = 8.8, 2.4 Hz, 1H), 7.66 (dd, J = 8.5, 4.5 Hz, 2H); 13C NMR (DMSO-
d6, 125 MHz) δ (ppm) 172.1, 166.2, 149.1, 140.5, 140.1, 133.2, 133.0, 130.5, 128.9, 128.3, 128.0, 
127.9, 126.1, 122.8, 121.9, 114.2; HRMS (ESI) (m/z) calcd for [C16H11NO4 + H]+, 282.0755, 
observed 282.0777. 
 
5-(Benzyloxy)-N-(4-bromophenyl)-1-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-
carboxamide (P40). Reaction conditions A, recrystallized from EtOAc (62%); Rf value 0.20 
(EtOAc/Hexanes = 30:70); mp 244-245 °C; IR (neat) n max: 3006, 2866, 1671, 1509, 1387, 1286, 
1240, 1214, 1094, 1028, 924, 811, 758 cm-1; 1H NMR (CDCl3, 500 MHz) δ (ppm) 12.58 (s, 1H), 
8.83 (d, J = 2.2 Hz, 1H), 8.01 (d, J = 8.9 Hz, 1H), 7.94 (dd, J = 9, 2.5 Hz, 1H), 7.89 (dd, J = 9, 2.5 
Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 8.6 Hz, 2H), 7.63 (t, J = 3.6 Hz, 1H), 7.47-7.36 (m, 
9H), 5.24 (s, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 172.0, 162.4, 150.3, 140.3, 137.8, 135.7, 
133.2, 132.8, 131.9, 130.9, 128.9, 128.6, 128.14, 128.11, 128.0, 127.9, 127.8, 124.6, 122.0, 121.7, 
120.4, 118.7, 116.5, 72.2; HRMS (ESI) (m/z) calcd for [C29H21BrN2O3 +H]+, 525.0803, observed 
525.0591.  
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N-(4-Bromophenyl)-5-hydroxy-1-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-
carboxamide (P41). Method A, white solid (83%); mp 253-254 °C; Rf value 0.74 (EtOAc/MeOH 
= 90:10); IR (neat) n max: 3227, 3061, 2926, 2849, 1633, 1555, 1300, 1074, 1004, 798 cm-1; 1H 
NMR (CDCl3, 500 MHz) δ (ppm) 12.06 (s, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 
7.98 – 7.91 (m, 3H), 7.76 (d, J = 2.3 Hz, 1H), 7.68-7.62 (m, 4H), 7.55 (dd, J = 8.7, 2.4 Hz, 1H), 
7.48 (d, J = 8.7 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ (ppm) 169.7, 162.1, 149.3, 140.4, 140.0, 
137.5, 133.2, 132.9, 132.0, 130.9, 128.22, 128.14, 128.0, 127.8, 122.0, 121.9, 120.5, 120.3, 116.8, 
115.9; HRMS (ESI) (m/z) calcd for [C22H15BrN2O3 +H]+, 435.0333, observed 435.0268. 
6.5. SF-2312 analog with C5 carbonyl  
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Ethyl 2-(diethoxyphosphoryl)pent-4-enoate (1). Triethyl phosphonoacetate (1.01 g, 4.51 mmol) 
was dissolved in THF (10 mL) and cooled in an ice bath. To this solution was added NaH 60% 
(197 mg, 4.92 mmol, 1.09 eq.) and let stir at 0 °C for 1h. Then, allyl bromide (0.42 mL, 4.85 mmol, 
1.08 mmol) was added and the solution was warmed to room temperature and left stirring 
overnight. Next day, the reaction was quenched with sat’d solution of ammonium chloride (5 mL) 
and diluted with H2O (10 mL). It was extracted with CHCl3 (3 ´ 20 mL), and then the combined 
organics were washed with brine (20 mL), dried over Na2SO4 and rotavaped resulting in pale 
yellow oil. It was purified by prep. HPLC using gradient elution with a mobile phase H2O/CH3CN 
(90/10 to 5/95%) to afford the title compound as a colorless oil (780 mg, 65%). Rf = 0.6 (100% 
EtOAc); IR (neat) n cm-1 2982, 1732, 1240, 1155, 1017, 961; 1H NMR (CDCl3, 500 MHz) d (ppm) 
5.76 (m, 1H), 5.12 (dd, J = 17.1, 1.5 Hz, 1H), 5.05 (dd, J = 10.2, 1.4 Hz, 1H), 4.16 (m, 6H), 3.03 
(ddd, J = 22.4, 11.2, 3.8 Hz, 1H), 2.71 (m, 1H), 2.59 (m, 1H), 1.34 (td, J = 7.1, 3.7 Hz, 6H), 1.28 
(t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz) d (ppm) 168.6 (d, J = 5 Hz), 134.6 (d, J = 16.2 
Hz), 117.13, 62.8 (d, J = 16.2) 62.7 (d, J = 6.2), 61.38, 45.96, 44.93, 31.0 (d, J = 3.8 Hz), 16.4 (dd, 
J = 5, 2.5Hz), 14.17; 31P NMR (CDCl3, 200 MHz) d (ppm) 22.6; HRMS (ESI) (m/z) calcd for 
[C11H21O5P + Na]+, 287.1013, observed 287.0935.  
 
 
O
PEtO
OEtO
OEt
 168 
 
2-(Diethoxyphosphoryl)pent-4-enoic acid (2). Ethyl 2-(diethoxyphosphoryl)pent-4-enoate 1 
(630 mg, 2.38 mmol) were dissolved in ethanol (5.0 mL). Then 2 N KOH (1.8 mL, 3.6 mmol, 1.5 
eq.) was added and the solution was stirred overnight. The sample was diluted with H2O (10 mL) 
and washed with CH2Cl2 (2 ´ 20 mL). It was then acidified with 2 N HCl to pH = 2 and extracted 
with CH2Cl2 (3 ´ 20 mL), combined organics were washed with brine, dried over Na2SO4 and 
rotavaped resulting in colorless oil (544 mg, 97% yield). Rf = 0.31 EtOAc/MeOH (90:10); IR (neat) 
n cm-1 2983, 1727, 1217, 1160, 1014; 1H NMR (CDCl3, 500 MHz) d (ppm) 8.90 (sb, 1H), 5.79 
(m, 1H), 5.14 (dd, J = 17.0, 1.7 Hz, 1H), 5.06 (d, J = 10.1 Hz, 1H), 4.20 (m, 4H), 3.06 (ddd, J = 
22.7, 10.9, 3.9 Hz, 1H), 2.70 (m, 1H), 2.54 (m, 1H), 1.35 (td, J = 7.1, 3.2 Hz, 6H); 13C NMR 
(CDCl3, 125 MHz) d (ppm) 170.4 (d, J = 3.8 Hz), 134.4 (d, J = 15 Hz), 117.2, 63.7 (d, J = 6.2 Hz), 
63.0 (d, J = 7.5 Hz), 45.8, 44.8, 30.9 (d, J = 5 Hz), 16.3 (d, 6.2 Hz); 31P NMR (CDCl3, 200 MHz) 
d (ppm) 23.6; HRMS (ESI) (m/z) calcd for [C9H17O5P + H]+, 237.0881, observed 237.0809.  
 
Diethyl (1-((benzyloxy)amino)-1-oxopent-4-en-2-yl) phosphonate (3). 2-(Diethoxy-
phosphoryl)pent-4-enoic acid 2 (644 mg, 2.73 mmol) and O-benzyloxy hydroxylamine 
hydrochloride (530 mg, 3.32 mmol, 1.2 eq.) were dissolved in CH2Cl2 (25 mL). DMAP (1.07 g, 
8.76 mmol, 3 eq.) and EDC.HCl (631 mg, 3. 29 mmol, 1.2 eq.) were added and the solution was 
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stirred for 36 h at room temperature.  It was then diluted with CH2Cl2 (25 mL) and washed with 1 
N HCl (2 ´ 25 mL), brine (25 mL), dried over Na2SO4 and rotavaped resulting in pale yellow oil 
(815 mg, 87% yield). Rf value 0.31 (100% EtOAc); IR (neat) n cm-1 3175, 2981, 1690, 1668, 1226, 
1017; 1H NMR (CDCl3, 500 MHz) d (ppm) 9.29 (s, 1H), 7.40-7.30 (m, 5H) , 5.75 (m, 1H), 5.11 
(dd, J = 17.0, 1.5 Hz, 1H), 5.04 (dd, J = 10.2, 1.5 Hz, 1H), 4.91 (s, 2H), 4.12 (m, 4H), 2.71 (m, 
2H), 2.52 (m, 1H), 1.31 (t, J = 7.1 Hz, 6H); 13C NMR (CDCl3, 125 MHz) d (ppm) 165.3, 135.3, 
134.4 (d, J = 13.8 Hz), 129.2, 128.6, 128.5, 117.4, 78.3, 63.3 (d, J = 6.2 Hz), 62.8 (d, J = 6.2 Hz), 
43.7 (d, 130 Hz), 30.7, 16.3 (dd, J = 6.2, 3.8 Hz); 31P NMR (CDCl3, 200 MHz) d (ppm) 24.3; 
HRMS (ESI) (m/z) calcd for [C16H12NO5P Na]+, 364.1279, observed 364.1177.  
 
Diethyl (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl) phosphonate (5). Diethyl (1-((benzyloxy)-
amino)-1-oxopent-4-en-2-yl) phosphonate 3 (509 mg, 1.49 mmol) was dissolved in dioxane/H2O-
1:1 (25 mL). Then, a solution of aqueous OsO4 4% (474 µL, 74.6 µmol, 5 mol%) was added and 
let stir for 30 min at room temp. To this solution, NaIO4 (957 mg, 4.47 mmol, 3 eq.) was added in 
portions and left stirring for 1 h. It was then diluted with H2O (20 mL) and extracted with CH2Cl2 
(3 ´ 20 mL), washed with brine (25 mL), dried over Na2SO4 and solvent was removed under 
vacuum resulting in yellow oil. It was purified by silica gel using (CHCl3/MeOH = 9:1) resulting 
yellow oil 4 (277 mg, 54% yield) and used for next step. This intermediate (167 mg, 0.486 mmol) 
was dissolved in CH2Cl2 (3.0 mL). Molecular Sieves 4 Å (100 mg) and PCC (316 mg, 1.46 mmol, 
3 eq.) were added and the mixture left stirring at room temp. overnight. It was then filtered through 
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a pad of celite and purified by silica gel containing 30% cysteine and eluted with 100% EtOAc to 
yield a yellow (130 mg, 78% yield). Rf value 0.68 EtOAc/MeOH (100:10); IR (neat) n cm-1 2983, 
1788, 1722, 1209, 1013; 1H NMR (CDCl3, 500 MHz) d (ppm) 7.50 (dd, J = 6.6, 2.9 Hz, 2H), 7.40 
– 7.35 (m, 3H), 4.29 – 4.13 (m, 4H), 3.21 (dd, J =  10, 5 Hz, 1H), 2.92 (m, 2H), 1.37 (t, J = 7.0 
Hz, 3H), 1.34 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz) d (ppm) 169.1 (d, J = 5 Hz), 166.6 
(d, J = 6.2 Hz), 133.2, 129.9, 129.4, 128.6, 78.9, 63.7 (dd, J = 63.8, 7.5 Hz), 36.7 (d, J = 16.2 Hz), 
27.9 (d, J = 3.8 Hz), 16.4 (t, J = 5 Hz); 31P NMR (CDCl3, 200 MHz) d (ppm) 19.6; HRMS (ESI) 
(m/z) calcd for [C15H20NO6P + H]+, 342.1096, observed 342.0992.  
 
(1-(Benzyloxy)-2,5-dioxopyrrolidin-3-yl) phosphonic acid (6). Diethyl (1-(benzyloxy)-2,5-
dioxopyrrolidin-3-yl) phosphonate 5 (125 mg, 0.366 mmol) was dissolved in dry CH2Cl2 (3.0 mL) 
and TMSI (156 µL, 1.10 mmol, 3 eq.) was added. It was stirred at room temperature overnight and 
then solvent was removed under vacuum. The residue was purified by prep HPLC resulting in 
colorless oil (52 mg, 50% yield). Rf value 0.54 (MeOH/H2O = 80:20); IR (neat)  n cm-1 1787, 1704, 
1391, 1206; 1H NMR (MeOH-d4, 500 MHz) d (ppm) 7.49 (dd, J = 6.7, 2.9 Hz, 2H), 7.39 – 7.34 
(m, 3H), 5.04 (s, 2H), 3.36 (ddd, J = 22.6, 9.5, 3.5 Hz, 1H), 2.99 (dt, J = 18.0, 10.0 Hz, 1H), 2.82 
(td, J = 18.3, 3.5 Hz, 1H); 13C NMR (MeOH-d4, 125 MHz) d (ppm) 171.9 (d, J = 4.6 Hz), 169.9 
(d, J = 5.6 Hz), 135.2, 131.0, 130.3, 129.6, 79.8, 39.0 (d, J = 135.9 Hz), 29.3 (d, J = 3.6 Hz); 31P 
NMR (CDCl3, 200 MHz) d (ppm) 17.6; HRMS (ESI) (m/z) calcd for [C11H11NO6P]-, 284.0324, 
observed 284.0381.  
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(1-Hydroxy-2,5-dioxopyrrolidin-3-yl) phosphonic acid (7). (1-(Benzyloxy)-2,5-dioxo-
pyrrolidin-3-yl) phosphonic acid 6 (38 mg, 0.133 mmol) was transferred to a vial equipped with a 
stir bar. It was dissolved on MeOH (2 mL) and bubbled with Ar for 10 min followed by the addition 
of Pd/C (10 mg). It was subjected for hydrogenolysis conditions. After 1 h, it was filtered through 
a plug of C18 and rotavaped resulting in colorless oil (22 mg, 84% yield). Rf value 0.48 
(MeOH/H2O = 60:40); IR (neat) n cm-1 3200-2200 broad peak, 1780, 1689, 1221; 1H NMR 3.31 
(ddd, J = 21.9, 9.1, 3.1 Hz, 1H), 3.05 (dt, J = 18.5, 9.2 Hz, 1H), 2.85 (td, J = 17.0, 3.0 Hz, 1H); 
HRMS (ESI) (m/z) calcd for [C4H4NNa2O6P +Na]+, 217.9819, observed 217.9781.  
6.6. SF-2312 analog with sulfonic acid group 
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Ethyl 2-(phenoxysulfonyl)acetate (S1). Ethyl 2-(chlorosulfonyl)acetate (1.65 g, 8.84 mmol) was 
dissolved in CH2Cl2 (5.0 mL). PhOH (890 mg, 9.46 mmol) was dissolved in CH2Cl2 (5.0 mL) and 
added dropwise to the above solution at room temperature and stirred for 1.5 h. Then, TEA (1.3 
ml, 9.34 mmol) was added dropwise at room temperature and left stirring overnight. Then, it was 
diluted with CH2Cl2 (20 mL), washed organic layer with 0.5 M HCl (2 ´ 20 mL), brine (20 mL) 
and dried over Na2SO4. The solvent was removed under vacuum resulting in yellow oil. It was 
purified using silica gel and EtOAc/Hexanes (5:95% followed by 30:70%) to provide the title 
compound as yellow oil (733 mg, 34%). Rf value 0.75 (EtOAc/Hexanes = 1:1). IR (neat) n max: 
3279, 2912, 1736, 1588, 1369, 1022 cm-1; 1H NMR (CDCl3, 500 MHz) d ppm 7.43 (dd, J = 8.7, 
7.0 Hz, 2H), 7.39 – 7.31 (m, 3H), 4.33 (q, J = 7.1 Hz, 2H), 4.17 (s, 2H), 1.34 (t, J = 7.2 Hz, 3H); 
13C NMR (CDCl3, 500 MHz) d ppm 161.5, 149.4, 130.1, 127.7, 122.2, 63.0, 54.0, 14.0; HRMS 
(ESI) (m/z) calcd for [C10H12O5S + Na]+, 267.0292, observed 267.0225.  
 
Ethyl 2-(phenoxysulfonyl)pent-4-enoate (S2). Ethyl 2-(phenoxysulfonyl)acetate S1 (730 mg, 
2.99 mmol) was dissolved in THF (10 mL) and cooled in an ice bath. NaH (125 mg, 3.12 mmol, 
1.04 eq.) was added and left stirring for 1h at the same temperature. Allyl bromide (272 µL, 3.14 
mmol, 1.05 eq.) was added and the solution was brought to room temperature and left stirring 
overnight. It was then quenched by the addition of Sat’d solution of NH4Cl (2.0 mL) and diluted 
with H2O (10 mL). It was extracted with ethyl acetate (3 ´ 20 mL), combined organics were 
washed with brine and dried over Na2SO4. The solvent was removed under vacuum resulting in 
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yellow oil. It was purified by prep. HPLC and after lyophilization a pale-yellow oil formed (386 
mg, 45%). Rf value 0.81 (EtOAc/Hexanes = 1:1); IR (neat) n max: 3280, 3083, 2984, 1738, 1487, 
1368, 1141, 1023, 865, 774 cm-1; 1H NMR (CDCl3, 500 MHz) d ppm 7.41 (m, 2H), 7.32 (m, 3H), 
5.76 (m, 1H), 5.23 (dd, J = 17.1, 1.4 Hz, 1H), 5.18 (dd, J = 10.2, 1.2 Hz, 1H), 4.31 (qt, J = 7.2, 3.6 
Hz, 2H), 4.17 (dd, J = 10.8, 4.2 Hz, 1H), 3.01 (m, 1H), 2.93 (m, 1H), 1.32 (t, J = 7.1 Hz, 4H); 13C 
NMR (CDCl3, 500 MHz) d ppm 164.2, 149.2, 131.3, 130.0, 127.4, 122.1, 119.6, 65.4, 62.8; HRMS 
(ESI) (m/z) calcd for [C13H16O5S + Na]+, 307.0605, observed 307.0605.  
 
2-(Phenoxysulfonyl)pent-4-enoic acid (S3). Ethyl 2-(phenoxysulfonyl)pent-4-enoate S2 (300 
mg, 1.06 mmol) was dissolved in EtOH (3.0 mL) and 2 N KOH (712 µL, 1.42 mmol, 1.34 eq.) 
was added. It was stirred at room temperature overnight. Then, sample was concentrated under 
vacuum and the residue was diluted H2O and acidified to pH = 2 with 2 N HCl. It was extracted 
with EtOAc (3 ´ 20 mL), combined extracts were washed with brine (30 mL) and dried over 
Na2SO4. The solvent was removed under vacuum resulting in yellow viscous oil (220 mg, 81%). 
Rf value 0.23 (CH2Cl2/MeOH = 90:10); IR (neat) n max: 3279, 1720, 1450, 1363, 1139, 1023, 
1000, 865, 519 cm-1; 1H NMR (CDCl3, 500 MHz) d ppm 9.99 (brs, 1H), 7.42 (m, 2H), 7.33 (m, 
3H), 5.80 (m, 1H), 5.27 (dd, J = 17.1, 1.4 Hz, 1H), 5.22 (dd, J = 10.1, 1.2 Hz, 1H), 4.23 (dd, J = 
10.4, 4.5 Hz, 1H), 3.01 (m, 1H); 13C NMR (CDCl3, 500 MHz) d ppm 169.0, 149.1, 130.8, 130.1, 
127.7, 122.0, 120.2, 65.0, 31.8;  HRMS (ESI) (m/z) calcd for [C11H12O5S + H]+, 257.0473, 
observed 257.0468.  
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Phenyl 1-((benzyloxy)amino)-1-oxopent-4-ene-2-sulfonate (S4). 2-(Phenoxysulfonyl)pent-4-
enoic acid S3 (202 mg, 0.788 mmol) was dissolved in CH2Cl2 and O-benzylhydroxylamine 
hydrochloride (140 mg, 0.877 mmol, 1.1 eq.) was added followed by DMAP (288 mg, 2.36 mmol, 
3.0 eq.). EDC.HCl (174 mg, 0.908 mmol, 1.2 eq.) was added and it was stirred at room temperature 
for 36 h. It was then diluted with CH2Cl2 (30 mL) and washed with 1 N HCl (2 ´ 20 mL), brine 
(30 mL) and dried over Na2SO4. The solvent was removed under vacuum and the residue was 
purified by silica gel and EtOAc/Hexanes = 30:70 to provide the product as colorless oil (88 mg, 
31%). Rf value 0.43 (EtOAc/Hexanes = 30:70); IR (neat)  n max: 3234, 2952, 1665, 1587, 1520, 
1488, 1375, 1189, 1144, 874, 766, 745, 568, 518 cm-1; 1H NMR (CDCl3, 500 MHz) d ppm 8.83 
(brs, 1H), 7.42-7.27 (m, 10H), 5.72 (m, 1H), 5.22 (dd, J = 17.0, 1.5 Hz, 1H), .17 (d, J = 9.9 Hz, 
1H), 4.91 (dd, J = 16, 11 Hz, 2H), 3.92 (dd, J = 10.1, 4.5 Hz, 1H), 2.93 (m, 2H); 13C NMR (CDCl3, 
500 MHz) d ppm 160.7, 149, 134.6, 131.0, 130.1, 129.4, 129.0, 128.7, 127.7, 122.2, 120.0, 78.7, 
64.6, 31.8; HRMS (ESI) (m/z) calcd for [C18H19NO5S + Na]+, 384.0871, observed 384.0866.  
 
Phenyl 1-(benzyloxy)-5-hydroxy-2-oxopyrrolidine-3-sulfonate (S5). Phenyl 1-((benzyloxy)-
amino)-1-oxopent-4-ene-2-sulfonate S4 (350 mg, 0.968 mmol) was dissolved in dioxane (10 mL) 
followed by the addition of H2O (4.0 mL). Aqueous OsO4 4% (310 µL, 0.045 mmol, 5 mol%) was 
added and stirred at room temperature for 30 min. Then, NaIO4 (626 mg, 2.93 mmol, 3.0 eq.) was 
added in portions and the mixture was stirred for 1 h at room temperature. It was then diluted with 
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H2O (20 mL) and extracted with CHCl3 (3´20 mL). The combined organics were washed with 
brine (25 mL), dried over Na2SO4 and rotavaped resulting in yellow semisolid residue. It was 
purified using silica gel and EtOAc/hexanes = 30:70 to provide white solid (156, 44%). Rf value 
0.47 (EtOAc/Hexanes = 1:1); IR (neat) n max: 3279, 1685, 1584, 1486, 1455, 1363, 1191, 1143, 
1094, 862 cm-1; trans isomer: 1H NMR (CDCl3, 500 MHz) d ppm 7.42-7.32 (m, 10H), 5.07 (ABq, 
DnAB = 22.19 Hz, JAB = 10.9 Hz, 2H), 4.95 (dd, J = 6.0, 3.5 Hz, 1H), 4.26 (dd, J = 9.6, 6.7 Hz, 
1H), 3.16 (d, J = 3.2 Hz, 1H),2.71 (m, 1H), 2.33 (ddd, J = 14.4, 9.5, 1.9 Hz, 1H); 13C NMR (CDCl3, 
500 MHz) d ppm 161.1, 149.3, 134.5, 130.1, 129.9, 129.4, 128.8, 127.7, 122.4, 79.5, 78.3, 55.9, 
27.7; Cis-isomer: 1H NMR (CDCl3, 500 MHz) d ppm 7.49-7.44 (m, 7H), 5.18 (ABq, DnAB = 27.67 
Hz, JAB = 10.2 Hz, 2H), 5.10 (dd, J = 11.48, 5.81 Hz, 1H), 4.05 (dd, J = 9.8, 2.1 Hz, 1H), 3.45 (d, 
J = 11.4 Hz, 1H), 2.75 (m, 1H), 2.50 (dt, J = 15.6, 1.6 Hz, 1H); 13C NMR (CDCl3, 500 MHz) d 
ppm 159.2, 149.4, 134.3, 130.2, 129.7, 129.3, 128.7, 127.9, 80.7, 79.0, 56.6, 29.0; HRMS (ESI) 
(m/z) calcd for [C17H17NO6S + Na]+, 386.0663, observed 386.0587.  
 
6.7. Tartaric acid analogs 
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2,5-Dioxotetrahydrofuran-3,4-diyl diacetate [TA1]. Tartaric acid (2.0 g, 0.013 mol) was mixed 
with acetic anhydride (5.0 mL, 0.053 mol, 4 eq.) and cooled in an ice bath. Three drops of conc. 
H2SO4 were added it was heated at 140 °C for 20 min. It was then cooled to room temperature and 
filtered. The solid was washed with toluene and diethyl ether resulting in a white solid (2.33 g, 
83%). Rf value 0.68 (EtOAc); MP 129-130 °C; IR (neat) n max: 2939, 1897, 1819, 1754, 1378, 
1196, 1034, 591 cm-1; 1H NMR (CDCl3, 500 MHz) d (ppm) 5.68 (s, 2H), 2.23 (s, 6H); 13C NMR 
(CDCl3, 125 MHz) δ (ppm) 169.7, 163.2, 72.1, 20.1. The spectra were consistent with the reported 
method.3  
 
2,3-Diacetoxy-4-((benzyloxy)amino)-4-oxobutanoic acid [TA2]. 2,5-Dioxotetrahydrofuran-3,4-
diyl diacetate 1 (300 mg, 1.39 mmol) was dissolved in CH2Cl2 (5.0 mL). O-benzylhydroxylamine 
hydrochloride (226 mg, 1.42 mmol, 1.01 eq.) and DMAP (190 mg, 1.55 mmol, 1.1 eq.) were added 
successively and the solution was refluxed 2 h. It was then cooled to room temperature and 
removed solvent under vacuum. The residue was dissolved in EtOAc (10 mL) and washed with 
H2O (10 mL), 2 N HCl (2 ´ 10 mL), brine (10 mL) and dried over Na2SO4. The solvent was 
removed under vacuum and the resulting solid was recrystallized from EtOAc to provide the 
desired product as white solid (262 mg, 56%). MP 177-178 °C; IR (neat) n max: 3293, 2790, 1733, 
1650, 1510, 1210, 1068 cm-1; 1H NMR (DMSO-d6, 500 MHz) d (ppm) 13.6 (brs, 1H), 11.6, (s, 
1H), 7.38 (m, 5H), 5.46 (d, J = 5 Hz, 1H), 5.42 (d, J = 5 Hz, 1H), 4.76 (dd, J = 15, 10 Hz, 2H); 
2.10 (s, 3H), 2.07 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 169.9, 167.9, 136.0, 129.4, 
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128.9, 128.8, 77.5, 71.4, 71.0, 21.0, 20.7; HRMS (ESI) (m/z) calcd for [C15H17NO8 + H]+, 
340.1021, observed 340.0944. 
 
4-((Benzyloxy)amino)-2,3-dihydroxy-4-oxobutanoic acid [TA3]. 2,3-Diacetoxy-4-
((benzyloxy)amino)-4-oxobutanoic acid 2 (131 mg, 0.386 mmol) was dissolved in MeOH (3.0 
mL) and NaOCH3 25% (175 µL, 0.810 mmol, 2.1 eq.) was added. It was left stirring at room 
temperature overnight. Then, the solvent was removed under vacuum and the residue was 
dissolved in H2O (2.0 mL) and acidified to pH = 3 using 2 N HCl. It was extracted with EtOAc (3 
´ 5.0 mL), dried over Na2SO4 and rotavaped to yield white solid (48 mg, 49%). MP 133-134 °C; 
IR (neat) n max: 3543, 3346, 3251, 2930, 1740, 1713, 1641, 1494, 1238, 1116, 1063 cm-1; 1H 
NMR (DMSO-d6, 500 MHz) d (ppm) 12.6 (brs, 1H), 11.1 (brs, 1H), 7.34-7.43 (m, 5H), 5.54 (brs, 
1H), 5.08 (brs, 1H), 4.79 (s, 2H), 4.32 (d, J = 5 Hz, 1H), 4.25 (d, J = 5 Hz, 1H); 13C NMR (DMSO-
d6, 125 MHz) δ (ppm) 174.0, 168.7, 136.4, 129.2, 128.7, 128.6, 77.4, 73.1, 72.2; HRMS (ESI) 
(m/z) calcd for [C11H13NO6 + Na]+, 278.0630, observed 278.0569. 
 
2,3-dihydroxy-4-(hydroxyamino)-4-oxobutanoic acid (TA4). 4-((Benzyloxy)amino)-2,3-
dihydroxy-4-oxobutanoic acid 3 (27.4 mg, 0.107 mmol) was dissolved in MeOH (2.0 mL) and 
Pd/C (10 mg) was added. It was then subjected to catalytic hydrogenolysis for 3 h which then 
filtered and the residue was passed through a plug of C18 to afford white solid (15 mg, 85%). MP 
139-140 °C; IR (neat) n max: 3232, 2926, 2851, 1709, 1419, 1207, 1109, 999 cm-1; 1H NMR 
(DMSO-d6, 500 MHz) d (ppm) 10.35 (brs, 1H), 8.77 (brs, 1H), 4.28 (d, J = 5 Hz, 1H), 4.22 (d, J 
HO
H
N
O
OH
OH
O
OBn
HO
H
N
O
OH
OH
O
OH
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= 5 Hz, 1H); 13C NMR (DMSO-d6, 125 MHz) δ (ppm) 174.1, 168.3, 72.9, 72.1; HRMS (ESI) (m/z) 
calcd for [C4H6NO6]-, 164.0201, observed 164.0185. 
---------------------------------------------------------------------- 
6.8. References: 
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β-carbolines.” Angew. Chem. Int. Ed. 2015, 54, 6012-6015. 
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6.9. Appendices 
 
6.9.1. Appendix A: NMR spectra 
 
Tropolone spectra  
 
Figure S.1. 1H NMR in CDCl3 for N-benzyl-6-(benzylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
Figure S.2. 13C NMR in CDCl3 for N-benzyl-6-(benzylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
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Figure S.3. 1H NMR in CDCl3 for N-benzyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
 
Figure S.4. 13C NMR in CDCl3 for N-benzyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
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Figure S.5. 1H NMR in CDCl3 for N-cyclohexyl-6-(cyclohexylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
 
Figure S.6. 13C NMR in CDCl3 for N-cyclohexyl-6-(cyclohexylamino)-7-oxocyclohepta-1,3,5-triene-1-
carboxamide. 
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Figure S.7. 1H NMR in CDCl3 for N-cyclohexyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
 
Figure S.8. 3C NMR in CDCl3 for N-cyclohexyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
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Figure S.9. 1H NMR in CDCl3 for N-hexyl-6-(hexylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
 
Figure S.10. 13C NMR in CDCl3 for N-hexyl-6-(hexylamino)-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
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Figure S.11. 1H NMR in CDCl3 for N-hexyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
 
Figure S.12. 13C NMR in CDCl3 for N-hexyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide.  
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Figure S.13. 1H NMR in CDCl3 for N-(cyclopropylmethyl)-6-((cyclopropylmethyl)amino)-7-oxocyclohepta-1,3,5-
triene-1-carboxamide. 
 
 
Figure S.14. 13C NMR in CDCl3 for N-(cyclopropylmethyl)-6-((cyclopropylmethyl)amino)-7-oxocyclohepta-1,3,5-
triene-1-carboxamide. 
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Figure S.15A. NOESY spectrum for N-(cyclopropylmethyl)-6-((cyclopropylmethyl)amino)-7-oxocyclohepta-1,3,5-
triene-1-carboxamide. 
 
 
 
Figure S.15B. NOESY spectrum for N-(cyclopropylmethyl)-6-((cyclopropylmethyl)amino)-7-oxocyclohepta-1,3,5-
triene-1-carboxamide  
 
 
OH
N N
H
O
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Figure S.16. 1H NMR in CDCl3 for N-(cyclopropylmethyl)-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-
carboxamide. 
 
 
Figure S.17. 13C NMR in CDCl3 for N-(cyclopropylmethyl)-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-
carboxamide. 
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Figure S.18. 1H NMR in CDCl3 for N-cyclopropyl-6-(cyclopropylamino)-7-oxocyclohepta-1,3,5-triene-1-
carboxamide. 
 
Figure S.19. 13C NMR in CDCl3 for N-cyclopropyl-6-(cyclopropylamino)-7-oxocyclohepta-1,3,5-triene-1-
carboxamide. 
 189 
 
Figure S.20. 1H NMR in CDCl3 for N-cyclopropyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
 
 
Figure S.21. 13C NMR in CDCl3 for N-cyclopropyl-6-hydroxy-7-oxocyclohepta-1,3,5-triene-1-carboxamide. 
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Figure S.22. 1H NMR in CDCl3 for diethyl (6-methoxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonate. 
 
Figure S.23. 13C NMR in CDCl3 for diethyl (6-methoxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonate. 
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Figure S.24. 31P NMR in CDCl3 for diethyl (6-methoxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonate. 
 
 
Figure S.25. 1H NMR in D2O for (6-hydroxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonic acid. 
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Figure S.26. 13C NMR in MeOH-d4 for (6-hydroxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonic acid. 
 
 
Figure S.27. 31P NMR in MeOH-d4 for (6-hydroxy-7-oxocyclohepta-1,3,5-trien-1-yl) phosphonic acid. 
Hydroxyquinoline NMR spectra  
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Figure S28. 1H NMR in CDCl3 for N-benzyl-8-hydroxyquinoline-7-carboxamide. 
 
 
Figure S29. 13C NMR in CDCl3 for N-benzyl-8-hydroxyquinoline-7-carboxamide. 
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Figure S30. 1H NMR in CDCl3 (8-hydroxyquinolin-7-yl) (morpholino) methanone. 
 
 
Figure S31. 13C NMR in CDCl3 for (8-hydroxyquinolin-7-yl)(morpholino) methanone. 
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Figure S32. 1H NMR in DMSO-d6 for 8-hydroxy-N-(2-methoxybenzyl)quinoline-7-carboxamide. 
 
 
Figure S33. 13C NMR in DMSO-d6 for 8-hydroxy-N-(2-methoxybenzyl)quinoline-7-carboxamide. 
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Figure S34. 1H NMR in DMSO-d6 for methyl 4-(8-hydroxyquinoline-7-carboxamido) benzoate. 
 
 
Figure S35. 13C NMR in DMSO-d6 for methyl 4-(8-hydroxyquinoline-7-carboxamido) benzoate. 
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Figure S36. 1H NMR in DMSO-d6 for N-(4-bromophenyl)-8-hydroxyquinoline-7-carboxamide. 
 
 
Figure S37. 13C NMR in DMSO-d6 for N-(4-bromophenyl)-8-hydroxyquinoline-7-carboxamide. 
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Figure S38. 1H NMR in DMSO-d6 for 8-hydroxy-N-(4-isopropylbenzyl)quinoline-7-carboxamide. 
 
 
Figure S39.13C NMR in DMSO-d6 for 8-hydroxy-N-(4-isopropylbenzyl)quinoline-7-carboxamide. 
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Figure S40. 1H NMR in CDCl3 for N-(4-fluorophenyl)-8-hydroxyquinoline-7-carboxamide. 
 
 
Figure S41. 13C NMR in CDCl3 for N-(4-fluorophenyl)-8-hydroxyquinoline-7-carboxamide. 
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Pyridone spectra 
 
Figure S42. 1H NMR in CDCl3 for ethyl 4-(benzyloxy)-2-((dimethylamino)methylene)-3-oxobutanoate.  
 
Figure S43. 13C NMR in CDCl3 for ethyl 4-(benzyloxy)-2-((dimethylamino)methylene)-3-oxobutanoate.  
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Figure S44. 1H NMR in CDCl3 for ethyl 5-(benzyloxy)-4-oxo-4H-pyran-3-carboxylate.   
 
 
 
Figure S45. 13C NMR in CDCl3 for ethyl 5-(benzyloxy)-4-oxo-4H-pyran-3-carboxylate.  
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Figure S46. 1H NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxylic acid.  
 
Figure S47. 13C NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxylic acid.  
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Figure S48. 1H NMR in CDCl3 N,1-dibenzyl-5-(benzyloxy)-N-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide.  
 
Figure S49. 13C NMR in CDCl3 for N,1-dibenzyl-5-(benzyloxy)-N-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide.  
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Figure S50. 1H NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-N-cyclohexyl-4-oxo-1,4-dihydropyridine-3-
carboxamide.  
 
 
Figure S51. 13C NMR for 1-benzyl-5-(benzyloxy)-N-cyclohexyl-4-oxo-1,4-dihydropyridine-3-carboxamide.  
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Figure S52. 1NMR in CDCl3 for 1-benzyl-N-cyclohexyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide.  
 
 
Figure S53. 13C NMR in CDCl3 for 1-benzyl-N-cyclohexyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide.  
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Figure S54. 1H NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-4-oxo-N-(pyridin-2-yl)-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S55. 13C NMR in CDCl3 for for 1-benzyl-5-(benzyloxy)-4-oxo-N-(pyridin-2-yl)-1,4-dihydropyridine-3-
carboxamide. 
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Figure S56. 1H NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-N-(pyridin-2-yl)-1,4-dihydropyridine-3-
carboxamide.  
 
Figure S57. 13C NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-N-(pyridin-2-yl)-1,4-dihydropyridine-3-
carboxamide.  
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Figure S58. 1H NMR in DMSO-d6 for 1-benzyl-5-(benzyloxy)-4-oxo-N-(pyridin-4-yl)-1,4-dihydropyridine-3-
carboxamide. 
 
 
Figure S59. 13C NMR in DMSO-d6 for 1-benzyl-5-(benzyloxy)-4-oxo-N-(pyridin-4-yl)-1,4-dihydropyridine-3-
carboxamide. 
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Figure S60. 1H NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-N-(pyridin-4-yl)-1,4-dihydropyridine-3-
carboxamide.  
 
 
Figure S61. 13C NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-N-(pyridin-4-yl)-1,4-dihydropyridine-3-
carboxamide.  
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Figure S62. 1H NMR in CDCl3 for N,1-dibenzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxamide.  
 
Figure S63. 13C NMR in CDCl3 for N,1-dibenzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxamide.  
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Figure S64. 1H NMR in CDCl3 for N,1-dibenzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
 
 
Figure S65. 13C NMR in CDCl3 for N,1-dibenzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
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Figure S66. 1H NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxylic acid. 
 
 
Figure S67. 13C NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxylic acid. 
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Figure S68. 1H NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxamide. 
 
 
Figure S69. 13C NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxamide. 
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Figure S70. 1H NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
 
 
Figure S71. 13C NMR in DMSO-d6 for 1-benzyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
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Figure S72. 1H NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-N-(4-bromophenyl)-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S73. 13C NMR in CDCl3 for 1-benzyl-5-(benzyloxy)-N-(4-bromophenyl)-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S74. 1H NMR in CDCl3 for 1-benzyl-N-(4-bromophenyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S75. 13C NMR in CDCl3 for 1-benzyl-N-(4-bromophenyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S76. 1H NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid. 
 
Figure S77. 13C NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid. 
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Figure S78. 1H NMR in CDCl3 for N,1-dicyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide.  
 
Figure S79. 13C NMR in CDCl3 for N,1-dicyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide.  
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Figure S80. 1H NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-N-(cyclopropylmethyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide.  
 
Figure S81. 13C NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-N-(cyclopropylmethyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide.  
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Figure S82. 1H NMR in CDCl3 for 1-cyclopropyl-N-(cyclopropylmethyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S83. 13C NMR in CDCl3 for 1-cyclopropyl-N-(cyclopropylmethyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S84. 1H NMR in CDCl3 for N-benzyl-5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S85. 13C NMR in CDCl3 for N-benzyl-5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S86. 1H NMR in CDCl3 for N-benzyl-1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
 
Figure S87. 13C NMR in CDCl3 for N-benzyl-1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
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Figure S88. 1H NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxamide. 
 
Figure S89. 13C NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-4-oxo-1,4-dihydropyridine-3-carboxamide. 
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Figure S90. 1H NMR in DMSO-d6 for 1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
 
Figure S91. 13C NMR in DMSO-d6 for 1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxamide. 
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Figure S92. 1H NMR in DMSO-d6 for 5-(benzyloxy)-1-cyclopropyl-N-(imino(1H-pyrazol-1-yl)methyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide. 
 
Figure S93. 13C NMR in DMSO-d6 for for 5-(benzyloxy)-1-cyclopropyl-N-(imino(1H-pyrazol-1-yl)methyl)-4-oxo-
1,4-dihydropyridine-3-carboxamide. 
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Figure S94. 1H NMR in CDCl3 for 1-cyclopropyl-5-hydroxy-N-(imino(1H-pyrazol-1-yl)methyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide. 
 
 
Figure S95. 13C NMR in CDCl3 for 1-cyclopropyl-5-hydroxy-N-(imino(1H-pyrazol-1-yl)methyl)-4-oxo-1,4-
dihydropyridine-3-carboxamide. 
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Figure S96. 1H NMR in DMSO-d6 for N-carbamoyl-1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S97. 13C NMR in DMSO-d6 for N-carbamoyl-1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S98. 1H NMR in CDCl3 for N-benzyl-5-(benzyloxy)-1-cyclopropyl-N-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
Figure S99. 13C NMR in CDCl3 for N-benzyl-5-(benzyloxy)-1-cyclopropyl-N-hydroxy-4-oxo-1,4-dihydropyridine-
3-carboxamide. 
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Figure S100. 1H NMR in CDCl3 for N-benzyl-1-cyclopropyl-N,5-dihydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
 
Figure S101. 13C NMR in CDCl3 for N-benzyl-1-cyclopropyl-N,5-dihydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S102. 1H NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-N-hydroxy-N-methyl-4-oxo-1,4-dihydropyridine-
3-carboxamide.  
 
Figure S103. 13C NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-N-hydroxy-N-methyl-4-oxo-1,4-
dihydropyridine-3-carboxamide.  
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Figure S104. 1H NMR in CDCl3 for 1-cyclopropyl-N,5-dihydroxy-N-methyl-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
 
 
Figure S105. 13C NMR in CDCl3 for 1-cyclopropyl-N,5-dihydroxy-N-methyl-4-oxo-1,4-dihydropyridine-3-
carboxamide. 
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Figure S106. 1H NMR in CDCl3 for 1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxylic acid. 
 
Figure S107. 13C NMR in CDCl3 for 1-cyclopropyl-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carboxylic acid. 
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Figure S108. 1H NMR in CDCl3 for 4-(1-methyl-1H-pyrazol-4-yl)aniline. 
 
Figure S109. 13C NMR in CDCl3 for 4-(1-methyl-1H-pyrazol-4-yl)aniline. 
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Figure S110. 1H NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-oxo-
1,4-dihydropyridine-3-carboxamide. 
 
 
Figure S111. 13C NMR in CDCl3 for 5-(benzyloxy)-1-cyclopropyl-N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-oxo-
1,4-dihydropyridine-3-carboxamide.  
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Figure S112. 1H NMR in DMSO-d6 for 1-cyclopropyl-5-hydroxy-N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-oxo-
1,4-dihydropyridine-3-carboxamide.  
 
 
Figure S113. 13C NMR in DMSO-d6 for 1-cyclopropyl-5-hydroxy-N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-4-oxo-
1,4-dihydropyridine-3-carboxamide. 
 236 
 
Figure S114. 1H NMR in CDCl3 for 5-(benzyloxy)-1-(cyclopropylmethyl)-4-oxo-1,4-dihydropyridine-3-carboxylic 
acid. 
 
 
Figure S115. 13C NMR in CDCl3 for 5-(benzyloxy)-1-(cyclopropylmethyl)-4-oxo-1,4-dihydropyridine-3-carboxylic 
acid. 
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Figure S116. 1H NMR in CDCl3 for N-benzyl-1-(cyclopropylmethyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide.  
 
Figure S117. 13C NMR in CDCl3 for N-benzyl-1-(cyclopropylmethyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-
carboxamide.  
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Figure S118. 1H NMR in DMSO-d6 for 5-hydroxy-1-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-carboxylic 
acid. 
 
 
Figure S119. 13C NMR in DMSO-d6 for 5-hydroxy-1-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-3-carboxylic 
acid. 
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Figure S120. 1H NMR in CDCl3 for 5-(benzyloxy)-N-(4-bromophenyl)-1-(naphthalen-2-yl)-4-oxo-1,4-
dihydropyridine-3-carboxamide.  
 
 
Figure S121. 13C NMR in CDCl3 for 5-(benzyloxy)-N-(4-bromophenyl)-1-(naphthalen-2-yl)-4-oxo-1,4-
dihydropyridine-3-carboxamide.  
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Figure S122. 1H NMR in CDCl3 for N-(4-bromophenyl)-5-hydroxy-1-(naphthalen-2-yl)-4-oxo-1,4-dihydropyridine-
3-carboxamide.  
 
 
Figure S123. 13C NMR in CDCl3 for N-(4-bromophenyl)-5-hydroxy-1-(naphthalen-2-yl)-4-oxo-1,4-
dihydropyridine-3-carboxamide.  
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Tartaric acid analog spectra  
 
 
Figure S124. 1H NMR in CDCl3 for 2,5-dioxotetrahydrofuran-3,4-diyl diacetate.  
 
Figure S125. 13C NMR in CDCl3 for 2,5-dioxotetrahydrofuran-3,4-diyl diacetate. 
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Figure S126. 1H NMR in DMSO-d6 for 2,3-diacetoxy-4-((benzyloxy)amino)-4-oxobutanoic acid. 
 
 
Figure S127. 13C NMR in DMSO-d6 for 2,3-diacetoxy-4-((benzyloxy)amino)-4-oxobutanoic acid. 
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Figure S128. 1H NMR in DMSO-d6 for 4-((benzyloxy)amino)-2,3-dihydroxy-4-oxobutanoic acid. 
 
Figure S129. 13C NMR in DMSO-d6 for 4-((benzyloxy)amino)-2,3-dihydroxy-4-oxobutanoic acid. 
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Figure S130. 1H NMR in DMSO-d6 for 2,3-dihydroxy-4-(hydroxyamino)-4-oxobutanoic acid. 
 
 
Figure S131. 13C NMR in DMSO-d6 for 2,3-dihydroxy-4-(hydroxyamino)-4-oxobutanoic acid. 
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SF-2312 analog spectra  
 
 
Figure S132. 1H NMR in CDCl3 for ethyl 2-(diethoxyphosphoryl)pent-4-enoate.  
 
 
Figure S133. 13C NMR in CDCl3 for ethyl 2-(diethoxyphosphoryl)pent-4-enoate. 
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Figure S134. 31P NMR in CDCl3 for ethyl 2-(diethoxyphosphoryl)pent-4-enoate.   
 
 
Figure S135. 1H NMR in CDCl3 for 2-(diethoxyphosphoryl)pent-4-enoic acid. 
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Figure S136. 13C NMR in CDCl3 for 2-(diethoxyphosphoryl)pent-4-enoic acid. 
 
Figure S137. 31P NMR in CDCl3 for 2-(diethoxyphosphoryl)pent-4-enoic acid. 
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Figure S138. 1H NMR in CDCl3 for diethyl (1-((benzyloxy)amino)-1-oxopent-4-en-2-yl)phosphonate. 
 
Figure S139. 13C NMR in CDCl3 for diethyl (1-((benzyloxy)amino)-1-oxopent-4-en-2-yl)phosphonate. 
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Figure S140. 31P NMR in CDCl3 for diethyl (1-((benzyloxy)amino)-1-oxopent-4-en-2-yl)phosphonate. 
 
 
Figure S141. 1H NMR in CDCl3 for diethyl (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl)phosphonate. 
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Figure S142. 13C NMR in CDCl3 for diethyl (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl)phosphonate. 
 
 
Figure S143. 31P NMR in CDCl3 for diethyl (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl)phosphonate. 
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Figure S144. 1H NMR in MeOH-d4 for (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl)phosphonic acid. 
 
Figure S145. 13C NMR in MeOH-d4 (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl)phosphonic acid. 
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Figure S146. 31P NMR in MeOH-d4 for (1-(benzyloxy)-2,5-dioxopyrrolidin-3-yl)phosphonic acid. 
 
Figure S147. 1H NMR in D2O for (1-hydroxy-2,5-dioxopyrrolidin-3-yl)phosphonic acid. 
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Figure S148. 13C NMR in D2O for (1-hydroxy-2,5-dioxopyrrolidin-3-yl)phosphonic acid. 
 
Figure S149. 31P NMR in D2O for (1-hydroxy-2,5-dioxopyrrolidin-3-yl)phosphonic acid. 
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Figure S150. 1H NMR in CDCl3 for ethyl 2-(phenoxysulfonyl)acetate. 
 
Figure S151. 13C NMR in CDCl3 for ethyl 2-(phenoxysulfonyl)acetate. 
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Figure S152. 1H NMR in CDCl3 for ethyl 2-(phenoxysulfonyl)pent-4-enoate. 
 
Figure S153. 13C NMR in CDCl3 for ethyl 2-(phenoxysulfonyl)pent-4-enoate. 
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Figure S154. 1H NMR in CDCl3 for 2-(phenoxysulfonyl)pent-4-enoic acid. 
 
Figure S155. 13C NMR in CDCl3 for 2-(phenoxysulfonyl)pent-4-enoic acid. 
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Figure S156. 1H NMR in CDCl3 for phenyl 1-((benzyloxy)amino)-1-oxopent-4-ene-2-sulfonate. 
 
Figure S157. 13C NMR in CDCl3 for phenyl 1-((benzyloxy)amino)-1-oxopent-4-ene-2-sulfonate. 
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Figure S158. 1H NMR in CDCl3 for phenyl 1-(benzyloxy)-5-hydroxy-2-oxopyrrolidine-3-sulfonate. 
 
Figure S159. 13C NMR in CDCl3 for phenyl 1-(benzyloxy)-5-hydroxy-2-oxopyrrolidine-3-sulfonate. 
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Figure S160. HSQC NMR in CDCl3 for phenyl 1-(benzyloxy)-5-hydroxy-2-oxopyrrolidine-3-sulfonate. 
 
 
Figure S161A. NOESY NMR in CDCl3 for phenyl 1-(benzyloxy)-5-hydroxy-2-oxopyrrolidine-3-sulfonate. 
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Figure S161B. NOESY NMR in CDCl3 for phenyl 1-(benzyloxy)-5-hydroxy-2-oxopyrrolidine-3-sulfonate. 
 
Figure S162. 1H NMR in MeOH-d4 for 1,5-dihydroxy-2-oxopyrrolidine-3-sulfonic acid.  
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Figure S162. 1H NMR in CDCl3 for 3-Hydroxy-2-methylenetridecanoic acid. 
 
 
Figure S163. 13C NMR in CDCl3 for 1H NMR in CDCl3 for 3-Hydroxy-2-methylenetridecanoic acid. 
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Figure S164. 1H NMR in CDCl3 for 4-Decyl-3-methyleneoxetan-2-one.  
 
Figure S165. 13C NMR in CDCl3 for for 4-Decyl-3-methyleneoxetan-2-one. 
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Figure S166. 1H NMR in CDCl3 for (Z)-4-Decyl-3-decylideneoxetan-2-one. 
  
Figure S167. 13C NMR in CDCl3 for (Z)-4-Decyl-3-decylideneoxetan-2-one. 
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Figure S168. 1H NMR in CDCl3 for (E)-4-Decyl-3-decylideneoxetan-2-one. 
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Figure S169. 13C NMR in CDCl3 for (E)-4-Decyl-3-decylideneoxetan-2-one. 
 
Figure S170. 1H NMR in CDCl3 for (3R,4R)-3,4-didecyloxetan-2-one. 
 
Figure S171. 13C NMR in CDCl3 for (3R,4R)-3,4-didecyloxetan-2-one. 
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Figure S172. 1H NMR in CDCl3 for (3R,4S)-3,4-didecyloxetan-2-one. 
 
Figure S173. 13C NMR in CDCl3 for (3R,4S)-3,4-didecyloxetan-2-one. 
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Figure S174. 1H NMR in CDCl3 for 5-(Pentylthio)pentan-1-ol. 
 
Figure S175. 13C NMR in CDCl3 for 5-(Pentylthio)pentan-1-ol. 
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Figure S176. 1H NMR in CDCl3 for 5-(Pentylthio)pentanal. 
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Figure S177. 1H NMR in CDCl3 for methyl-3-hydroxy-2-methylene-7-(pentylthio)heptanoate. 
 
Figure S178. 13C NMR in CDCl3 for methyl-3-hydroxy-2-methylene-7-(pentylthio)heptanoate. 
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Figure S179. 1H NMR in CDCl3 for 3-hydroxy-2-methylene-7-(pentylthio)heptanoic acid. 
 
 
Figure S180. 13C NMR in CDCl3 for 3-hydroxy-2-methylene-7-(pentylthio)heptanoic acid. 
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Figure S181. 1H NMR in CDCl3 for 3-Methylene-4-(4-(pentylthio)butyl)oxetan-2-one. 
 
Figure S182. 13C NMR in CDCl3 for 3-Methylene-4-(4-(pentylthio)butyl)oxetan-2-one. 
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Figure S183. 1H NMR in CDCl3 for (E)-3-Decylidene-4-(4-(pentylthio)butyl)oxetan-2-one. 
 
Figure S184. 13C NMR in CDCl3 for (E)-3-Decylidene-4-(4-(pentylthio)butyl)oxetan-2-one. 
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Figure S185. 1H NMR in CDCl3 for (Z)-3-Decylidene-4-(4-(pentylthio)butyl)oxetan-2-one. 
 
Figure S186. 13C NMR in CDCl3 for (Z)-3-Decylidene-4-(4-(pentylthio)butyl)oxetan-2-one. 
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Figure S187. 1H NMR in CDCl3 for (Z)-3-Decylidene-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
 
Figure S188. 13C NMR in CDCl3 for (Z)-3-Decylidene-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
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Figure S189. 1H NMR in CDCl3 for (E)-3-Decylidene-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
 
Figure S190. 13C NMR in CDCl3 for (E)-3-Decylidene-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
f1	(ppm)
3.
51
3.
21
20
.7
4
5.
57
1.
19
2.
0
0
4
.3
7
1.
0
3
1.
0
0
0
.8
6
9
0
.8
8
3
0
.8
9
6
0
.9
0
8
0
.9
22
0
.9
37
1.
26
8
1.
37
8
1.
4
6
3
1.
76
4
1.
77
6
1.
8
6
12.
0
9
9
2.
11
5
2.
6
21
2.
6
302
.6
37
2.
6
8
1
2.
6
9
2
2.
6
9
8
2.
71
0
4
.9
8
24
.9
9
8
5.
0
13
6
.3
4
66
.3
6
2
6
.3
77
7.
26
0
-100102030405060708090100110120130140150160170180190200210220230
f1	(ppm)
14
.0
2
14
.3
0
22
.5
0
22
.5
3
29
.0
9
29
.4
4
29
.5
4
31
.2
1
52
.2
1
52
.2
5
52
.8
3
52
.8
8
76
.9
6
77
.2
1
77
.4
7
78
.5
8
78
.6
7
13
4
.7
3
13
7.
4
2
13
7.
4
7
16
4
.1
7
	
	
14
.0
2
14
.3
022
.5
0
22
.5
3
22
.5
6
22
.6
522
.8
5
24
.3
1
24
.4
12
8
.6
2
29
.0
929
.4
4
29
.5
4
29
.6
6
29
.9
1
31
.2
1
32
.0
5
33
.0
5
33
.1
2
 276 
 
Figure S191. 1H NMR in CDCl3 for (E)-3-Decylidene-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
 
Figure S192. 13C NMR in CDCl3 for (E)-3-Decylidene-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
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Figure S193. 1H NMR in CDCl3 for (Z)-3-Decylidene-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
 
Figure S194. 13C NMR in CDCl3 for (Z)-3-Decylidene-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
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Figure S195. 1H NMR in CDCl3 for (3R,4R)-3-decyl-4-(4-(pentylthio)butyl)oxetan-2-one. 
 
Figure S196. 13C NMR in CDCl3 for (3R,4R)-3-decyl-4-(4-(pentylthio)butyl)oxetan-2-one. 
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Figure S197. 1H NMR in CDCl3 for (3R,4S)-3-decyl-4-(4-(pentylthio)butyl)oxetan-2-one. 
 
Figure S198. 13C NMR in CDCl3 for (3R,4S)-3-decyl-4-(4-(pentylthio)butyl)oxetan-2-one. 
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Figure S199. 1H NMR in CDCl3 for (3R,4R)-3-Decyl-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
 
Figure S200. 13C NMR in CDCl3 for (3R,4R)-3-Decyl-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
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Figure S201. 1H NMR in CDCl3 for (3R,4R)-3-Decyl-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
 
Figure S202. 13C NMR in CDCl3 for (3R,4R)-3-Decyl-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
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Figure S203. 1H NMR in CDCl3 for (3R,4S)-3-Decyl-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
 
Figure S204. 13C NMR in CDCl3 for (3R,4S)-3-Decyl-4-(4-(pentylsulfinyl)butyl)oxetan-2-one. 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
f1	(ppm)
5.
8
8
18
.8
6
8
.7
2
3.
73
1.
0
4
1.
0
0
0
.8
9
0
.9
1
0
.9
2
0
.9
3
0
.9
5
0
.9
7
1.
29
1.
391.
4
1
1.
4
2
1.
56
1.
78
1.
8
0
1.
9
0
2.
6
6
2.
6
7
2.
6
9
2.
70
2.
722.
72
3.
6
2
3.
6
4
3.
6
4
3.
6
5
3.
6
6
3.
6
7
4
.5
4
4
.5
5
4
.5
6
4
.5
7
4
.5
85.
14
0102030405060708090100110120130140150160170180190200210220
f1	(ppm)
13
.8
3
14
.1
122
.3
2
29
.3
1
29
.3
9
29
.5
3
29
.5
7
31
.0
1
52
.0
3
52
.6
6
52
.8
5
75
.0
8
75
.1
9
17
1.
9
1
13
.8
3
14
.1
122
.3
2
22
.3
8
22
.4
5
22
.6
8
23
.9
7
25
.0
0
25
.0
927
.5
9
29
.3
1
29
.3
9
29
.5
3
29
.5
7
29
.7
1
29
.9
0
29
.9
431
.0
1
31
.8
9
 283 
 
 
Figure S205. 1H NMR in CDCl3 for (3R,4S)-3-Decyl-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
 
Figure S206. 13C NMR in CDCl3 for (3R,4S)-3-Decyl-4-(4-(pentylsulfonyl)butyl)oxetan-2-one. 
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Figure S207. 1H NMR in CDCl3 for hept-6-ene-1-sulfonamide. 
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Figure S208. 1H NMR in CDCl3 for (Z)-6-(2-Oxo-4-(4-(pentylthio)butyl)oxetan-3-ylidene)hexane-1-sulfonamide. 
 
Figure S209. 13C NMR in CDCl3 for (Z)-6-(2-Oxo-4-(4-(pentylthio)butyl)oxetan-3-ylidene)hexane-1-sulfonamide. 
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Figure S210. 1H NMR in CDCl3 for (Z)-6-(2-Oxo-4-(4-(pentylsulfinyl)butyl)oxetan-3-ylidene)hexane-1-
sulfonamide. 
 
Figure S211. 13C NMR in CDCl3 for (Z)-6-(2-Oxo-4-(4-(pentylsulfinyl)butyl)oxetan-3-ylidene)hexane-1-
sulfonamide. 
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Figure S212. 1H NMR in CDCl3 for (Z)-6-(2-Oxo-4-(4-(pentylsulfonyl)butyl)oxetan-3-ylidene)hexane-1-
sulfonamide. 
 
Figure S213. 13C NMR in CDCl3 for for (Z)-6-(2-Oxo-4-(4-(pentylsulfonyl)butyl)oxetan-3-ylidene)hexane-1-
sulfonamide. 
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6.9.2. Appendix B: Crystallographic data 
 
 
Figure S214. The complete numbering scheme of T8 with 50% thermal ellipsoid probability levels.  The hydrogen 
atoms are shown as circles for clarity. 
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Figure S215. The Fourier difference map of total electron density in T8 (0.08e/Å3 isolines) highlights the plane of 
the tropolone, excluding contributions from H1 and H2 so as to show their effective position. 
 
 
 
Figure S216. The hydrogen bonding in T8 with hydrogen atoms shown as circles for clarity. The hydrogen bond 
interaction is highlighted with a dashed line. O1, O2, N4 and their symmetry equivalent positions are labeled.  
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  Table S1.  Crystal data and structure refinement for T8. 
Identification code  007b-17055 
Empirical formula  C12 H13 N O3 
Formula weight  219.23 
Temperature  93(2) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1029(3) Å a= 95.624(5)°. 
 b = 9.6604(6) Å b= 95.659(5)°. 
 c = 10.7216(7) Å g = 92.232(5)°. 
Volume 522.79(6) Å3 
Z 2 
Density (calculated) 1.393 Mg/m3 
Absorption coefficient 0.831 mm-1 
F(000) 232 
Crystal size 0.200 x 0.200 x 0.100 mm3 
Crystal color and habit colorless block 
Diffractometer Rigaku Saturn 944+ CCD 
Theta range for data collection 4.165 to 66.645°. 
Index ranges -6<=h<=6, -11<=k<=11, -12<=l<=12 
Reflections collected 18590 
Independent reflections 1815 [R(int) = 0.0286] 
Observed reflections (I > 2sigma(I)) 1717 
Completeness to theta = 66.645° 98.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.82438 
Solution method SHELXT-2014/5 (Sheldrick, 2014) 
Refinement method SHELXL-2014/7 (Sheldrick, 2014) 
Data / restraints / parameters 1815 / 0 / 154 
Goodness-of-fit on F2 1.067 
Final R indices [I>2sigma(I)] R1 = 0.0298, wR2 = 0.0757 
R indices (all data) R1 = 0.0315, wR2 = 0.0771 
Extinction coefficient 0.0242(16) 
Largest diff. peak and hole 0.223 and -0.156 e.Å-3 
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 Table S2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 007b-17055.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 1912(2) 6205(1) 5296(1) 24(1) 
O(2) 2048(2) 4677(1) 3295(1) 25(1) 
O(3) 7063(2) 9477(1) 6841(1) 34(1) 
N(4) 3338(2) 8238(1) 7052(1) 25(1) 
C(1) 3690(2) 6620(1) 4671(1) 19(1) 
C(2) 3821(2) 5752(1) 3469(1) 21(1) 
C(3) 5462(2) 5856(1) 2543(1) 24(1) 
C(4) 7444(2) 6870(1) 2448(1) 26(1) 
C(5) 8271(2) 8000(1) 3285(1) 26(1) 
C(6) 7383(2) 8369(1) 4464(1) 23(1) 
C(7) 5467(2) 7804(1) 5109(1) 20(1) 
C(8) 5355(2) 8575(1) 6421(1) 22(1) 
C(9) 2919(2) 8914(1) 8286(1) 26(1) 
C(10) 3527(2) 8011(1) 9334(1) 25(1) 
C(11) 1558(3) 6872(1) 9518(1) 31(1) 
C(12) 1907(2) 8166(1) 10432(1) 26(1) 
________________________________________________________________________________ 
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 Table S3.   Bond lengths [Å] and angles [°] for  007b-17055. 
_____________________________________________________  
O(1)-C(1)  1.2567(13) 
O(2)-C(2)  1.3369(14) 
O(2)-H(2)  0.915(19) 
O(3)-C(8)  1.2282(14) 
N(4)-C(8)  1.3339(15) 
N(4)-C(9)  1.4563(14) 
N(4)-H(4)  0.873(15) 
C(1)-C(7)  1.4423(15) 
C(1)-C(2)  1.4755(16) 
C(2)-C(3)  1.3690(16) 
C(3)-C(4)  1.3989(17) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.3684(18) 
C(4)-H(4A)  0.9500 
C(5)-C(6)  1.4022(17) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.3781(16) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.5324(15) 
C(9)-C(10)  1.5048(17) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.5011(17) 
C(10)-C(12)  1.5029(16) 
C(10)-H(10)  1.0000 
C(11)-C(12)  1.5043(16) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(2)-O(2)-H(2) 106.2(11) 
C(8)-N(4)-C(9) 123.57(10) 
C(8)-N(4)-H(4) 116.1(9) 
C(9)-N(4)-H(4) 120.3(9) 
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O(1)-C(1)-C(7) 122.96(10) 
O(1)-C(1)-C(2) 113.24(9) 
C(7)-C(1)-C(2) 123.77(10) 
O(2)-C(2)-C(3) 116.31(10) 
O(2)-C(2)-C(1) 112.78(9) 
C(3)-C(2)-C(1) 130.89(10) 
C(2)-C(3)-C(4) 129.35(11) 
C(2)-C(3)-H(3) 115.3 
C(4)-C(3)-H(3) 115.3 
C(5)-C(4)-C(3) 128.25(11) 
C(5)-C(4)-H(4A) 115.9 
C(3)-C(4)-H(4A) 115.9 
C(4)-C(5)-C(6) 127.44(11) 
C(4)-C(5)-H(5) 116.3 
C(6)-C(5)-H(5) 116.3 
C(7)-C(6)-C(5) 133.24(11) 
C(7)-C(6)-H(6) 113.4 
C(5)-C(6)-H(6) 113.4 
C(6)-C(7)-C(1) 126.79(10) 
C(6)-C(7)-C(8) 112.67(10) 
C(1)-C(7)-C(8) 120.53(10) 
O(3)-C(8)-N(4) 122.76(11) 
O(3)-C(8)-C(7) 119.89(10) 
N(4)-C(8)-C(7) 117.34(10) 
N(4)-C(9)-C(10) 113.08(10) 
N(4)-C(9)-H(9A) 109.0 
C(10)-C(9)-H(9A) 109.0 
N(4)-C(9)-H(9B) 109.0 
C(10)-C(9)-H(9B) 109.0 
H(9A)-C(9)-H(9B) 107.8 
C(11)-C(10)-C(12) 60.10(8) 
C(11)-C(10)-C(9) 118.91(10) 
C(12)-C(10)-C(9) 117.54(10) 
C(11)-C(10)-H(10) 116.2 
C(12)-C(10)-H(10) 116.2 
C(9)-C(10)-H(10) 116.2 
 294 
C(10)-C(11)-C(12) 60.01(8) 
C(10)-C(11)-H(11A) 117.8 
C(12)-C(11)-H(11A) 117.8 
C(10)-C(11)-H(11B) 117.8 
C(12)-C(11)-H(11B) 117.8 
H(11A)-C(11)-H(11B) 114.9 
C(10)-C(12)-C(11) 59.89(8) 
C(10)-C(12)-H(12A) 117.8 
C(11)-C(12)-H(12A) 117.8 
C(10)-C(12)-H(12B) 117.8 
C(11)-C(12)-H(12B) 117.8 
H(12A)-C(12)-H(12B) 114.9 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
 295 
 Table S4.   Anisotropic displacement parameters  (Å2x 103) for 007b-17055.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 26(1)  26(1) 21(1)  0(1) 9(1)  -8(1) 
O(2) 26(1)  25(1) 22(1)  -2(1) 7(1)  -6(1) 
O(3) 29(1)  36(1) 34(1)  -9(1) 7(1)  -12(1) 
N(4) 29(1)  26(1) 20(1)  -3(1) 7(1)  -8(1) 
C(1) 19(1)  21(1) 19(1)  6(1) 3(1)  1(1) 
C(2) 19(1)  21(1) 22(1)  4(1) 2(1)  0(1) 
C(3) 26(1)  28(1) 20(1)  2(1) 6(1)  1(1) 
C(4) 24(1)  34(1) 22(1)  8(1) 9(1)  3(1) 
C(5) 22(1)  30(1) 28(1)  10(1) 7(1)  -2(1) 
C(6) 21(1)  23(1) 27(1)  5(1) 3(1)  -2(1) 
C(7) 19(1)  21(1) 21(1)  4(1) 3(1)  1(1) 
C(8) 22(1)  20(1) 23(1)  2(1) 2(1)  -1(1) 
C(9) 33(1)  25(1) 22(1)  -3(1) 7(1)  -3(1) 
C(10) 22(1)  30(1) 23(1)  -1(1) 6(1)  0(1) 
C(11) 40(1)  27(1) 27(1)  -1(1) 12(1)  -3(1) 
C(12) 29(1)  28(1) 22(1)  0(1) 8(1)  -1(1) 
______________________________________________________________________________ 
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 Table S5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 007b-17055. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 1070(40) 4764(18) 3968(18) 53(5) 
H(4) 2260(30) 7560(15) 6690(14) 30(4) 
H(3) 5218 5135 1867 29 
H(4A) 8329 6761 1708 31 
H(5) 9599 8603 3040 31 
H(6) 8290 9174 4909 28 
H(9A) 1059 9173 8275 32 
H(9B) 4046 9783 8457 32 
H(10) 5425 7819 9535 30 
H(11A) 2243 6000 9807 37 
H(11B) -75 6748 8930 37 
H(12A) 488 8836 10405 31 
H(12B) 2806 8088 11282 31 
________________________________________________________________________________ 
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 Table S6.  Torsion angles [°] for 007b-17055. 
________________________________________________________________  
O(1)-C(1)-C(2)-O(2) -1.15(14) 
C(7)-C(1)-C(2)-O(2) 177.05(10) 
O(1)-C(1)-C(2)-C(3) -179.72(12) 
C(7)-C(1)-C(2)-C(3) -1.51(19) 
O(2)-C(2)-C(3)-C(4) 178.38(11) 
C(1)-C(2)-C(3)-C(4) -3.1(2) 
C(2)-C(3)-C(4)-C(5) 1.7(2) 
C(3)-C(4)-C(5)-C(6) 2.9(2) 
C(4)-C(5)-C(6)-C(7) -2.8(2) 
C(5)-C(6)-C(7)-C(1) -2.6(2) 
C(5)-C(6)-C(7)-C(8) 177.23(12) 
O(1)-C(1)-C(7)-C(6) -176.77(11) 
C(2)-C(1)-C(7)-C(6) 5.19(18) 
O(1)-C(1)-C(7)-C(8) 3.43(17) 
C(2)-C(1)-C(7)-C(8) -174.61(9) 
C(9)-N(4)-C(8)-O(3) 1.22(18) 
C(9)-N(4)-C(8)-C(7) -177.74(10) 
C(6)-C(7)-C(8)-O(3) -8.11(15) 
C(1)-C(7)-C(8)-O(3) 171.71(11) 
C(6)-C(7)-C(8)-N(4) 170.87(10) 
C(1)-C(7)-C(8)-N(4) -9.30(16) 
C(8)-N(4)-C(9)-C(10) -106.89(13) 
N(4)-C(9)-C(10)-C(11) -77.66(13) 
N(4)-C(9)-C(10)-C(12) -146.91(11) 
C(9)-C(10)-C(11)-C(12) -106.96(12) 
C(9)-C(10)-C(12)-C(11) 109.21(12) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table S7.  Hydrogen bonds for 007b-17055  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(2)-H(2)...O(1) 0.915(19) 1.896(18) 2.4903(11) 120.7(14) 
 O(2)-H(2)...O(1)#1 0.915(19) 2.022(18) 2.7948(11) 141.2(15) 
 N(4)-H(4)...O(1) 0.873(15) 1.877(15) 2.6124(12) 140.7(13) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y+1,-z+1       
 
 
 
 
 
 
 
 
 
 
 
